

# CITATION REPORT

List of articles citing

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

DOI: 10.1056/nejm200001203420301

New England Journal of Medicine, 2000, 342, 145-53.

**Source:** <https://exaly.com/paper-pdf/31741944/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2291	Oversight Hearings Promote NSF Insight. <b>1979</b> , 29, 433-434		
2290	ISCHEMIC STROKE: MECHANISMS, EVALUATION, AND TREATMENT. <b>1995</b> , 551-586		
2289	Risk factors and stroke prevention. European Stroke Initiative (EUSI). <b>2000</b> , 10 Suppl 3, 12-21		38
2288	Cerebrovascular disease. <b>2000</b> , 102, IV75-80		18
2287	Cardiac complications of end-stage renal disease. <b>2000</b> , 7, 210-9		7
2286	Comprehensive management of type 2 diabetes. <b>2000</b> , 35, 33-6, 41-4, 47-8; discussion 48-50		2
2285	Management of Stroke in Older People; A Pharmacological Perspective. <b>2000</b> , 30, 60-65		2
2284	Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction. <b>2000</b> , 321, 1113-6		17
2283	Prevention of ischaemic stroke. <b>2000</b> , 321, 1455-9		32
2282	Medical treatment for acute coronary syndromes. <b>2000</b> , 15, 441-62		8
2281	Bibliography. Current world literature. Pediatrics. <b>2000</b> , 15, B151-74		
2280	Current World Literature. <b>2000</b> , 9, 293-321		
2279	Current World Literature. <b>2000</b> , 9, 555-590		
2278	An overview of antihypertensive therapy in the 20th century. <b>2000</b> , 40, 967-77		14
2277	Perioperative management of selected endocrine disorders. <b>2000</b> , 38, 31-67		47
2276	Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells. <b>2000</b> , 18, 1051-6		40
2275	Update on recent clinical trials in congestive heart failure. <b>2000</b> , 15, 293-303		11

2274	Large multicentre hypertension trials. <b>2000</b> , 9, 285-92	
2273	The results of the GISSI-Prevenzione trial in the general framework of secondary prevention. <b>2000</b> , 21, 949-52	17
2272	The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group. <b>2000</b> , 40, 815-25	15
2271	STOPPING at the CAPPP of good HOPE. <b>2000</b> , 15, 451-2	9
2270	Renal implications of the renin-angiotensin-aldosterone system blockade in heart failure. <b>2000</b> , 18, 1545-51	17
2269	Low density lipoprotein oxidation, antioxidants, and atherosclerosis. <b>2000</b> , 15, 355-63	65
2268	The renin-angiotensin-aldosterone system and carotid artery disease in mild-to-moderate primary hypertension. <b>2000</b> , 18, 1401-9	15
2267	Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto. <b>2000</b> , 15 Suppl 5, 69-80	74
2266	Reducing the risk and impact of retinopathy: new screening and treatment strategies. Proceedings of a Round Table Meeting, 27 September 1999, Brussels. <b>2000</b> , 17, S1-S6	
2265	Consider this: It's too little!. <b>2000</b> , 50, 280-1	
2264	The HOPE Study: practical implications for people with diabetes. <b>2000</b> , 17, 191-194	7
2263	Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. <b>2000</b> , 57, 1803-17	317
2262	Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. <b>2000</b> , 58, 1703-10	257
2261	HOPE for diabetes in the new millennium. Heart Outcomes Prevention Evaluation. <b>2000</b> , 2, 1-2	16
2260	Insulin action in vascular endothelium: potential mechanisms linking insulin resistance with hypertension. <b>2000</b> , 2, 285-92	89
2259	Drugs used in secondary prevention after myocardial infarction: case presentation. <b>2000</b> , 50, 405-17	3
2258	Implications of recent hypertension trials for the generalist physician: whom do we treat, and how?. <b>2000</b> , 1, 22-24	
2257	Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!. <b>2000</b> , 1, 25-27	81

2256	Why do antioxidants fail to provide clinical benefit?. <b>2000</b> , 1, 38-40	32
2255	Debate: Does it matter how you lower blood pressure?. <b>2000</b> , 1, 69-71	
2254	Angiotensin receptor blockers in heart failure after the ELITE II trial. <b>2000</b> , 1, 79-82	4
2253	SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. <b>2000</b> , 3, 145-151	90
2252	Calcium antagonists, ACE inhibitors, and the risk of cancer in hypertensive patients. <b>2000</b> , 14, 285-6	3
2251	The renin-angiotensin system in the year 2000. <b>2000</b> , 14, 649-66	18
2250	Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. <b>2000</b> , 14, 749-63	160
2249	Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. <b>2000</b> , 14, 667-85	31
2248	Blocking the tissue renin-angiotensin system: the future cornerstone of therapy. <b>2000</b> , 14 Suppl 2, S23-31	7
2247	Cerebral complications of hypertension. <b>2000</b> , 14, 605-16	45
2246	Apoptosis in the vasculature: mechanisms and functional importance. <b>2000</b> , 130, 947-62	246
2245	Diabetes mellitus and coronary heart disease--from prevention to intervention: Part I. <b>2000</b> , 30, 351-9	8
2244	High salt intake and cardiovascular disease: is there a connection?. <b>2000</b> , 16, 662-4	9
2243	Cardiovascular risk in diabetes: a brief review. <b>2000</b> , 14, 108-15	68
2242	Diffuse coronary artery disease and endothelial dysfunction: form follows function. <b>2000</b> , 9, 19-25	
2241	Genesis of the normal and abnormal arterial pulse. <b>2000</b> , 25, 303-67	77
2240	Modern management of acute myocardial infarction. <b>2000</b> , 25, 677-782	8
2239	Current concepts and controversies in the pathogenesis, prevention, and treatment of the macrovascular complications of diabetes. <b>2000</b> , 135, 437-43	8

2238	Aldosterone, a new appreciation of its role in heart failure. <b>2000</b> , 20, 1107-15	7
2237	The role of the renin-angiotensin-aldosterone system in the management of heart failure. <b>2000</b> , 20, 368S-378S	5
2236	Practical issues in the treatment of patients with heart failure. <b>2000</b> , 20, 385S-391S	1
2235	Possible interaction between aspirin and ACE inhibitors: update on unresolved controversy. <b>2000</b> , 6, 313-318	4
2234	Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. <b>2000</b> , 410, 303-316	66
2233	Post-hospitalization management of high-risk coronary patients. <b>2000</b> , 85, 13B-20B	116
2232	Late-onset heart failure as a mechanism for adverse long-term outcome in diabetic patients undergoing revascularization (a 13-year report from the Lady Davis Carmel Medical Center registry). <b>2000</b> , 85, 1420-6	17
2231	Case 5: hypertension and coronary artery disease. <b>2000</b> , 85, 1039-40	1
2230	Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). <b>2000</b> , 86, 635-8	54
2229	Profiling risk from arrhythmic or hemodynamic death. <b>2000</b> , 86, 126K-132K	9
2228	Role of plaque rupture in acute coronary syndromes. <b>2000</b> , 86, 15J-23J	14
2227	The new directions in the understanding and management of acute coronary syndromes: general discussion. <b>2000</b> , 86, 51J-52J	
2226	An ischemia-guided approach for risk stratification in patients with acute coronary syndromes. <b>2000</b> , 86, 27M-35M	34
2225	Which antihypertensive drug classes have been shown to be beneficial? What are their benefits? A critique of hypertension treatment trials. <b>2000</b> , 14, 357-66	5
2224	Antiarrhythmic Impact of Anti-Ischemic, Anti-Failure and Other Cardiovascular Strategies. <b>2000</b> , 4, 194-205	2
2223	Beta-Blockers. <b>2000</b> , 4, 301-308	1
2222	Can we prevent congestive heart failure? Excerpts from a symposium. <b>2000</b> , 23, IV1-3	
2221	The anti-ischemic potential of angiotensin-converting enzyme inhibition: insights from the heart outcomes prevention evaluation trial. <b>2000</b> , 23, IV9-14	12

2220	Class effects and evidence-based medicine. <b>2000</b> , 23, IV15-9	18
2219	Coronary heart disease: clinical trials review. <b>2000</b> , 2, 189-93	1
2218	Perspectives on cardiac allograft vasculopathy. <b>2000</b> , 2, 259-71	18
2217	Development and assessment of antiatherosclerotic therapies beyond low-density lipoprotein cholesterol and blood pressure. <b>2000</b> , 2, 281-3	
2216	Percutaneous coronary intervention versus medical therapy for coronary heart disease. <b>2000</b> , 2, 290-6	5
2215	Endothelial function as a therapeutic target in coronary artery disease. <b>2000</b> , 2, 303-7	7
2214	Oxidative stress in congestive heart failure. <b>2000</b> , 2, 206-11	49
2213	Management of heart failure. <b>2000</b> , 2, 221-4	1
2212	Joint National Committee VI: individualized versus indiscriminate therapy for hypertension. <b>2000</b> , 2, 243-6	3
2211	Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?. <b>2000</b> , 2, 253-9	28
2210	Diastolic pressure, systolic pressure, or pulse pressure?. <b>2000</b> , 2, 271-9	35
2209	Effects of antihypertensive therapy on hypertensive vascular disease. <b>2000</b> , 2, 280-8	30
2208	Antihypertensive drug therapy in the third millennium: are there benefits beyond blood pressure?. <b>2000</b> , 2, 291-4	1
2207	Role of the sympathetic nervous system in human renovascular hypertension. <b>2000</b> , 2, 319-26	11
2206	The need to lower systolic blood pressure. <b>2000</b> , 2, 433-40	4
2205	Atherosclerotic renal artery stenosis: surgery, percutaneous transluminal angioplasty, or medical therapy?. <b>2000</b> , 2, 482-9	7
2204	The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure. <b>2000</b> , 2, 378-83	11
2203	Vasopeptidase inhibition: a new direction in cardiovascular treatment. <b>2000</b> , 2, 384-91	7

2202	Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. <b>2000</b> , 2, 402-11		40
2201	Studies examining risk reduction in subjects with multiple metabolic and cardiovascular risk factors. <b>2000</b> , 2, 129-31		
2200	Angiotensin-converting enzyme inhibitors in antihypertensive therapy. <b>2000</b> , 2, 165-6		1
2199	Postmenopausal hypertension. <b>2000</b> , 2, 202-7		31
2198	Transient Ischemic Attack and Secondary Stroke. <b>2000</b> , 2, 329-342		
2197	[Renin-angiotensin-aldosterone system and fibrinolysis]. <b>2000</b> , 95, 683-8		1
2196	The role of ACE inhibitors in the treatment of hypertensive elderly patients. <b>2000</b> , 33, 433-7		2
2195	Atherosclerosis-associated endothelial dysfunction. <b>2000</b> , 89 Suppl 9, IX/70-4		27
2194	ENS Communications. <b>2000</b> , 247, 729-749		
2193	CORRESPONDENCE. <b>2000</b> , 61, 289-289		
2192	Twenty questions on atherosclerosis. <b>2000</b> , 13, 139-43		7
2191	Antihypertensive Therapy and Vascular Protection. <b>2000</b> , 30, 1460		1
2190	Regular review: treatment possibilities for unstable angina. <b>2000</b> , 321, 1269-75		3
2189	Diabetic uraemia and haemodialytic treatments. <b>2001</b> , 131, 40-50		
2188	References. <b>2000</b> , 173, S83		
2187	ACE-Hemmer und arterielle Gefäßwand. <b>2000</b> , 20, 192-194		
2186	Antihypertensive therapy and the risk of type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 969-70	59.2	108
2185	Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. <b>2000</b> , 35, 1021-4		311

2184	The renin angiotensin system and cardiovascular disease: hope or hype?. <b>2000</b> , 1, 142-6	18
2183	The HOPE Study (Heart Outcomes Prevention Evaluation). <b>2000</b> , 1, 18-20	74
2182	Acute effects of ACE inhibition on coronary endothelial dysfunction. <b>2000</b> , 1, 361-4	13
2181	ACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease. <b>2000</b> , 1, 234-9	5
2180	Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. <b>2000</b> , 1, 151-8	18
2179	Replacement of the transmembrane anchor in angiotensin I-converting enzyme (ACE) with a glycosylphosphatidylinositol tail affects activation of the B2 bradykinin receptor by ACE inhibitors. <b>2000</b> , 275, 16110-8	66
2178	Clinical trials in cardiovascular medicine: are we looking for statistical significance or clinical relevance?. <b>2000</b> , 84, 129-33	2
2177	Improving patient outcomes in heart failure: evidence and barriers. <b>2000</b> , 84 Suppl 1, i8-10:discussion i50	17
2176	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. <b>2000</b> , 321, 412-9	1350
2175	Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). <b>2000</b> , 102, 1748-54	216
2174	J-shaped relation between blood pressure and stroke. <b>2000</b> , 35, E15; author reply E16	
2173	Physiology and pathophysiology of the adipose tissue renin-angiotensin system. <b>2000</b> , 35, 1270-7	385
2172	Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy. <b>2000</b> , 1, S17-20	1
2171	Genetic modifiers of atherosclerosis in mice. <b>2000</b> , 20, 2336-45	132
2170	How well are patients with atherosclerotic disease treated? Secondary prevention in primary care. <b>2000</b> , 18, 232-6	8
2169	Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. <b>2000</b> , 36, 523-30	36
2168	J-shaped relation between blood pressure and stroke. <b>2000</b> , 35, E16	
2167	There is a non-linear relationship between mortality and blood pressure. <b>2000</b> , 21, 1635-8	10



2166	Is more better? About dose levels of ACE inhibitors in chronic heart failure. <b>2000</b> , 21, 1902-3		1
2165	Heart failure and glucose abnormalities: an increasing combination with poor functional capacity and outcome. <b>2000</b> , 21, 1293-4		9
2164	C-reactive protein, inflammation and atherosclerosis: do we really understand it yet?. <b>2000</b> , 21, 958-60		13
2163	Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. <b>2000</b> , 93, 567-74		27
2162	Should the results of the HOPE study affect nephrological practice? For the HOPE investigators. <b>2000</b> , 15, 453-4		4
2161	Preventing sexual transmission of HIV--new ideas from sub-Saharan Africa. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 970-2	59.2	27
2160	ACE inhibition in cardiovascular disease. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 201-2	59.2	67
2159	Exercise--toning up the endothelium?. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 503-5	59.2	45
2158	Investigators' responsibilities for human subjects in developing countries. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 967-9	59.2	123
2157	Effect of ramipril on cardiovascular events in high-risk patients. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 64; author reply 66	59.2	23
2156	The Heart Outcomes Protection Evaluation (HOPE) study: relevance to ophthalmological practice?. <b>2000</b> , 14 ( Pt 1), 1-2		2
2155	Tackling myocardial infarction. <b>2000</b> , 38, 17-22		0
2154	Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. <b>2000</b> , 58, 828-36		105
2153	Impairment of cerebrovascular reactivity by methionine-induced hyperhomocysteinemia and amelioration by quinapril treatment. <b>2000</b> , 31, 2907-11		33
2152	Pharmacotherapy following myocardial infarction--a review of current treatment practices. <b>2000</b> , 1, 1105-16		4
2151	Clinical Trials: The HOPE Trial. <b>2000</b> , 9, 172-173		
2150	Gene therapy for hypertension and restenosis. <b>2000</b> , 1, 211-6		2
2149	Managing cardiovascular risk in patients with diabetes. <b>2000</b> , 84 Suppl 1, i23-5:discussion i50		

2148	Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond. <b>2000</b> , 1, S14-6	2
2147	Angiotensin II receptor subtypes in the skeletal muscle vasculature of patients with severe congestive heart failure. <b>2000</b> , 102, 2210-3	28
2146	To block the renin system or the calcium channel in hypertension--where do we stand?. <b>2000</b> , 1, 325-7	
2145	AT(1) receptor blockade and atherosclerosis : hopeful insights into vascular protection. <b>2000</b> , 101, 1496-7	25
2144	The past, present and future of hypertension management: a potential role for AT(1)-receptor antagonists. <b>2000</b> , 1, 5-10	12
2143	Current perspectives on the use of gene therapy for hypertension. <b>2000</b> , 87, 1118-22	20
2142	Vitamin E supplementation and cardiovascular events in high-risk patients. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 154-60	59.2 1573
2141	The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. <b>2000</b> , 21, 1440-9	134
2140	Variations in the care of elderly persons with diabetes among endocrinologists, general internists, and geriatricians. <b>2000</b> , 55, M601-6	21
2139	Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. <b>2000</b> , 1, 217-33	31
2138	Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?. <b>2000</b> , 1, S41-3	1
2137	The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). <b>2000</b> , 1, 328-35	103
2136	Insulin-like growth factor induces up-regulation of AT(1)-receptor gene expression in vascular smooth muscle cells. <b>2000</b> , 1, 273-7	19
2135	Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?. <b>2000</b> , 160, 1905-11	46
2134	Implantable cardioverter defibrillator therapy: the sickest patients benefit the most. <b>2000</b> , 101, 1638-40	97
2133	Evidence for oxidative activation of c-Myc-dependent nuclear signaling in human coronary smooth muscle cells and in early lesions of Watanabe heritable hyperlipidemic rabbits: protective effects of vitamin E. <b>2000</b> , 102, 2111-7	53
2132	Ongoing Clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction. <b>2000</b> , 1, 131-6	1
2131	Insulin resistance and cardiovascular disease. <b>2000</b> , 106, 453-8	791

2130	Impaired nitric oxide modulation of myocardial oxygen consumption in genetically cardiomyopathic hamsters. <b>2000</b> , 32, 2299-306	13
2129	Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. <b>2000</b> , 109, 371-7	47
2128	Interaction between aspirin and angiotensin-converting enzyme inhibitors: real or imagined. <b>2000</b> , 109, 431-3	12
2127	Diastolic heart failure: miles to go before we sleep. <b>2000</b> , 109, 683-5	14
2126	The HOPE study and diabetes. Heart Outcomes Prevention Evaluation. <b>2000</b> , 355, 1183; author reply 1183-4	3
2125	What does STOP-2 tell us about management of hypertension?. <b>2000</b> , 355, 652; author reply 653	1
2124	INSIGHT and NORDIL. International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Nordic Diltiazem Study. <b>2000</b> , 356, 1927; author reply 1928-9	1
2123	First-line antihypertensive therapy. <b>2000</b> , 356, 508-9	4
2122	HOPE and elderly patients attending geriatric day hospital. Heart Outcomes Prevention Evaluation Study. <b>2000</b> , 356, 511-2	1
2121	Diltiazem after thrombolysis. <b>2000</b> , 356, 1604-5	
2120	HOPE and extension of the indications for ACE inhibitors? Heart Outcomes Prevention Evaluation. <b>2000</b> , 355, 246-7	15
2119	Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. <b>2000</b> , 355, 688-700	379
2118	Diabetes--a common, growing, serious, costly, and potentially preventable public health problem. <b>2000</b> , 50 Suppl 2, S77-84	183
2117	Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. <b>2000</b> , 50, 231-9	25
2116	Potentiation of the effects of bradykinin on its receptor in the isolated guinea pig ileum. <b>2000</b> , 21, 1257-64	21
2115	Use of angiotensin-converting enzyme inhibitors and angiotensin II antagonists in renal transplantation: Delaying the progression of chronic allograft nephropathy?. <b>2000</b> , 14, 138-144	3
2114	Secondary prevention after myocardial infarction: reducing the risk of further cardiovascular events. <b>2000</b> , 4, 82-91	4
2113	Cilostazol improved walking distances and was safe in patients with intermittent claudication. <b>2000</b> , 4, 46	

2112 At The Bedside with Professor Karl Swedberg. **2000**, 4, 57-58

2111 Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. **2000**, 140, 727-50 142

2110 Genetics of coronary heart disease: current knowledge and research principles. **2000**, 140, S11-26 55

2109 Importance of microembolization and inflammation in atherosclerotic heart disease. **2000**, 140, S90-102 23

2108 Cholesterol and atherosclerosis. **2000**, 1529, 299-309 87

2107 Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. **2000**, 36, 646-61 1093

2106 Survival of renal transplant patients after first myocardial infarction: a look to the past and promises for the future. **2000**, 36, 211-3 1

2105 Introduction. **2000**, 36, S1-S3 3

2104 Rationale for angiotensin II receptor blockers in patients with low-renin hypertension. **2000**, 36, S24-30 52

2103 Postoperative drug therapy to extend survival after coronary artery bypass grafting. **2000**, 69, 1315-6 8

2102 Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. **2000**, 355, 1575-81 1159

2101 Dressing heart-failure patients on Savile Row--tailored treatment?. **2000**, 355, 2012-3 14

2100 Differences between blood-pressure-lowering drugs. **2000**, 356, 352-3 23

2099 Vasopeptidase inhibition and angio-oedema. **2000**, 356, 608-9 170

2098 Selection of initial antihypertensive drug therapy. **2000**, 356, 1942-3 23

2097 Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. **2000**, 356, 1949-54 290

2096 Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. **2000**, 356, 1955-64 1249

2095 Epidemiology and risk factors for heart failure in the elderly. **2000**, 16, 407-18 25

2094	Management of Hypertension in Patients with Diabetes Mellitus. <b>2000</b> , 7, 267-288	2
2093	High HOPEs for ramipril. <b>2000</b> , &NA,, 3	
2092	Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. <b>2000</b> , 36, 780-9	179
2091	Angiotensin I-converting enzyme: genotype and disease associations. <b>2000</b> , 2, 105-15	84
2090	Risks of coronary heart disease in women: current understanding and evolving concepts. <b>2000</b> , 75, 1289-303	29
2089	Therapeutic potential of ACE inhibitors for the treatment of hypertension in Type 2 diabetes. <b>2000</b> , 9, 2601-17	7
2088	Pharmacologic Update - ACE/Kininase II Inhibitors in Older Patients With Cardiovascular Diseases: "HOPE" Springs Eternal. <b>2000</b> , 9, 171-171	
2087	Angiotensin AT1 receptor over-expression in hypercholesterolaemia. <b>2000</b> , 32, 386-9	69
2086	Meccanismo d'azione degli inibitori del sistema renina-angiotensina. <b>2000</b> , 1, 79-83	
2085	Recomendaciones para la elecci3n del tratamiento farmacol3gico en la hipertensi3n arterial. <b>2000</b> , 17, 402-408	
2084	[Arterial hypertension: the better we know it, the worse we treat it]. <b>2000</b> , 114, 379-80	2
2083	[Renin-angiotensin system blockade reduces cardiovascular mortality and morbidity attributable to arterial hypertension by primary and secondary prevention. The end of the road?]. <b>2000</b> , 115, 178-80	3
2082	Use of ACE-inhibitors lowered the rate of mortality, reinfarction, and hospital readmission in patients with heart failure or left ventricular dysfunction. <b>2000</b> , 4, 74	
2081	Nifedipine, a calcium antagonist, was just as effective as co-amilozide, a diuretic, in preventing stroke, MI, heart failure or cardiovascular death in hypertensive patients. <b>2000</b> , 4, 101-103	
2080	Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. <b>2000</b> , 60, 975-83	32
2079	Zofenopril. <b>2000</b> , 20, 371-384	12
2078	Infarct Size as Assessed by Peak Enzyme Levels is Reduced in Patients Who are Using Angiotensin-Converting Enzyme Inhibitors at the Onset of Infarction. <b>2000</b> , 20, 415-423	1
2077	Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. <b>2000</b> , 36, 438-43	190

2076	Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature. <b>2000</b> , 36, 668-73	44
2075	How deadly is the "deadly quartet"? A post-CABG evaluation. <b>2000</b> , 36, 1159-65	36
2074	ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). <b>2000</b> , 36, 970-1062	73 <sup>1</sup>
2073	Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators. <b>2000</b> , 36, 2047-53	24
2072	Angiotensin-converting enzyme inhibitor treatment after myocardial infarction. A selective approach for maximum benefit. <b>2000</b> , 36, 2054-5	4
2071	Hypertension in menopausal women--a special case, for special treatment?. <b>2001</b> , 15, 397-405	4
2070	HOPE and MICRO-HOPE: review of the results and implications for people with diabetes. <b>2001</b> , 5, 41-44	1
2069	ACE-inhibitors have significant benefits for people with heart failure and left-ventricular dysfunction. <b>2001</b> , 5, 22-23	2
2068	Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. <b>2001</b> , 7, 221-8	68
2067	Cardiomyopathy and heart failure in diabetes. <b>2001</b> , 30, 1031-46	16
2066	Interaction between aspirin and ACE inhibitors in patients with heart failure. <b>2001</b> , 24, 167-82	16
2065	Antihypertensive therapy and cancer risk. <b>2001</b> , 24, 727-39	18
2064	Perindopril: an updated review of its use in hypertension. <b>2001</b> , 61, 867-96	48
2063	Pathophysiology of sodium and water retention in heart failure. <b>2001</b> , 96, 122-31	50
2062	Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. <b>2001</b> , 35, 376-85	139
2061	Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?. <b>2001</b> , 37, 1-8	112
2060	Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular function and no clinical heart failure. <b>2001</b> , 37, 1214-20	19
2059	Are all angiotensin-converting enzyme inhibitors interchangeable?. <b>2001</b> , 37, 1456-60	51

2058	A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. <b>2001</b> , 37, 1757-64	60
2057	ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) <sup>31</sup> This document was approved by the American College of Cardiology Board of Trustees in April 2001 and by the American Heart Association Science Advisory and Coordinating Committee in March 2001. <sup>32</sup> When citing this document, the American College of Cardiology and	86
2056	Angiotensin-converting enzyme inhibition is associated with reduced troponin release in , Jr, Dove non-ST-elevation acute coronary syndromes. <b>2001</b> , 38, 724-8 <sup>1</sup> , 37, 2239	23
2055	Potential of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. <b>2001</b> , 38, 1402-8	43
2054	Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. <b>2001</b> , 38, 1662-7	60
2053	AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. <b>2001</b> , 38, 1581-3	210
2052	Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. <b>2001</b> , 135, 73-87	713
2051	Medical treatment of peripheral arterial disease and claudication. <i>New England Journal of Medicine</i> , <b>2001</b> , 344, 1608-21	59.2 856
2050	Nota de la Redacci3. <b>2001</b> , 36, 304	
2049	Management of type 2 diabetes. Evolving strategies for treatment. <b>2001</b> , 28, 401-19, viii	1
2048	Variabilidad y coste de la terapia antihipertensiva. <b>2001</b> , 18, 364-373	
2047	Polypharmacy of heart failure. Creating a rational pharmacotherapeutic protocol. <b>2001</b> , 19, 583-96, viii	12
2046	Sr. Director. <b>2001</b> , 36, 303-304	
2045	[New diagnostic criteria for myocardial infarction: order in chaos]. <b>2001</b> , 54, 669-74	3
2044	Dermal neurovascular dysfunction in type 2 diabetes. <b>2001</b> , 24, 1468-75	115
2043	Importancia de tratar adecuadamente la hipertensi3 arterial. <b>2001</b> , 54, 133-135	1
2042	[Pathophysiological bases of unstable coronary syndrome]. <b>2001</b> , 26 Suppl 1, 2-8	1
2041	Economics of antihipertensive therapy in the elderly. <b>2001</b> , 18, 515-25	3

2040	Contemporary management of chronic stable angina. <b>2001</b> , 18, 109-21		8
2039	Improving Quality of Life for Patients with Angina Pectoris. <b>2001</b> , 9, 473-481		3
2038	Diabetes, hypertension, and cardiovascular disease: an update. <b>2001</b> , 37, 1053-9		906
2037	Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?. <b>2001</b> , 104, 1856-62		197
2036	Prevention of type 2 diabetes mellitus by changes in lifestyle. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 696; author reply 696-7	59.2	16
2035	Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 861-9	59.2	5467
2034	Beyond the usual strategies for blood pressure reduction: therapeutic considerations and combination therapies. <b>2001</b> , 3, 346-53		12
2033	Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with omapatrilat, a vasopeptidase inhibitor. <b>2001</b> , 3, 307-12		3
2032	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in combination: theory and practice. <b>2001</b> , 3, 383-7		10
2031	Management of high-risk hypertensive patients with diabetes: potential role of angiotensin II receptor antagonists. <b>2001</b> , 3, 225-35		2
2030	Book Review. <b>2001</b> , 3, 59-59		
2029	Ace-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats. <b>2001</b> , 33, 395-403		36
2028	Nitric oxide and atherosclerosis. <b>2001</b> , 5, 88-97		293
2027	Formulating clinical strategies for angiotensin antagonism: a review of preclinical and clinical studies. <b>2001</b> , 110, 471-80		10
2026	Medical therapy or coronary artery bypass graft surgery for chronic stable angina: an update using decision analysis. <b>2001</b> , 111, 89-95		18
2025	Optimizing medical management of patients with pre-end-stage renal disease. <b>2001</b> , 111, 559-68		11
2024	Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. <b>2001</b> , 104, 2673-8		1545
2023	Preoperative cardiac risk stratification: ritual or requirement?. <b>2001</b> , 15, 626-30		



2022 At the bedside. **2001**, 5, 69-70

2021 Cholesterol: an important but relatively overemphasized risk factor for ischemic heart disease. **2001**, 57, 593-601 5

2020 The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. **2001**, 141, S1-11 21

2019 ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. **2001**, 141, 800-7 34

2018 The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial. **2001**, 142, 375-7 15

2017 Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors. **2001**, 142, 577-85 37

2016 Diabetes mellitus: Relevance to dental treatment. **2001**, 91, 263-70 49

2015 Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway. **2001**, 104, 939-44 54

2014 Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure. **2001**, 3, S25-S28 5

2013 Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction. **2001**, 22, 953-62 8

2012 [Cerebral complications of hypertension in the elderly]. **2001**, 22, 959-68 7

2011 Cardiac mechanotransduction: from sensing to disease and treatment. **2001**, 22, 254-60 52

2010 Angiotensin-converting enzyme inhibitors. **2001**, 56, 13-75 44

2009 Insulin Resistance and Cardiovascular Disease. **2001**, 86, 713-718 193

2008 Current concepts of the pathogenesis of the acute coronary syndromes. **2001**, 104, 365-72 1205

2007 Risk of cardiovascular events associated with selective COX-2 inhibitors. **2001**, 286, 954-9 1193

2006 The kidney in diabetes: how to control renal and related cardiovascular complications. **2001**, 37, S2-6 17

2005 Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. **2001**, 37, 484-489 163

2004	Authors[rsquo ] reply.. <b>2001</b> , 37, 1322-1323	1
2003	Plasma renin activity and insulin resistance in African American and white children: the Bogalusa Heart Study. <b>2001</b> , 14, 212-7	19
2002	A glance back: one year into the millennium. <b>2001</b> , 14, 1-2	
2001	Rationalizing the treatment of hypertension. <b>2001</b> , 14, 3S-7S	6
2000	Diabetes and hypertension: how low should you go and with which drugs?. <b>2001</b> , 14, 17S-26S	9
1999	Low-dose combination therapy: the rationalization for an ACE inhibitor and a calcium channel blocker in higher risk patients. <b>2001</b> , 14, 8S-11S	12
1998	Angiotensin-converting enzyme inhibition to enhance vascular health--clinical and research models. <b>2001</b> , 14, 264S-269S	14
1997	Ongoing trials of angiotensin-converting enzyme inhibition: what they can tell us. <b>2001</b> , 14, 270S-275S	5
1996	Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. <b>2001</b> , 14, 963-8	64
1995	Calcium channel blockers in hypertension: reappraisal after new trials and major meta-analyses. <b>2001</b> , 14, 1074-81	22
1994	Diabetes mellitus and diabetes-associated vascular disease. <b>2001</b> , 12, 225-30	73
1993	Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. <b>2001</b> , 306, 1-17	301
1992	Optimal medical management of patients with chronic ischemic heart disease. <b>2001</b> , 47, 154-96	
1991	Therapeutic implications of inflammation in atherosclerotic cardiovascular disease. <b>2001</b> , 71, 2066-74	26
1990	Cardiopulmonary rehabilitation and cancer rehabilitation. 1. Cardiac rehabilitation. <b>2001</b> , 82, S47-S51	1
1989	Cardiopulmonary rehabilitation and cancer rehabilitation. 1. Cardiac rehabilitation. <b>2001</b> , 82, S47-S51	
1988	Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. <b>2001</b> , 357, 455-62	193
1987	Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. <b>2001</b> , 357, 995-1001	576

1986	Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. <b>2001</b> , 357, 1321-4	82
1985	Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. <b>2001</b> , 358, 1033-41	2580
1984	Cardiovascular protection and blood pressure reduction: a meta-analysis. <b>2001</b> , 358, 1305-15	753
1983	Vasopeptidase inhibitors. <b>2001</b> , 358, 1525-32	98
1982	The lowering of blood pressure after stroke. <b>2001</b> , 358, 1995-6	1
1981	Blood-pressure reduction and cardiovascular risk in HOPE study. <b>2001</b> , 358, 2130-1	195
1980	Perioperative cardiac complications. <b>2001</b> , 85, 1151-69, vi	13
1979	Early recognition and treatment of glucose abnormalities to prevent type 2 diabetes mellitus and coronary heart disease. <b>2001</b> , 76, 1137-43	10
1978	Diabetes mellitus and coronary heart disease. <b>2001</b> , 30, 857-81	36
1977	Prediction of cardiac mortality after myocardial infarction: the role of maximal treadmill stress echocardiography. <b>2001</b> , 14, 38-43	3
1976	Update in pharmacologic treatment of hypertension. <b>2001</b> , 19, 279-94, v	10
1975	Vitamin E supplementation in the prevention of coronary heart disease. <b>2001</b> , 76, 1131-6	41
1974	The looming polypharmacy crisis in the management of patients with heart failure. Potential solutions. <b>2001</b> , 19, 541-5	8
1973	Ensayos clínicos de morbimortalidad y utilización de fármacos antihipertensivos. <b>2001</b> , 18, 47-48	
1972	Hipertensión arterial (III). Aspectos diagnósticos y terapéuticos. <b>2001</b> , 13, 167-171	
1971	Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. <b>2001</b> , 104, 1863-7	420
1970	Diabetes and hypertension. <b>2001</b> , 10, 311-21	31
1969	Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 494-502	59.2 4999

1968	[Diabetes mellitus, inflammation and coronary atherosclerosis: current and future perspectives]. <b>2001</b> , 54, 751-63	19
1967	Step care therapy for hypertension in diabetic patients. <b>2001</b> , 76, 1266-74	8
1966	Adjunctive therapies in the treatment of acute coronary syndromes. <b>2001</b> , 76, 391-405	1
1965	SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. <b>2001</b> , 166, 1311-5	220
1964	[New pharmacological agents in heart failure]. <b>2001</b> , 54, 624-34	1
1963	Tratamiento de la insuficiencia cardíaca. Medidas preventivas. Factores de riesgo asociados. <b>2001</b> , 8, 1994-2000	
1962	[Rational prescribing and cost reduction in the treatment of arterial hypertension: a simulation exercise]. <b>2001</b> , 15, 327-35	2
1961	Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. <b>2001</b> , 10, 101-10	20
1960	Challenges for the prevention of primary and secondary stroke: the importance of lowering blood pressure and total cardiovascular risk. <b>2001</b> , 10, 344-51	23
1959	The renin-angiotensin system in the twenty-first century. <b>2001</b> , 10, 327-43	14
1958	Pharmacoeconomics of hypertension management: the place of combination therapy. <b>2001</b> , 19, 337-47	25
1957	Managing chronic stable angina needs understanding of the benefits or various treatment options. <b>2001</b> , 17, 10-15	
1956	What is the optimal blood pressure in patients with diabetes mellitus?. <b>2001</b> , 1, 173-7	2
1955	Antiatherosclerotic effects of ACE inhibitors: where are we now?. <b>2001</b> , 1, 315-20	7
1954	Cardiovascular consequences and management of high-normal blood pressure--more work needs to be done. <b>2001</b> , 10, 188-9	1
1953	Treatment of obesity hypertension and diabetes syndrome. <b>2001</b> , 38, 705-8	81
1952	Therapeutic potential of angiotensin II receptor antagonists. <b>2001</b> , 10, 1687-701	12
1951	Antihypertensive drugs. <b>2001</b> , 24, 233-245	

1950	Hypertension and diabetes: the scope of the problem. <b>2001</b> , 2, 25-31	11
1949	An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus. <b>2001</b> , 4, 199-204	3
1948	Pharmacotherapy of hypertension in patients with diabetes mellitus. <b>2001</b> , 2, 1805-16	4
1947	Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. <b>2001</b> , 10, 83-91	73
1946	Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. <b>2001</b> , 22, 554-72	628
1945	Angiotensin II and atherosclerosis: relevance for renal disease. <b>2001</b> , 135, 235-49	3
1944	Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. <b>2001</b> , 32, 1539-45	74
1943	Increased NAD(P)H oxidase and reactive oxygen species in coronary arteries after balloon injury. <b>2001</b> , 21, 739-45	128
1942	Angiotensin-converting enzyme inhibitors and progression of renal disease: evidence from clinical studies. <b>2001</b> , 135, 200-11	12
1941	Angiotensin-induced inflammation and vascular injury. <b>2001</b> , 135, 138-52	1
1940	Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. <b>2001</b> , 104, 2855-64	840
1939	Are ACE inhibitors a "magic bullet" against oxidative stress?. <b>2001</b> , 104, 1571-4	196
1938	Insulin resistance and cardiovascular disease. <b>2001</b> , 86, 713-8	357
1937	Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. <b>2001</b> , 103, 799-805	308
1936	Akuter Myokardinfarkt bei Patienten mit Diabetes mellitus. <b>2001</b> , 21, 176-185	
1935	Clinical approach to the patient with thrombosis. <b>2001</b> , 261-278	1
1934	Antiplatelet treatment in peripheral arterial disease. <b>2001</b> , 458-470	
1933	The impact of heart failure on prognosis of diabetic and non-diabetic patients with myocardial infarction: a 15-year follow-up study. <b>2001</b> , 3, 83-90	19

1932	The role of angiotensin receptor blockers in the management of chronic heart failure. <b>2001</b> , 161, 667-72	21
1931	Guidelines for the management of hypertension for general practitioners. <b>2001</b> , 24, 613-34	109
1930	Selection of antihypertensive therapy for patients with hypertensive renal disease. <b>2001</b> , 285, 2774-6	5
1929	Long-Term Treatment with Angiotensin-Converting Enzyme Inhibitors, Beta-Blockers or a Combination of Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers in Low-Risk Patients after Acute Myocardial Infarction: The ABC Study. <b>2001</b> , 1, 20-25	
1928	The kidney in cardiovascular disease. <b>2001</b> , 134, 707-9	21
1927	Vascular smooth muscle growth: autocrine growth mechanisms. <b>2001</b> , 81, 999-1030	305
1926	A Comparison of Clinical Outcomes and Risks for Major Adverse Cardiac Events between the Pre- and Post-Stent Period. <b>2001</b> , 31, 1123	
1925	Should all patients with heart failure now receive an ACE inhibitor. <b>2001</b> , 3, 635-6	1
1924	Proposed Cardiovascular Risk Assessment Algorithm Using High-Sensitivity C-Reactive Protein and Lipid Screening. <b>2001</b> , 47, 28-30	151
1923	Antihypertensive drugs and monitoring. <b>2001</b> , 12, 369-371	1
1922	Undertreatment of Cardiac Risk Factors in Adolescents with Renal Failure. <b>2001</b> , 21, 285-289	6
1921	Docetaxel induced cardiotoxicity. <b>2001</b> , 86, 219	19
1920	Geriatric medicine. <b>2001</b> , 322, 86-89	7
1919	Rapid assessment of chest pain. <b>2001</b> , 323, 586-7	13
1918	Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. <b>2001</b> , 281, H2337-65	187
1917	What are the elements of good treatment for hypertension?. <b>2001</b> , 322, 1107-9	20
1916	ACE inhibitor-induced angioedema of the intestine: Case report, incidence, pathophysiology, diagnosis and management. <b>2001</b> , 15, 827-32	27
1915	Editorial note. <b>2001</b> , 3, 322	

1914	Coronary capillary remodeling in non-insulin-dependent diabetic rats: amelioration by inhibition of angiotensin converting enzyme and its potential clinical implications. <b>2001</b> , 24, 75-81	12
1913	Non-AT(1)-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. <b>2001</b> , 2, 103-6	34
1912	Angiotensin II-receptor blockers: clinical relevance and therapeutic role. <b>2001</b> , 58, 671-83	36
1911	Guidelines for management of patients with chronic heart failure in Australia. <b>2001</b> , 174, 459-66	37
1910	Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications. <b>2001</b> , 109, 115-22; quiz 9	3
1909	Should angiotensin-converting enzyme inhibitors be added to the water supply of patients with diabetes?. <b>2001</b> , 7, 59-61	2
1908	Selective reporting of pharmaceutical data leads major medical journals to change editorial policy. <b>2001</b> , 3, 321-2	2
1907	Quality indicators for the management of heart failure in vulnerable elders. <b>2001</b> , 135, 694-702	18
1906	Heart failure in older people: the epidemic we had to have. <b>2001</b> , 174, 432-3	6
1905	Containing the costs of managing hypertension. <b>2001</b> , 174, 556-7	1
1904	On Not Being the Last to Give Up the Old or the First to Adopt the New. <b>2001</b> , 38, 759-760	1
1903	Beyond remodeling: a new paradigm for angiotensin-converting enzyme inhibitors following myocardial infarction. <b>2001</b> , 37 Suppl 1, S31-4	3
1902	Diabetes and coronary artery disease--therapy and outcomes. <b>2001</b> , 12, 149-52	2
1901	Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy?. <b>2001</b> , 10, 617-24	32
1900	Prediction of Difficult Mask Ventilation. <b>2001</b> , 45, 233-234	1
1899	Lower Extremity Neuropathies Associated with Lithotomy Positions. <b>2001</b> , 45, 235-236	
1898	Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. <b>2001</b> , 37 Suppl 1, S21-30	46
1897	Treatment of heart failure: state of the art and prospectives. <b>2001</b> , 38 Suppl 2, S59-63	7

1896	Endothelial function and coronary artery disease. <b>2001</b> , 12, 383-9	272
1895	Is there a place for combining angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure?. <b>2001</b> , 10, 643-8	9
1894	. <b>2001</b> , 8, 257-264	5
1893	ABCs of cardiovascular disease risk management. <b>2001</b> , 9, 96-105	13
1892	Medical management of peripheral arterial disease. <b>2001</b> , 9, 238-45	44
1891	Perioperative Care of the Diabetic Patient. <b>2001</b> , 29, 1-9	9
1890	The Use of Dexamethasone for Preventing Postoperative Nausea and Vomiting in Females Undergoing Thyroidectomy: A Dose-Ranging Study. <b>2001</b> , 45, 237-238	
1889	Current strategies and perspectives for correcting endothelial dysfunction in atherosclerosis. <b>2001</b> , 38 Suppl 2, S35-41	17
1888	Coronary vascular endothelial function and myocardial ischemia: why should we worry about endothelial dysfunction?. <b>2001</b> , 12, 475-84	11
1887	Practice Advisory for the Prevention of Perioperative Peripheral Neuropathies: A Report by the American Society of Anesthesiologists Task Force on Prevention of Perioperative Peripheral Neuropathies. <b>2001</b> , 45, 234-235	1
1886	Analysis of Risk Factors for Myocardial Infarction and Cardiac Mortality After Major Vascular Surgery. <b>2001</b> , 45, 238-239	
1885	Adjunctive Therapies in the Treatment of Acute Coronary Syndromes. <b>2001</b> , 76, 391-405	8
1884	Nutraceuticals: vitamins and other nutrients in coronary heart disease. <b>2001</b> , 12, 639-46	24
1883	Implications from the Heart Outcomes Prevention Evaluation Study. <b>2001</b> , 10, 61-3	
1882	Oxidative stress and vascular damage in hypertension. <b>2001</b> , 10, 247-55	109
1881	Antihypertensive drug therapy in older patients. <b>2001</b> , 10, 263-9	4
1880	Hypertension trials: 1990 to 2000. <b>2001</b> , 10, 501-5	8
1879	Evolving strategies for renoprotection: non-diabetic chronic renal disease. <b>2001</b> , 10, 523-31	8



1878	Prognostic implications of endothelial dysfunction: does it mean anything?. <b>2001</b> , 12, 435-43	32
1877	The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?. <b>2001</b> , 10, 597-601	19
1876	Recurring Brachial Plexus Neuropathy in a Diabetic Patient After Shoulder Surgery and Continuous Interscalene Block. <b>2001</b> , 45, 236-237	
1875	Vasopeptidase Inhibitors: A New Class of Drugs. <b>2001</b> , 1, 96-102	1
1874	Commentary: Clinical Research on Older Adults in Canada. <b>2001</b> , 20, 17-20	1
1873	Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors. <b>2001</b> , 38 Suppl 3, S3-11	14
1872	Diabetes and all-cause and coronary heart disease mortality among US male physicians. <b>2001</b> , 161, 242-7	141
1871	Initial antihypertensive therapy. What are the current drugs of choice?. <b>2001</b> , 110, 39-40, 43-4, 47-8 passim	13
1870	Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. <b>2001</b> , 16, 459-68	104
1869	Quality of medical care and excess mortality in older patients with mental disorders. <b>2001</b> , 58, 565-72	353
1868	Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction. <b>2001</b> , 161, 538-44	36
1867	Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors. <b>2001</b> , 11 Suppl 1, 85-95	29
1866	Acute myocardial infarction: patent or die?. <b>2001</b> , 62, 590-1	
1865	Interventions for deliberately altering blood pressure in acute stroke. <b>2000</b> , CD000039	13
1864	Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. <b>2001</b> , 100, 13-17	48
1863	Losartan, an angiotensin type 1 receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. <b>2001</b> , 100, 13	19
1862	Endstage renal disease owing to diabetic nephropathy in Mississippi: an examination of factors influencing renal survival in a population prone to late referral. <b>2001</b> , 49, 284-91	19
1861	Ischaemic Heart Disease. <b>2001</b> ,	0

1860	Do we Know How to Diagnose Diabetes and do we Need to Screen for the Disease?. 3-21	
1859	ACE inhibitors for 'diastolic' heart failure? reasons not to jump to premature conclusions about the efficacy of ACE inhibitors among older patients with heart failure. <b>2001</b> , 3, 637-9	6
1858	Small artery remodeling in hypertension: can it be corrected?. <b>2001</b> , 322, 7-11	27
1857	Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension. <b>2001</b> , 135, 1074-8	34
1856	Diagnosis and management of stable coronary artery disease. <b>2001</b> , 3, 781-800	
1855	Management of acute coronary syndromes. <b>2001</b> , 3, 817-855	
1854	The clinical implication of tissue renin angiotensin systems. <b>2001</b> , 16, 317-27	34
1853	Cardiovascular Risk Management in Type 2 Diabetes: From Clinical Trials to Clinical Practice. <b>2001</b> , 11, 474-490	5
1852	Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?. <b>2001</b> , 10, 625-31	25
1851	Antioxidant vitamins and enzymatic and synthetic oxygen-derived free radical scavengers in the prevention and treatment of cardiovascular disease. <b>2001</b> , 3, 28-45	33
1850	Lercanidipine: a novel dihydropyridine calcium-channel blocker. <b>2001</b> , 3, 398-407	30
1849	Reversal of endothelial dysfunction in humans. <b>2001</b> , 12, 463-73	13
1848	Vascular complications in diabetes and their prevention. <b>2001</b> , 6, 249-55	32
1847	Effects of Verapamil on Top of Trandolapril on Exercise Tolerance and Cardiac Performance in Patients with Hypertension and Reduced Left Ventricular Function. <b>2001</b> , 1, 310-319	
1846	Reducing cardiovascular risk in diabetes. Which factors to modify first?. <b>2001</b> , 109, 26-30, 33-6	10
1845	Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards. <b>2001</b> , 161, 1145-58	41
1844	Vascular Effects of ACE Inhibition Independent of the Renin-Angiotensin System in Hypertensive Renovascular Disease : A Randomized, Double-Blind, Crossover Trial. <b>2001</b> , 37, 40-45	10
1843	Current world literature. <b>2001</b> , 14, 93-125	

1842	Choice of drug treatment for obesity-related hypertension: where is the evidence?. <b>2001</b> , 19, 667-74	63
1841	Current World Literature. <b>2001</b> , 12, 439-454	
1840	Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors. <b>2001</b> , 103, 346-7	22
1839	AHA Science Advisory. Wine and your heart: A science advisory for healthcare professionals from the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association. <b>2001</b> , 32, 591-4	10
1838	Angiotensin AT(1) receptor stimulates heat shock protein 27 phosphorylation in vitro and in vivo. <b>2001</b> , 38, 1260-5	25
1837	Current World Literature. <b>2001</b> , 10, 271-293	
1836	Current World Literature. <b>2001</b> , 10, 453-480	
1835	[Treatment of hypertension in obesity]. <b>2001</b> , 26, 209-21	1
1834	[Secondary prevention after cardiac infarct; therapeutic efficiency--cost-benefit ratio]. <b>2001</b> , 42, 713-9	0
1833	[Drug therapy of arterial hypertension. Results of new intervention studies]. <b>2001</b> , 42, 1610-8	1
1832	The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. <b>2001</b> , 79, 21-9	135
1831	Prevention of strokes. <b>2001</b> , 3, 321-7	5
1830	Anticoagulation and heart failure. <b>2001</b> , 3, 72-7	3
1829	Differences in outcome between percutaneous coronary intervention and coronary bypass grafting. <b>2001</b> , 3, 173-4	
1828	Pathophysiology and treatment of the dyslipidemia of insulin resistance. <b>2001</b> , 3, 416-23	22
1827	Implications of recent heart failure trials for patients with hypertension. <b>2001</b> , 3, 504-10	7
1826	The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension. <b>2001</b> , 3, 511-8	7
1825	Drugs for cardiovascular risk reduction in the diabetic patient. <b>2001</b> , 1, 133-9	4

1824	Treatment of hypertension in diabetic patients with nephropathy. <b>2001</b> , 1, 251-60	6
1823	Health outcomes associated with calcium antagonists. <b>2001</b> , 3, 228-9	
1822	What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?. <b>2001</b> , 3, 422-8	8
1821	Antioxidants and endothelial dysfunction in hyperlipidemia. <b>2001</b> , 3, 53-60	50
1820	Angiotensin, inflammation, hypertension, and cardiovascular disease. <b>2001</b> , 3, 61-7	46
1819	Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes. <b>2001</b> , 3, 340-9	4
1818	The antiatherogenic effects of antihypertensive treatment: trials completed and ongoing. <b>2001</b> , 3, 350-9	13
1817	Lessons learned from prematurely terminated clinical trials. <b>2001</b> , 3, 360-6	2
1816	Choices in medical management for prevention of acute ischemic stroke. <b>2001</b> , 1, 33-8	3
1815	Renal Artery Stenosis. <b>2001</b> , 3, 187-194	2
1814	Coronary Artery Disease in Postmenopausal Women. <b>2001</b> , 3, 67-79	5
1813	[The anti-atherogenic mechanism of action of physical training in patients with coronary heart disease]. <b>2001</b> , 90, 799-806	3
1812	Hope of microHope. <b>2001</b> , 39, 72-74	
1811	Debate: does it matter how you lower blood pressure?. <b>2001</b> , 2, 63-66	3
1810	No effects on myocardial ischaemia in patients with stable ischaemic heart disease after treatment with ramipril for 6 months. <b>2001</b> , 2, 99-105	3
1809	How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial. <b>2001</b> , 2, 151-155	
1808	Dose response of ACE inhibitors: implications of the SECURE trial. <b>2001</b> , 2, 155-159	8
1807	Diuretics: again the first step in the treatment of most patients with hypertension. <b>2001</b> , 2, 244-248	5

1806	Comments on ALLHAT and doxazosin. <b>2001</b> , 2, 254-256	7
1805	Coronary artery disease in uremia: Etiology, diagnosis, and therapy. <b>2001</b> , 60, 2059-78	73
1804	Renoprotection: one or many therapies?. <b>2001</b> , 59, 1211-26	120
1803	How important is atheromatous renal artery stenosis as a cause of end-stage renal disease?. <b>2001</b> , 14, 143-5	7
1802	Factors influencing survival of diabetic patients after initiation of renal replacement therapy. <b>2001</b> , 6, 79-84	1
1801	Multiple risk factor intervention in type 2 diabetes: an opportunity not to be missed. <b>2001</b> , 3, 1-8	8
1800	Insulin resistance and beta-cell dysfunction as therapeutic targets in type 2 diabetes. <b>2001</b> , 3, 219-29	8
1799	Coronary heart disease: pathophysiological events and risk factors. <b>2001</b> , 26, 213-218	3
1798	Use of beta-blockers in obesity hypertension: potential role of weight gain. <b>2001</b> , 2, 275-80	63
1797	Interactions between sodium and angiotensin. <b>2001</b> , 28, 1070-3	11
1796	Blood pressure lowering in diabetes: a brief review of the current evidence and description of a new trial. <b>2001</b> , 28, 1108-11	6
1795	Progress in reducing the burden of stroke. <b>2001</b> , 28, 1091-5	8
1794	Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes. <b>2001</b> , 26, 351-61	14
1793	A critique of hypertension treatment trials and of their evaluation. <b>2001</b> , 7, 149-64	7
1792	Diabetes mellitus--a more solid ground for treatment. <b>2001</b> , 249, 391-3	2
1791	Episodes of ST-segment depression is related to changes in ambulatory blood pressure and heart rate in intermittent claudication. <b>2001</b> , 250, 398-405	8
1790	How large studies may mislead: the HOPE Study. <b>2001</b> , 18, 208-211	9
1789	Dyslipidaemia and diabetes. <b>2001</b> , 18, 201-207	10

1788	10. Normo-osmolar, non-ketotic, hyponatraemic hyperglycaemia associated with impaired renal function. <b>2001</b> , 18, 211-211		
1787	N-3 to n-6 fatty acids for managing hyperlipidemia, diabetes, hypertension and atherosclerosis: Is there evidence?. <b>2001</b> , 103, 407-418		3
1786	High n-6 to n-3 ratio of dietary fatty acids rather than serum cholesterol as a major risk factor for coronary heart disease. <b>2001</b> , 103, 418-422		24
1785	[Hypoglycemia risk factors. Long term complications of poorly controlled diabetics]. <b>2001</b> , 30, 108-16		
1784	Der schmale Grat zwischen Prävention und Placebo: Nahrungsergänzungsmittel. <b>2001</b> , 31, 367-375		1
1783	Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 851-60	59.2	4418
1782	Hypertension in the elderly. <b>2001</b> , 33, 563-9		8
1781	Heart failure therapy at the turn of the century. <b>2001</b> , 6, 7-14		12
1780	The role of ACE-inhibitors in patients with coronary artery disease. <b>2001</b> , 15, 103-5		
1779	The EUROPA trial: design, baseline demography and status of the substudies. <b>2001</b> , 15, 169-79		34
1778	Angiotensin converting enzyme inhibitors and restenosis: let's stop teasing ourselves. <b>2001</b> , 15, 293-5		
1777	Gender and drug treatment as determinants of mortality in a cohort of heart failure patients. <b>2001</b> , 17, 329-35		3
1776	Myocardial infarction in patients with normal coronary arteries: proposed pathogenesis and predisposing risk factors. <b>2001</b> , 11, 11-7		3
1775	Serial changes on quantitative myocardial perfusion SPECT in patients undergoing revascularization or conservative therapy. <b>2001</b> , 8, 428-37		25
1774	Use of cardiovascular drugs by home-dwelling coronary patients aged 75 years and older. A population-based cross-sectional survey in Helsinki, Finland. <b>2001</b> , 57, 513-6		15
1773	Metabolic and hemodynamic response of adipose tissue to angiotensin II. <b>2001</b> , 9, 486-91		51
1772	ACE inhibitors for all--'Hope' for the heart and failure for the kidneys?. <b>2001</b> , 15, 147-51		0
1771	Why are thiazide diuretics declining in popularity?. <b>2001</b> , 15, 287-9		5

1770	Peripheral vascular disease and hypertension: a forgotten association?. <b>2001</b> , 15, 447-54	49
1769	Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension. <b>2001</b> , 15, 559-65	12
1768	ACE inhibitors in vascular disease: some PROGRESS, more HOPE. <b>2001</b> , 15, 833-5	9
1767	Cardiovascular monitoring and therapy for HIV-infected patients. <b>2001</b> , 946, 236-73	14
1766	The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. <b>2001</b> , 87, 1058-63	192
1765	Angiotensin, fibrinolysis, and vascular homeostasis. <b>2001</b> , 87, 18C-24C	48
1764	Angiotensin II and atherosclerosis. <b>2001</b> , 87, 25C-32C	138
1763	Guidelines for interpretation of electron beam computed tomography calcium scores from the Dallas Heart Disease Prevention Project. <b>2001</b> , 87, 1387-8	5
1762	The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. <b>2001</b> , 88, 1L-20L	164
1761	Why vascular biology matters. <b>2001</b> , 88, 5K-9K	72
1760	Inflammatory pathways in atherosclerosis and acute coronary syndromes. <b>2001</b> , 88, 10K-15K	181
1759	Effect of lipid-lowering agents, angiotensin-converting enzyme inhibitors, and calcium antagonists on coronary disease risk. <b>2001</b> , 88, 21M-25M	6
1758	Oxidative pathways in cardiovascular disease: roles, mechanisms, and therapeutic implications. <b>2001</b> , 89, 187-206	166
1757	Obtaining event status at the close of the Treatment of Mild Hypertension Study: methods and implication for other trials. <b>2001</b> , 22, 56-61	2
1756	[Drug prospects in the treatment of heart insufficiency]. <b>2001</b> , 50, 38-49	1
1755	Protection against ischemia: a physiological function of the renin-angiotensin system. <b>2001</b> , 62, 261-71	44
1754	What is the optimal medical management of ischemic heart failure?. <b>2001</b> , 43, 433-55	19
1753	An evidence-based review of the resting electrocardiogram as a screening technique for heart disease. <b>2001</b> , 44, 55-67	50

1752	Statistical significance versus clinical relevance in cardiovascular medicine. <b>2001</b> , 44, 155-67	11
1751	Optimal medical management of patients with chronic ischemic heart disease. <b>2001</b> , 26, 189-238	
1750	Manipulating the vascular biology of coronary atherosclerosis in diabetes: new opportunities. <b>2001</b> , 137, 82-92	1
1749	[Pathophysiology and therapeutic aspects of left ventricular "remodeling" in the post-infarct phase]. <b>2001</b> , 28, 117-22	
1748	Proteinuria and cardiovascular disease. <b>2001</b> , 38, S8-S13	34
1747	Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. <b>2001</b> , 38, 1245-50	53
1746	Achieving maximal renal protection in nondiabetic chronic renal disease. <b>2001</b> , 38, 1365-71	12
1745	Current therapeutic algorithms for type 2 diabetes. <b>2001</b> , 4, 38-49	3
1744	Pharmacotherapy in congestive heart failure: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in congestive heart failure: do they differ in their renal effects in man?. <b>2001</b> , 7, 156-161	2
1743	Pharmacotherapy in congestive heart failure. Prematurely terminated clinical trials and their application to cardiovascular medicine. <b>2001</b> , 7, 265-271	3
1742	Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines. <b>2001</b> , 21, 954-87	2
1741	Quantifying the interaction between angiotensin-converting enzyme inhibitors and aspirin: are we using the right method?. <b>2001</b> , 21, 1247-9	1
1740	Diabetes. <b>2001</b> , 59, 159-72	4
1739	The acute management of myocardial infarction. <b>2001</b> , 59, 89-112	1
1738	Elevated blood alcohol and risk of injury among bicyclists. <b>2001</b> , 285, 2445-6	1
1737	Effects of vitamin E on lipid peroxidation in healthy persons. <b>2001</b> , 285, 1178-82	195
1736	Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. <b>2001</b> , 24, 919-24	27
1735	Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. <b>2001</b> , 38, E28-32	329



1734	Workshop: mechanisms and cardiovascular damage in hypertension. <b>2001</b> , 37, 594-8	56
1733	The HOPE Study and MICRO-HOPE Substudy: effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. <b>2001</b> , 1, 44-51	5
1732	Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management. <b>2001</b> , 85, E9	28
1731	What is the optimal medical management of ischaemic heart failure?. <b>2001</b> , 59, 135-58	5
1730	Ramipril and the development of diabetes. <b>2001</b> , 286, 1882-5	390
1729	Health benefits of breastfeeding promotion. <b>2001</b> , 285, 2446-7	4
1728	Increased risk for ischaemic events is related to combined RAS polymorphism. <b>2001</b> , 85, 458-62	18
1727	Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2001</b> , 24, 654-8	30
1726	Signal transduction mechanisms of the angiotensin II type AT(1)-receptor: looking beyond the heterotrimeric G protein paradigm. <b>2001</b> , 2, 4-10	26
1725	Diabetes, hypertension, and cardiovascular disease: an update. <b>2001</b> , 38, E11	4
1724	Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. <b>2001</b> , 88, 298-304	111
1723	Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease: Can we afford to do it? (Can we afford not to?). <b>2001</b> , 104, 1564-70	41
1722	Amoebic encephalitis due to <i>Sappinia diploidea</i> . <b>2001</b> , 285, 2450-1	71
1721	Kinins, receptors, kininases and inhibitors--where did they lead us?. <b>2001</b> , 382, 43-7	38
1720	Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. <b>2001</b> , 38, 1150-7	103
1719	Prevention of stroke. <b>2001</b> , 8, 257-64	3
1718	Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. <b>2001</b> , 2, S1-73	267
1717	From endothelial dysfunction to clinical events Concept and update on the ENCORE trials. <b>2001</b> , 3, B12-B19	2

1716	Elevated levels of plasma von Willebrand factor and the risk of macro- and microvascular disease in type 2 diabetic patients with microalbuminuria. <b>2001</b> , 16, 2028-33	13
1715	Treatment patterns in stable angina: objectives and reality. <b>2001</b> , 3, O8-O11	
1714	Have we jugulated the epidemic of heart failure? One swallow does not make a summer. <b>2001</b> , 22, 188-90	3
1713	Specific organ protection by blocking the renin-angiotensin system. <b>2001</b> , 16 Suppl 6, 40-2	36
1712	Lessons from the recent trials on hypertension treatment. <b>2001</b> , 16 Suppl 6, 43-5	1
1711	Advances in nephrology: successes and lessons learnt from diabetes mellitus. <b>2001</b> , 16 Suppl 7, 46-50	5
1710	Increased QT dispersion with the D-allele of the ACE polymorphism. <b>2001</b> , 22, 618-21	0
1709	The HOPE study: comparison with other trials of secondary prevention. <b>2001</b> , 22, 1307-10	13
1708	Why patients with heart failure die. <b>2001</b> , 22, 1523-4	
1707	The Denolin lecture. Congestive heart failure: a half century perspective. <b>2001</b> , 22, 825-36	33
1706	Does it matter where you go with an acute myocardial infarction?. <b>2001</b> , 22, 1764-6	4
1705	Treatment of stable angina pectoris: is there a role for dipyridamole?. <b>2001</b> , 22, 1762-4	1
1704	Molecular interactions of vasoactive systems in cardiovascular damage. <b>2001</b> , 38 Suppl 2, S7-9	13
1703	Angiotensin II subtype 1 receptor blockers and renal function. <b>2001</b> , 161, 1492-9	47
1702	Current approaches to therapy for vascular injury. <b>2001</b> , 2, 753-64	
1701	Clinical differences among angiotensin II receptor antagonists. <b>2001</b> , 2, 19-24	7
1700	Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. <b>2001</b> , 38, 932-7	975
1699	Clinical practice. Extracranial carotid stenosis. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1113-8	59.2 70

1698	Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. <b>2001</b> , 22, 1601-12	38
1697	Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. <b>2001</b> , 22, 2085-103	84
1696	Organizing diabetes care: identify, monitor, prioritize, intensify. <b>2001</b> , 24, 1515-6	9
1695	Blood pressure and inflammation in apparently healthy men. <b>2001</b> , 38, 399-403	521
1694	Angiotensin II type 1 receptor blockers. <b>2001</b> , 103, 904-12	401
1693	AHA Science Advisory: Wine and your heart: a science advisory for healthcare professionals from the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association. <b>2001</b> , 103, 472-5	163
1692	A cardiac prevention and rehabilitation programme for all patients at first presentation with coronary artery disease. <b>2001</b> , 85, 533-8	13
1691	Matching the right drug to the right patient in essential hypertension. <b>2001</b> , 86, 113-20	19
1690	Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice. <b>2001</b> , 103, 3123-8	63
1689	Noninvasive assessment of the diabetic patient for coronary artery disease. <b>2001</b> , 24, 1519-21	14
1688	Twenty-first century phox: not yet ready for widespread screening. <b>2001</b> , 103, 7-9	21
1687	Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2001</b> , 37, 19-27	87
1686	Blood pressure control and benefits of antihypertensive therapy: does it make a difference which agents we use?. <b>2001</b> , 38, 537-42	31
1685	Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. <b>2001</b> , 24, 2091-6	200
1684	Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. <b>2001</b> , 37, 250-4	229
1683	Current perspective on the role of apoptosis in atherothrombotic disease. <b>2001</b> , 88, 998-1003	146
1682	Cross sectional study estimating prevalence of heart failure and left ventricular systolic dysfunction in community patients at risk. <b>2001</b> , 86, 172-8	43
1681	Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen. <b>2001</b> , 21, 1071-7	30

1680	Blood pressure and stroke; the PROGRESS trial. <b>2001</b> , 2, 153-5	2
1679	Attenuated myocardial vasodilator response in patients with hypertensive hypertrophy revealed by oxygenation-dependent magnetic resonance imaging. <b>2001</b> , 104, 1214-7	52
1678	Prothrombotic megakaryocyte and platelet changes in hypertension are reversed following treatment: a pilot study. <b>2001</b> , 12, 144-9	31
1677	Cost effectiveness of ramipril treatment for cardiovascular risk reduction. <b>2001</b> , 85, 539-43	26
1676	Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. <b>2001</b> , 104, 1615-21	439
1675	Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. <b>2001</b> , 104, 1985-91	248
1674	A single (investigator)-blind randomised control trial comparing the effects of quinapril and nifedipine on platelet function in patients with mild to moderate hypertension. <b>2001</b> , 12, 274-8	12
1673	Heart failure in the 21st century: a cardiogeriatric syndrome. <b>2001</b> , 56, M88-96	127
1672	Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. <b>2001</b> , 86, 217-20	9
1671	Glycemic control and heart failure among adult patients with diabetes. <b>2001</b> , 103, 2668-73	542
1670	Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. <b>2001</b> , 103, 987-92	836
1669	Paradoxical regulation of short promoter human renin transgene by angiotensin ii. <b>2001</b> , 37, 403-7	11
1668	Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. <b>2001</b> , 37, 587-93	89
1667	The Year in Review: Cardiology. <b>2001</b> , 14, 18-40	
1666	Diabetic heart disease: clinical considerations. <b>2001</b> , 85, 463-9	24
1665	Angiotensin II receptor blockers and cardiovascular outcomes: the evidence now and in the future. <b>2001</b> , 2 Suppl 2, S12-6	4
1664	Diabetic cardiomyopathy: fact or fiction?. <b>2001</b> , 85, 247-8	83
1663	Left ventricle and arteries: structure, function, hormones, and disease. <b>2001</b> , 37, 346-9	15

1662	Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. <b>2001</b> , 103, 448-54	313
1661	Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. <b>2001</b> , 37, 1047-52	664
1660	Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. <b>2001</b> , 104, 522-6	157
1659	The real cost of aspirin. <b>2001</b> , 77, 423	1
1658	Mediators of chronic heart failure: how drugs work. <b>2001</b> , 35, 1066-74	2
1657	Incidence of Dementia and Alzheimer Disease in Nigeria and the United StatesReply. <b>2001</b> , 285, 2448	1
1656	Informed choice in cancer screening. <b>2001</b> , 285, 2776-8	33
1655	Inflammatory markers in coronary artery disease: let prevention douse the flames. <b>2001</b> , 286, 2154-6	34
1654	Prevention of atherosclerosis by specific AT1-receptor blockade with candesartan cilexetil. <b>2001</b> , 2, S77-S80	2
1653	Vitamin E Supplementation in Healthy PersonsReply. <b>2001</b> , 285, 2449	
1652	Translation of genomic research into health care. <b>2001</b> , 285, 2447-8	6
1651	Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications. <b>2001</b> , 2 Suppl 2, S4-7	4
1650	Preventing stroke: is preventing microemboli enough?. <b>2001</b> , 103, 2321-2	10
1649	Manipulation of the renin-angiotensin system. <b>2001</b> , 104, E14-8	62
1648	AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. <b>2001</b> , 104, 1577-9	464
1647	Diabetes in elderly adults. <b>2001</b> , 56, M5-13	139
1646	Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. <b>2001</b> , 38, 922-6	385
1645	Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). <b>2001</b> , 103, 919-25	606

1644	Prospects for ARB in the next five years. <b>2001</b> , 2, 215-8	4
1643	Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. <b>2001</b> , 104, 19-24	286
1642	Role of reactive oxygen species in angiotensin ii signaling : the plot thickens. <b>2001</b> , 21, 471-2	2
1641	Role of the renin-angiotensin system in vascular diseases: expanding the field. <b>2001</b> , 38, 1382-7	234
1640	Arterial wave reflections and survival in end-stage renal failure. <b>2001</b> , 38, 434-8	699
1639	Review: Adipose tissue: passive sump or active pump?. <b>2001</b> , 1, 110-114	5
1638	[Decreased platelet aggregation during angiotensin-converting enzyme inhibitor therapy. Results of a pilot study]. <b>2001</b> , 126, 707-11	2
1637	Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. <b>2001</b> , 6, 175-81	36
1636	Management of acute coronary syndromes. <b>2001</b> , 164, 917-22	4
1635	Macrovascular disease in diabetes: current status. <b>2001</b> , 109 Suppl 2, S474-86	4
1634	[The treatment of arterial hypertension. An inquiry among doctors in general practice]. <b>2001</b> , 126, 1454-9	3
1633	Flavonoid antioxidants. <b>2001</b> , 8, 797-807	626
1632	Blood pressure reduction as part of the multifactorial approach to treatment of cardiovascular disease. <b>2001</b> , 3, B32-B36	
1631	Aging-associated changes in vascular activity: a potential link to geriatric cardiovascular disease. <b>2001</b> , 10, 348-54	41
1630	Achieving blood pressure targets in the management of hypertension. <b>2001</b> , 2, 6-12	45
1629	A critical evaluation of the NICE guidelines for post-myocardial infarction prophylaxis. National Institute for Clinical Excellence. <b>2001</b> , 2, 2079-84	2
1628	Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. <b>2001</b> , 29, 270-9	27
1627	Diagnosis and management of myocardial ischemia (angina) in the elderly patient. <b>2001</b> , 10, 337-44	14

1626	The Captopril Prevention Project, further analyses on left ventricular hypertrophy and diabetes. <b>2001</b> , 10, 60-1	1
1625	Treatment of hypertension in the elderly. <b>2002</b> , 11, 11-20; quiz 20-2	14
1624	Percutaneous coronary intervention vs. medical therapy: what are the implications for women?. <b>2002</b> , 11, 347-55	1
1623	From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. <b>2002</b> , 4, 519-32	13
1622	Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. <b>2002</b> , 40, 511-5	485
1621	Destabilization of AT(1) receptor mRNA by calreticulin. <b>2002</b> , 90, 53-8	42
1620	Relation between blood pressure after an acute coronary event and subsequent cardiovascular risk. <b>2002</b> , 88, 555-8	1
1619	Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. <b>2002</b> , 25, 2016-21	395
1618	ACE gene insertion/deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients. <b>2002</b> , 25, 1002-8	127
1617	NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. <b>2002</b> , 4, 899-914	172
1616	Peripheral arterial disease: epidemiology and drug therapy. <b>2002</b> , 11, 258-66	14
1615	CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane. <b>2002</b> , 91, 749-56	72
1614	ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. <b>2002</b> , 40, 859-65	77
1613	Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. <b>2002</b> , 39, 969-75	43
1612	Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. <b>2002</b> , 91, 406-13	620
1611	The RENAAL Study Investigation. <b>2002</b> , 20, 19-20	3
1610	Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. <b>2002</b> , 33, 862-75	166
1609	Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. <b>2002</b> , 105, 1650-5	907

1608	The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. <b>2002</b> , 105, 393-6	318
1607	Blood pressure control and diabetic retinopathy. <b>2002</b> , 86, 365-7	36
1606	Resolution of renal artery thrombus with direct administration of tissue plasminogen activator. <b>2002</b> , 88, 558	
1605	Blood pressure as a surrogate end point for hypertension. <b>2002</b> , 36, 87-92	4
1604	Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. <b>2002</b> , 105, 457-61	57
1603	Optimising stroke outcomes through evidence-based nursing practice: an Australian perspective. <b>2002</b> , 1, 227-35	1
1602	Can ACE Inhibitors Promote Detrimental Vascular Effects After Percutaneous Injury?. <b>2002</b> , 40, e5-6; author reply e5-6	2
1601	Long-Term Management of Blood Pressure after Stroke. <b>2002</b> , 2, 272-279	
1600	Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. <b>2002</b> , 162, 1737-45	253
1599	Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). <b>2002</b> , 106, 1909-12	102
1598	Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group V: management of cardiovascular-renal complications. <b>2002</b> , 105, e159-64	22
1597	The underlying risk of death after myocardial infarction in the absence of treatment. <b>2002</b> , 162, 2405-10	124
1596	Angiotensin II type 1 and 2 receptors in conduit arteries of normal developing microswine. <b>2002</b> , 22, 1113-21	14
1595	Helping patients follow prescribed treatment: clinical applications. <b>2002</b> , 288, 2880-3	580
1594	The Prevention or Delay of Type 2 Diabetes. <b>2002</b> , 20, 109-116	3
1593	Principles from clinical trials relevant to clinical practice: Part I. <b>2002</b> , 106, 1015-21	78
1592	Treatment of acute ischemic stroke: Part II: neuroprotection and medical management. <b>2002</b> , 106, 1736-40	28
1591	Combined treatment with indapamide and perindopril but not perindopril alone reduced the risk for recurrent stroke. <b>2002</b> , 7, 42-42	



1590	Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. <b>2002</b> , 87, 252-5	69
1589	Critical review of unstable angina and non-ST elevation myocardial infarction. <b>2002</b> , 78, 717-26	15
1588	Prevention of diabetes in cardiovascular studies: implications for the aetiology of type 2 diabetes. <b>2002</b> , 2, 384-389	
1587	Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. <b>2002</b> , 7, 275-9	137
1586	Renin-angiotensin system antagonism and lipid-lowering therapy in cardiovascular risk management. <b>2002</b> , 3, 96-102	3
1585	Regression of left ventricular hypertrophy: hoping for a longer life. <b>2002</b> , 3, 141-4	4
1584	Vasopeptidase inhibitors in heart failure. <b>2002</b> , 3, 156-9	6
1583	Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. <b>2002</b> , 3, 270-6	6
1582	Endothelial dysfunction, angiotensin-converting enzyme inhibitors and calcium antagonists. <b>2002</b> , 16 Suppl 1, S34-7	9
1581	First-line treatment for hypertension. <b>2002</b> , 23, 179-82	6
1580	Urate predicts subsequent cardiac death in stroke survivors. <b>2002</b> , 23, 788-93	39
1579	The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. <b>2002</b> , 23, 960-6	38
1578	Urate levels as a predictor of cardiac deaths: causal relation or mere association?. <b>2002</b> , 23, 760-1	11
1577	Definition of new targets in cardiovascular prevention from young into old age. <b>2002</b> , 23, 507-9	
1576	Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. <b>2002</b> , 87, 448-52	69
1575	New evidence for stroke prevention: scientific review. <b>2002</b> , 288, 1388-95	202
1574	Do diabetes and hypertension interact to accelerate vascular ageing?. <b>2002</b> , 20, 1693-6	14
1573	The renin-angiotensin system: a review of trials with angiotensin-converting enzyme inhibitors and angiotensin receptor blocking agents. <b>2002</b> , 4, A53-A57	4

1572	Intermittent claudication and endothelial dysfunction. <b>2002</b> , 4, B35-B40	3
1571	Atherogenesis--recent insights into basic mechanisms and their clinical impact. <b>2002</b> , 17, 2055-64	30
1570	Angiotensin II type 1 receptors and oestrogen status: interaction or dissociation?. <b>2002</b> , 20, 1267-9	2
1569	Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction. <b>2002</b> , 34, 514-22	3
1568	What vitamins should I be taking?. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1914-6; author reply 1914-6	5
1567	Obesity and heart failure--risk factor or mechanism?. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 358-9	59.2 53
1566	The use of ranolazine in cardiovascular disease. <b>2002</b> , 11, 117-23	10
1565	Coronary artery disease and intermittent claudication: how to manage the patient. <b>2002</b> , 4, B58-B62	1
1564	Mechanisms of vascular disease in hypertension with special reference to diabetes. <b>2002</b> , 2, 139-48	1
1563	Acute-phase reactants and coronary heart disease. <b>2002</b> , 2, 417-28	25
1562	Treating high blood pressure in diabetes: the evidence. <b>2002</b> , 2, 127-37	5
1561	[Blood coagulation in normotensives and hypertensives in relation to their body mass index]. <b>2002</b> , 127, 2374-8	2
1560	Blood pressure and coronary heart disease: a review of the evidence. <b>2002</b> , 2, 355-68	47
1559	Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. <b>2002</b> , 165, 1103-6	77
1558	Klinische Aspekte der Hyperkaliämie. <b>2002</b> , 27, 43-46	1
1557	Dysglycemia: a key cardiovascular risk factor. <b>2002</b> , 2, 165-74	13
1556	The management of stroke patients by neurologists: common questions and new observations. <b>2002</b> , 22, 53-61	2
1555	Diabetes and impaired glucose tolerance: a review of the epidemiological and trial evidence for their role in cardiovascular risk. <b>2002</b> , 2, 383-9	5

1554	Blockade of endothelial enzymes: new therapeutic targets. <b>2002</b> , 16 Suppl 1, S100-3	10
1553	Losartan and the meaning of LIFE. <b>2002</b> , 16, 289-91	1
1552	Doxazosin, an inferior antihypertensive agent?. <b>2002</b> , 16, 375-7	4
1551	Blood pressure and clinical outcomes in the International Stroke Trial. <b>2002</b> , 33, 1315-20	739
1550	Obesity, cardiovascular risk and pharmacotherapy. <b>2002</b> , 11, 260-2	1
1549	Ethnicity affects vasodilation, but not endothelial tissue plasminogen activator release, in response to bradykinin. <b>2002</b> , 22, 1023-8	35
1548	Results from the TIP (Tritace in Proteinuria) intensified monitoring project. <b>2002</b> , 25, 80-6	1
1547	Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. <b>2002</b> , 3, 72-8	26
1546	Are preventive drugs preventive enough? A study of patients' expectation of benefit from preventive drugs. <b>2002</b> , 2, 527-33	64
1545	Use of ramipril in preventing stroke: double blind randomised trial. <b>2002</b> , 324, 699-702	286
1544	The Role of Inflammation in Atherosclerosis. <b>2002</b> , 13, 203-216	1
1543	Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. <b>2002</b> , 88, 20-4	18
1542	Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: lifestyle and medical management of risk factors. <b>2002</b> , 105, e153-8	52
1541	Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. <b>2002</b> , 39, 634-8	85
1540	Vascular inflammation and the renin-angiotensin system. <b>2002</b> , 22, 1257-66	493
1539	The impact of JNC-VI guidelines on treatment recommendations in the US population. <b>2002</b> , 39, 897-902	40
1538	The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors. <b>2002</b> , 3, 66-71	6
1537	Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. <b>2002</b> , 106, 1077-82	285

1536	Pharmacotherapy for peripheral arterial disease: emerging therapeutic options. <b>2002</b> , 53, 627-33	11
1535	Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. <b>2002</b> , 22, 1845-51	191
1534	Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. <b>2002</b> , 90, 770-6	310
1533	Management of the diabetic patient approaching end-stage renal failure. <b>2002</b> , 2, 121-126	2
1532	New therapeutic options in congestive heart failure: Part I. <b>2002</b> , 105, 2099-106	99
1531	Hormone replacement therapy for prevention: more evidence, more pessimism. <b>2002</b> , 288, 99-101	32
1530	Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. <b>2002</b> , 39, 756-60	77
1529	The frequent need for three or more drugs to treat essential hypertension. What evidence for optimal combinations?. <b>2002</b> , 3, 103-8	2
1528	Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <b>2002</b> , 23, 1809-40	580
1527	Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. <b>2002</b> , 51, 1699-707	273
1526	Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. <b>2002</b> , 88, 159-62	34
1525	Interactions of nitric oxide and peroxynitrite with low-density lipoprotein. <b>2002</b> , 383, 547-52	48
1524	Effect of a standardized nurse case-management telephone intervention on resource use in patients with chronic heart failure. <b>2002</b> , 162, 705-12	323
1523	Contemporary medical options for treating patients with heart failure. <b>2002</b> , 105, 2244-6	15
1522	Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2002</b> , 288, 2981-97	4348
1521	Vascular viewpoint. <b>2002</b> , 7, 157-158	
1520	Sympathetic nervous system in heart failure. <b>2002</b> , 106, 2417-8	19
1519	The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. <b>2002</b> , 13 Suppl 3, S173-8	75

1518	Recent advances in understanding endogenous fibrinolysis: implications for molecular-based treatment of vascular disorders. <b>2002</b> , 4, 1-10	10
1517	Multiple drug targets in the management of type 2 diabetes. <b>2002</b> , 3, 203-21	25
1516	Special management needs of the elderly hypertensive patient. <b>2002</b> , 3 Suppl 1, S25-31	1
1515	Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. <b>2002</b> , 105, 304-9	47
1514	Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. <b>2002</b> , 106, 2224-30	223
1513	Conventional therapy and newer drug classes for cardiovascular protection in hypertension. <b>2002</b> , 13 Suppl 3, S208-15	7
1512	Identification of a novel redox-sensitive gene, Id3, which mediates angiotensin II-induced cell growth. <b>2002</b> , 105, 2423-8	68
1511	Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic?. <b>2002</b> , 87, 75-6	54
1510	The Alphabet Strategy: The ABC of reducing diabetes complications. <b>2002</b> , 2, 58-59	6
1509	Hypertension staging through ambulatory blood pressure monitoring. <b>2002</b> , 40, 792-4	5
1508	Multiple ischaemic events set the pattern in patent foramen ovale. <b>2002</b> , 88, 24-24	
1507	The prevention or delay of type 2 diabetes. <b>2002</b> , 25, 742-9	452
1506	The Prevention or Delay of Type 2 Diabetes. <b>2002</b> , 15, 147-157	2
1505	Obesity, hypertension, and insulin resistance. <b>2002</b> , 25, 2088-97	46
1504	Anti-angiogenic therapy for uveal melanoma--more haste, less speed. <b>2002</b> , 86, 368-9	9
1503	Evaluation and treatment of patients with systemic hypertension. <b>2002</b> , 105, 2458-61	13
1502	Eplerenone--a novel selective aldosterone blocker. <b>2002</b> , 36, 1567-76	34
1501	Critical Pathways. <b>2002</b> , 1, 184-193	

1500	Cardiovascular risk factors in progressive renal disease. <b>2002</b> , 2, 191-4	1
1499	A Practical Guide to Understanding the 2002 ACC/AHA Guidelines for the Management of Patients With Non-ST Segment Elevation Acute Coronary Syndromes. <b>2002</b> , 1, 129-149	
1498	Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. <b>2002</b> , 88, 100-7	11
1497	Preventive management of stroke. <b>2002</b> , 1415-1428	
1496	Comorbidity and cardiovascular risk factors in patients with chronic kidney disease. <b>2002</b> , 22, 494-506	13
1495	Prevention of plaque rupture: a new paradigm of therapy. <b>2002</b> , 137, 823-33	31
1494	Growth hormone therapy for adults: not ready for prime time?. <b>2002</b> , 137, 190-6	11
1493	Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists. <b>2002</b> , 16 Suppl 2, S17-23	12
1492	Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication. <b>2002</b> , 42, 1291-8	13
1491	Risk factor modification in intermittent claudication: effect on life expectancy and walking capacity. <b>2002</b> , 4, B50-B54	2
1490	Long-term renal consequences of hypertension for normal and diseased kidneys. <b>2002</b> , 11, 73-80	77
1489	Clinical trial evidence for cardiovascular risk reduction in type 2 diabetes. <b>2002</b> , 16, 24-43	3
1488	Effect of the Heart At Work program on awareness of risk factors, self-efficacy, and health behaviors. <b>2002</b> , 44, 228-36	26
1487	Lowering blood pressure for cardiovascular risk reduction: moving the goalposts or spreading the net?. <b>2002</b> , 20, 1945-8	2
1486	Recent developments in the treatment of obesity-related hypertension. <b>2002</b> , 11, 497-502	7
1485	Highlights of latest American College of Cardiology and American Heart Association Guidelines for Management of Patients with Acute Myocardial Infarction. <b>2002</b> , 10, 35-43	7
1484	Critical Pathways. <b>2002</b> , 1, 184-193	1
1483	A Practical Guide to Understanding the 2002 ACC/AHA Guidelines for the Management of Patients With Non-ST Segment Elevation Acute Coronary Syndromes. <b>2002</b> , 1, 129-149	

1482	Augmentation index as a measure of peripheral vascular disease state. <b>2002</b> , 17, 543-51	221
1481	Right enzyme? Wrong place?. <b>2002</b> , 20, 591-2	
1480	Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. <b>2002</b> , 17, 355-9	31
1479	Hypertension and diabetes. <b>2002</b> , 11, 221-8	47
1478	Metabolic effects of angiotensin-converting enzyme inhibition: the role of bradykinin. <b>2002</b> , 9, 323-328	13
1477	Use of Angiotensin-Converting Enzyme Inhibitors to Prevent Cardiovascular Disease. <b>2002</b> , 5, 61-67	
1476	Critical pathway for acute ST-segment elevation myocardial infarction: estimating its potential impact in the TIMI 9 Registry. <b>2002</b> , 1, 107-12	3
1475	Losartan titration versus diuretic combination in type 2 diabetic patients. <b>2002</b> , 20, 715-9	10
1474	Systolic and diastolic blood pressure control in antihypertensive drug trials. <b>2002</b> , 20, 1461-4	191
1473	Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. <b>2002</b> , 20, 71-8	91
1472	From theory into practice: arterial haemodynamics in clinical hypertension. <b>2002</b> , 20, 1901-15	53
1471	Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?. <b>2002</b> , 20, 2099-110	92
1470	Treating hypertension in patients with diabetes. <b>2002</b> , 27, 11-21; quiz 21-3	1
1469	Left ventricular hypertrophy and remodelling of resistance arteries: the role of activation of the renin-angiotensin-aldosterone system in hypertension. <b>2002</b> , 20, 1295-6	4
1468	"Treating Hypertension" or "Lowering Blood Pressure"? Extending the Concept. <b>2002</b> , 11, 68-70	3
1467	Management of the patient with chronic renal failure in the evidence based era. <b>2002</b> , 57, 257-65	
1466	Blood pressure variability, target organ damage and cardiovascular events. <b>2002</b> , 20, 1725-9	38
1465	Evaluation of mechanical arterial properties: clinical, experimental and therapeutic aspects. <b>2002</b> , 102, 51-67	94

1464	Vascular ageing. <b>2002</b> , 102, 601-602	5
1463	Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. <b>2002</b> , 103, 131-6	34
1462	Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension. <b>2002</b> , 103, 151-5	16
1461	Evaluation of mechanical arterial properties: clinical, experimental and therapeutic aspects. <b>2002</b> , 102, 51	59
1460	Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. <b>2002</b> , 103, 131	12
1459	Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension. <b>2002</b> , 103, 151	10
1458	Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. <b>2002</b> , 162, 2325-32	104
1457	Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents. <b>2002</b> , 42, 1187-99	39
1456	Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. <b>2002</b> , 137, 555-62	384
1455	Secondary prevention of stroke and the expanding role of the neurologist. <b>2002</b> , 13 Suppl 1, 12-6	15
1454	Predictors of normotension on withdrawal of antihypertensive drugs in elderly patients: prospective study in second Australian national blood pressure study cohort. <b>2002</b> , 325, 815	29
1453	Pathogenesis of the acute coronary syndromes and therapeutic implications. <b>2002</b> , 32, 225-31	31
1452	Further reduction in mortality following myocardial infarction. <b>2002</b> , 63, 610-4	1
1451	Antihypertensive drugs. <b>2002</b> , 240-249	
1450	Premature lower extremity atherosclerosis: clinical aspects. <b>2002</b> , 323, 11-6	6
1449	Renin angiotensin aldosterone and adrenergic modulation in chronic heart failure: contemporary concepts. <b>2002</b> , 324, 267-75	7
1448	The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. <b>2002</b> , 323, 17-24	36
1447	Concise Update to Managing Adult Diabetes. <b>2002</b> , 95, 4-9	



1446	Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. <b>2002</b> , 288, 2432-40	389
1445	Prevention of heart failure. <b>2002</b> , 17, 512-7	5
1444	DIABETES MELLITUS. <b>2002</b> , 4, 703-752	3
1443	Should we treat high-normal blood pressure?. <b>2002</b> , 20, 2057-62	5
1442	Inotropic activity of hydroindene amidinohydrazones. <b>2002</b> , 45, 127-36	20
1441	Congestive heart failure: what should be the initial therapy and why?. <b>2002</b> , 2, 1-6	21
1440	Improved prognosis of patients presenting with clinical markers of spontaneous reperfusion during acute myocardial infarction. <b>2002</b> , 88, 352-6	29
1439	Renal dysfunction complicating the treatment of hypertension. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 1256-61	59.2 236
1438	Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. <b>2002</b> , 51, 1131-7	888
1437	Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. <b>2002</b> , 23, 831-4	149
1436	Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. <b>2002</b> , 112, 126-34	43
1435	Current medical therapies for patients with peripheral arterial disease: a critical review. <b>2002</b> , 112, 49-57	109
1434	Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. <b>2002</b> , 112, 110-4	99
1433	Manipulating the renin-angiotensin system: more than we bargained for?. <b>2002</b> , 112, 152-3	
1432	Vascular and cardiac benefits of angiotensin receptor blockers. <b>2002</b> , 113, 409-18	108
1431	The vulnerable plaque and acute coronary syndromes. <b>2002</b> , 113, 668-80	82
1430	Peripheral arterial disease: medical care and prevention of complications. <b>2002</b> , 5, 119-30	19
1429	The importance of lipid evaluation and management in the prevention and treatment of acute myocardial infarction. <b>2002</b> , 5, 131-7	1

1428	Reducing the knowledge-practice gap in the management of patients with cardiovascular disease. <b>2002</b> , 5, 12-5	11
1427	Cardiovascular medications taken by patients aged $\geq 70$ years hospitalized for acute coronary syndromes before hospitalization and at hospital discharge. <b>2002</b> , 5, 173-6	3
1426	Treating hypertension in the patient who has had a stroke. <b>2002</b> , 4, 135	
1425	Premature termination of clinical trials--lessons learned. <b>2002</b> , 4, 219-25	4
1424	Clinical impact of renin-angiotensin system blockade: angiotensin-converting enzyme inhibitors vs. angiotensin receptor antagonists. <b>2002</b> , 4, 11-9, 31	5
1423	Update on the management of diabetes and hypertension. <b>2002</b> , 4, 3-10	9
1422	Prognostic value of coronary vascular endothelial dysfunction. <b>2002</b> , 106, 653-8	1144
1421	Prorenin uptake in the heart: a prerequisite for local angiotensin generation?. <b>2002</b> , 34, 1463-72	23
1420	Beyond blood pressure: the endothelium and atherosclerosis progression. <b>2002</b> , 15, 115S-122S	120
1419	The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a case-control study. <b>2002</b> , 39, 219-24	26
1418	Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. <b>2002</b> , 39, 315-22	59
1417	Activation of vascular tissue angiotensin-converting enzyme (ACE) in heart failure. Effects of ACE inhibitors. <b>2002</b> , 39, 776-9	10
1416	Refractory angina pectoris: mechanism and therapeutic options. <b>2002</b> , 39, 923-34	109
1415	Physicians' interpretation of "class effects": a need for thoughtful re-evaluation. <b>2002</b> , 40, 19-26	8
1414	Optimizing the diabetic formulary: beyond aspirin and insulin. <b>2002</b> , 40, 652-61	24
1413	Effect of long-term therapy with ramipril in high-risk women. <b>2002</b> , 40, 693-702	46
1412	Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial. <b>2002</b> , 40, 917-25	18
1411	Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. <b>2002</b> , 40, 961-6	40

1410	Angiotensin receptor blockers in heart failure: a work in progress. <b>2002</b> , 40, 1422-4		3
1409	If only cardiologists did properly measure blood pressure. Blood pressure recordings in daily practice and clinical trials. <b>2002</b> , 40, 2201-3		23
1408	C-reactive protein predicts death in patients with previous premature myocardial infarction--a 10 year follow-up study. <b>2002</b> , 160, 433-40		70
1407	Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. <b>2002</b> , 161, 65-74		39
1406	The use of antioxidant supplements in coronary heart disease. <b>2002</b> , 164, 211-9		97
1405	Targeting the atherosclerotic process in clinical practice. A new look at established agents. <b>2002</b> , 165, 189-90		
1404	Clinical practice. Transient ischemic attack. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 1687-92	59.2	136
1403	Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. <b>2002</b> , 123, 1667-76		156
1402	Prevention of heart failure. <b>2002</b> , 8, 333-46		67
1401	What is the meaning of LIFE? Implications of the Losartan Intervention for Endpoint reduction in hypertension trial for heart failure physicians. <b>2002</b> , 8, 197-201		5
1400	Who should treat patients with peripheral arterial disease - the vascular specialist. <b>2002</b> , 24, 1-3		6
1399	Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a meta-analysis. <b>2002</b> , 25, 373-8		17
1398	A benefit-risk assessment of agents used in the secondary prevention of stroke. <b>2002</b> , 25, 943-63		3
1397	Treatment of heart failure in patients with diabetes mellitus. <b>2002</b> , 62, 285-307		5
1396	Cefditoren Pivoxil. <b>2002</b> , 62, 337-338		1
1395	Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. <b>2002</b> , 62, 339-85		13
1394	Ramipril: a review of its use in the prevention of cardiovascular outcomes. <b>2002</b> , 62, 1381-405		43
1393	Tolerability of Ramipril 10 mg/day in High-Risk Cardiovascular Chinese Patients. <b>2002</b> , 22, 771-781		2

1392	Does the angiotensin II receptor antagonist losartan improve cognitive function?. <b>2002</b> , 19, 723-32	25
1391	Trends in prescribing ACE-inhibitors for congestive heart failure in elderly people. <b>2002</b> , 14, 516-21	10
1390	What is the appropriate treatment of hypertension in elders?. <b>2002</b> , 57, M483-6	34
1389	alpha-Tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients. <b>2002</b> , 25, 524-9	46
1388	Risk-benefit assessment of angiotensin II receptor antagonists. <b>2002</b> , 1, 137-52	2
1387	Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. <b>2002</b> , 77, 45-54	287
1386	Clinical practice. Nephropathy in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1145-51	59.2 455
1385	The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. <b>2002</b> , 11, 293-301	38
1384	Metformin: an update. <b>2002</b> , 137, 25-33	734
1383	Antagonistas de los receptores de la angiotensina II. Una revisi3n farmacoterap3utica. <b>2002</b> , 19, 129-138	
1382	[Renal function protection in type 2 diabetic patients]. <b>2002</b> , 118, 297-8	0
1381	Epidemiologic analyses of risk factors, risk indicators, risk markers, and causal factors. The example of albuminuria and the risk of cardiovascular disease in diabetes. <b>2002</b> , 31, 537-51	8
1380	Antihipertensivos cl3sicos o modernos en el tratamiento de la hipertensi3n arterial: ¿debe seguir existiendo controversia en su elecci3n?. <b>2002</b> , 28, 560-572	0
1379	Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events. <b>2002</b> , 106, 2775-80	63
1378	Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?. <b>2002</b> , 3, 1543-56	4
1377	Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. <b>2002</b> , 277, 16847-52	87
1376	The risk of stroke following coronary revascularization -- a population-based long-term follow-up study. <b>2002</b> , 36, 231-6	7
1375	ACE inhibition and atherogenesis. <b>2002</b> , 80, 354-9	32

1374	Intermittent claudication: pharmaco-economic and quality-of-life aspects of treatment. <b>2002</b> , 20, 169-81	12
1373	Antihypertensive drugs: an overview. <b>2002</b> , 2, 77-89	21
1372	Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. <b>2002</b> , 2, 157-62	22
1371	Is diabetic retinopathy an inflammatory disease?. <b>2002</b> , 86, 363-5	249
1370	Pharmacotherapeutic options for the management of myocardial infarction. <b>2002</b> , 3, 1153-68	1
1369	The angiotensin-receptor blockers: from antihypertensives to cardiovascular all-round medications in 10 years?. <b>2002</b> , 11, 328-38	9
1368	Systolic hypertension as a cardiovascular risk factor. <b>2002</b> , 11, 134-43	8
1367	Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression. <b>2002</b> , 80, 48-58	9
1366	Effects of angiotensin receptor blockade on haemodynamics and gene expression after myocardial infarction. <b>2002</b> , 3, 239-49	4
1365	Selenium and vitamin E supplements for prostate cancer: evidence or embellishment?. <b>2002</b> , 59, 9-19	62
1364	Angiotensin blockade for hypertension: a promise fulfilled. <b>2002</b> , 359, 990-2	39
1363	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. <b>2002</b> , 359, 995-1003	4163
1362	Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. <b>2002</b> , 359, 1004-10	1297
1361	Risk reduction for stroke and coronary events. <b>2002</b> , 359, 1249; author reply 1250-1	
1360	Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. <b>2002</b> , 359, 1269-75	514
1359	Renoprotection with antihypertensive agents. <b>2002</b> , 359, 1694-5	
1358	Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study. <b>2002</b> , 359, 2199; author reply 2203-4	3
1357	Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. <b>2002</b> , 359, 2199-200; author reply 2203-4	2

1356	MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. <b>2002</b> , 360, 7-22	6581
1355	Who is fooling us?. <b>2002</b> , 360, 89	4
1354	Two decades of progress in preventing vascular disease. <b>2002</b> , 360, 2-3	281
1353	Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. <b>2002</b> , 360, 1037-43	188
1352	Screening for and treatment of left-ventricular abnormalities in diabetes mellitus. <b>2002</b> , 360, 1251-2; author reply 1252	
1351	Screening for and treatment of left-ventricular abnormalities in diabetes mellitus. <b>2002</b> , 360, 1252	
1350	Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. <b>2002</b> , 360, 1455-61	460
1349	Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. <b>2002</b> , 360, 1903-13	6898
1348	Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury. <b>2002</b> , 73, 1522-7	14
1347	A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?. <b>2002</b> , 8, 313-20	11
1346	Ramipril reduces the risk of developing diabetes in high-risk people. <b>2002</b> , 6, 63-64	
1345	Amlodipine and chlorthalidone are equally effective for stage I isolated systolic hypertension. <b>2002</b> , 6, 114-115	
1344	Routine statin treatment after acute coronary syndromes?. <b>2002</b> , 143, 940-2	6
1343	Prognosis after acute myocardial infarction continues to improve in the reperfusion era in the community of Gēteborg. <b>2002</b> , 144, 89-94	22
1342	Abdominal aortic calcific deposits are associated with increased risk for congestive heart failure: the Framingham Heart Study. <b>2002</b> , 144, 733-9	44
1341	The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited. <b>2002</b> , 144, 941-7	26
1340	Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial. <b>2002</b> , 15, 193-8	21
1339	Are there meaningful differences in blood pressure control with current antihypertensive agents?. <b>2002</b> , 15, 14S-21S	9

1338	Angiotensin and vascular fibrinolytic balance. <b>2002</b> , 15, 3S-8S	54
1337	Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn?. <b>2002</b> , 15, 22S-27S	15
1336	Clinical applications of arterial stiffness; definitions and reference values. <b>2002</b> , 15, 426-44	856
1335	ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations?. <b>2002</b> , 15, 367-71	17
1334	Risk stratification of older patients. <b>2002</b> , 15, 77S-81S	5
1333	Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. <b>2002</b> , 15, 85S-93S	22
1332	PAI-1 in human hypertension: relation to hypertensive groups. <b>2002</b> , 15, 683-90	31
1331	Cardiac angiotensin II: an intracrine hormone?. <b>2002</b> , 15, 1109-16	16
1330	Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade. <b>2002</b> , 15, 108S-114S	12
1329	Therapeutic strategies to halt renal fibrosis. <b>2002</b> , 2, 177-81	40
1328	Activation of bradykinin B1 receptor by ACE inhibitors. <b>2002</b> , 2, 1787-93	39
1327	Diabetes mellitus and cardiovascular disease. <b>2002</b> , 13, 15-30	10
1326	Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. <b>2002</b> , 24, 1484-501	37
1325	Amlodipine for all undergoing PCI? The evidence is unconvincing. <b>2002</b> , 84, 30-32	2
1324	C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. <b>2002</b> , 51, 1596-600	598
1323	[Prevention and treatment of ischemic heart disease in patients with diabetes mellitus]. <b>2002</b> , 55, 975-86	8
1322	Hipertensi3n arterial y diabetes. Avances terap3uticos. <b>2002</b> , 99, 73-80	
1321	Morbimortalidad cardiovascular en la diabetes mellitus tipo 2. <b>2002</b> , 19, 193-196	

- 1320 Chronic renal ischemia: pathophysiologic mechanisms of cardiovascular and renal disease. **2002**, 13, 1085-92 19
- 1319 [Prevention and treatment of congestive heart failure in diabetic patients]. **2002**, 55, 1083-7 3
- 1318 Prevention of cardiovascular diseases. Coronary artery disease, congestive heart failure, and stroke. **2002**, 18, 463-83, vii 9
- 1317 Prevenci3n secundaria del infarto de miocardio y calidad de vida relacionada con la salud. **2002**, 119, 9-12 8
- 1316 Abdominal aortic calcific deposits are associated with increased risk for congestive heart failure: The Framingham Heart Study. **2002**, 144, 733-739 87
- 1315 Hypertension in special populations. **2002**, 20, 303-19, vii 24
- 1314 Clinical pharmacology of antihypertensive drugs. **2002**, 20, 265-80 7
- 1313 Chronic renal ischemia: implications for cardiovascular disease risk. **2002**, 13, 1187-98 15
- 1312 Acute ischemic syndromes. Adjunctive therapy. **2002**, 20, 159-75, ix-x
- 1311 [Significant incidence of type 2 diabetes on high-risk Spanish population. The IGT Study (2)]. **2002**, 118, 287-93 5
- 1310 Management of intermittent claudication. **2002**, 20, 521-34 5
- 1309 Antihipertensivos cl3sicos o modernos en el tratamiento de la hipertensi3n arterial: ¿debe seguir existiendo controversia en su elecci3n?. **2002**, 28, 539-540
- 1308 [Beyond blood pressure reduction in the treatment of arterial hypertension. Clinical implications of the LIFE study]. **2002**, 55, 887-94
- 1307 Cardiology and cardiac surgery. **2002**, 176, 8
- 1306 Guideline-discordant care in acute myocardial infarction: predictors and outcomes. **2002**, 177, 26-31 18
- 1305 Chronic Complications of Diabetes. **2002**, 95, 30-34 1
- 1304 An Unjustified Return to the Past. **2002**, 33, 879-881 6
- 1303 Re: Feasibility and Safety of Moderate Hypothermia After Massive Hemispheric Infarction. **2002**, 33, 877-878 1



1302	Ramipril Prior to Thrombolysis Attenuates the Early Increase of PAI-1 in Patients with Acute Myocardial Infarction. <b>2002</b> , 88, 180-185	20
1301	Irbesartan was renoprotective in patients with type 2 diabetes, hypertension, and microalbuminuria. <b>2002</b> , 136, 82-4	1
1300	Antioxidant therapy for atherosclerotic vascular disease: the promise and the pitfalls. <b>2002</b> , 282, H797-802	22
1299	Un recepteur membranaire pour la rhine : et l'enzyme devient hormone. <b>2002</b> , 18, 686-688	
1298	Optimising Stroke Outcomes through Evidence-Based Nursing Practice: An Australian Perspective. <b>2002</b> , 1, 227-235	1
1297	The Unusually Shaped Bifrontal Hematoma. <b>2002</b> , 33, 876-877	
1296	Diabetes, diversity, and disparity: what do we do with the evidence?. <b>2002</b> , 92, 543-8	70
1295	Potential of Fibrinolytic Therapy in Acute Myocardial Infarction: Expanding the Role of ACE-Inhibitors. <b>2002</b> , 88, 176-178	8
1294	Re: Crossed Nonaphasia in a Dextral With Left Hemispheric Lesions: A Functional Magnetic Resonance Imaging Study of Mirrored Brain Organization. <b>2002</b> , 33, 878-879	1
1293	Management of Stable Angina and Unstable Angina/Non-ST-elevation Myocardial Infarction. <b>2002</b> , 30, 64-70	
1292	Pharmacogenomics in cardiovascular diseases. <b>2002</b> , 44, 479-98	23
1291	Atherothrombosis: plaque instability and thrombogenesis. <b>2002</b> , 44, 381-94	36
1290	What is the place of beta-blockade in patients who have experienced a myocardial infarction with preserved left ventricular function? Evidence and (mis)interpretation. <b>2002</b> , 44, 243-50	17
1289	Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. <b>2002</b> , 44, 275-92	41
1288	Controlling hypertension to reduce the risk of stroke. <b>2002</b> , 17, 186-91	2
1287	Role of inflammation in cardiovascular disease: how to use C-reactive protein in clinical practice. <b>2002</b> , 17, 174-85	15
1286	Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia. <b>2002</b> , 436, 145-50	24
1285	Introduction. <b>2002</b> , 89, 1-2	

1284	The role of the renin-angiotensin system in the development of cardiovascular disease. <b>2002</b> , 89, 3A-9A; discussion 10A	366
1283	Angiotensin II and trials of cardiovascular outcomes. <b>2002</b> , 89, 11A-16A; discussion 16A-17A	50
1282	From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. <b>2002</b> , 89, 18A-25A; discussion 25A-26A	127
1281	The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?. <b>2002</b> , 89, 27A-33A	46
1280	Discussion. <b>2002</b> , 89, 16-17	3
1279	Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). <b>2002</b> , 89, 686-90	54
1278	Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers. <b>2002</b> , 89, 1207-9	30
1277	Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus. <b>2002</b> , 90, 42G-50G	140
1276	Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure. <b>2002</b> , 90, 992-3	9
1275	Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. <b>2002</b> , 90, 1045-9	24
1274	Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. <b>2002</b> , 90, 1204-10	69
1273	Combination therapy for dyslipidemia: safety and regulatory considerations. <b>2002</b> , 90, 50K-60K	85
1272	Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. <b>2002</b> , 63, 817-21	103
1271	New horizons for stroke prevention: PROGRESS and HOPE. <b>2002</b> , 1, 149-56	55
1270	Vitamin E in cardiovascular disease: has the die been cast?. <b>2002</b> , 11 Suppl 7, S443-7	11
1269	Chronic dialysis patients have high risk for pulmonary embolism. <b>2002</b> , 39, 1011-7	102
1268	Quality of prereferral care in patients with chronic renal insufficiency. <b>2002</b> , 40, 30-6	29
1267	ACE inhibitors and survival of hemodialysis patients. <b>2002</b> , 40, 1023-9	152

1266	Management of intermittent claudication: the importance of secondary prevention. <b>2002</b> , 23, 100-7	21
1265	Importance of blood pressure control in patients with diabetes mellitus. <b>2002</b> , 16, 87-91	1
1264	Diabetes and macrovascular disease. <b>2002</b> , 16, 235-45	79
1263	Treatment of peripheral arterial disease. <b>2002</b> , 4, 26-40	7
1262	Miscellaneous medications for the management of atherosclerosis: Mayhem or miracle?. <b>2002</b> , 15, 275-287	
1261	Considerations for treating dyslipidemia in special diabetic populations. <b>2002</b> , 18, 88-95	0
1260	Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. <b>2002</b> , 18 Suppl 3, S82-5	55
1259	ST-Segment Elevation Myocardial Infarction. <b>2002</b> , 4, 3-23	1
1258	Management After Myocardial Infarction. <b>2002</b> , 4, 41-54	
1257	Isolated Systolic Hypertension in the Elderly. <b>2002</b> , 4, 87-93	5
1256	Prevention of Left Ventricular Remodeling After Myocardial Infarction. <b>2002</b> , 4, 97-108	6
1255	Endocrine Heart Disease. <b>2002</b> , 4, 181-192	
1254	Myocardial and Pericardial Disease in HIV. <b>2002</b> , 4, 497-509	21
1253	Atherosclerotic Risk Factors in Patients with Ischemic Cerebrovascular Disease. <b>2002</b> , 4, 445-453	9
1252	Cardiovascular disease: much more aggressive in patients with type 2 diabetes. <b>2002</b> , 4, 134-42	24
1251	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. <b>2002</b> , 4, 363-72	28
1250	Prevention of ischemic stroke. <b>2002</b> , 4, 164-71	4
1249	Is heart failure with preserved systolic function an overlooked enigma?. <b>2002</b> , 4, 187-93	3

1248	Prevention of heart failure. <b>2002</b> , 4, 194-9	6
1247	Should we put angiotensin-converting enzyme inhibitors in the water supply?. <b>2002</b> , 4, 249-50	
1246	The use of ACE inhibitors on diabetic patients without renal disease. <b>2002</b> , 2, 21-5	2
1245	Role of ACE inhibitors in treating hypertensive diabetic patients. <b>2002</b> , 2, 251-7	9
1244	Cardiovascular risk factors in diabetic patients with hypertension. <b>2002</b> , 2, 263-6	2
1243	The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond. <b>2002</b> , 2, 423-30	
1242	Blood pressure control--effects on diabetic nephropathy progression: how low does blood pressure have to be?. <b>2002</b> , 2, 530-8	5
1241	Blood pressure-independent impact of antihypertensive agents on cardiovascular and renal disease. <b>2002</b> , 4, 445-52	5
1240	Systemic hypertension in postmenopausal women: a clinical approach. <b>2002</b> , 4, 464-70	27
1239	Progress in secondary prevention of stroke with PROGRESS. The perindopril protection against recurrent stroke study. <b>2002</b> , 4, 39-40	6
1238	Vasopeptidase inhibition: effective blood pressure control for vascular protection. <b>2002</b> , 4, 78-84	7
1237	Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers. <b>2002</b> , 4, 333-5	2
1236	Evolving strategies for the use of combination therapy in hypertension. <b>2002</b> , 4, 343-9	37
1235	Managing the hypertensive patient with ischemic heart disease. <b>2002</b> , 4, 350-7	
1234	Optimizing blood pressure control in the obese patient. <b>2002</b> , 4, 358-62	4
1233	Are angiotensin converting enzyme inhibitors and angiotensin receptor blockers becoming the treatment of choice in African-Americans?. <b>2002</b> , 4, 286-9	11
1232	Are clinical endpoint benefits of angiotensin converting enzyme inhibitors independent of their blood pressure effects?. <b>2002</b> , 4, 290-7	1
1231	Prevention of Ischemic Stroke. <b>2002</b> , 4, 393-403	5

1230	Angiotensin II-induced upregulation of MAP kinase phosphatase-3 mRNA levels mediates endothelial cell apoptosis. <b>2002</b> , 97, 1-8	26
1229	[Primary prevention of cardiovascular diseases by nonpharmacological means]. <b>2002</b> , 97, 77-87	2
1228	[Modern therapy in acute coronary syndrome]. <b>2002</b> , 97, 236-43	
1227	Treatment of type 2 diabetic patients with kidney disease with AT1-receptor antagonists: lessons from recent trials. <b>2002</b> , 6, 175-181	4
1226	Effect of continuous versus dichotomous outcome variables on study power when sample sizes of orthopaedic randomized trials are small. <b>2002</b> , 122, 96-8	67
1225	Stroke prevention: management of modifiable vascular risk factors. <b>2002</b> , 249, 507-17	56
1224	The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study. <b>2002</b> , 251, 508-17	27
1223	FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics. <b>2002</b> , 16, 353-60	14
1222	Ischemic heart disease after renal transplantation. <b>2002</b> , 61, 356-69	26
1221	Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?. <b>2002</b> , 62, 192-8	24
1220	Impact of renal failure on the risk of myocardial infarction and death. <b>2002</b> , 62, 1776-83	65
1219	Strategies to decrease cardiovascular mortality in patients with end-stage renal disease. <b>2002</b> , 5-10	14
1218	Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection. <b>2002</b> , S53-60	8
1217	Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the Cardiovascular Health Study. <b>2002</b> , 50, 416-23	48
1216	Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?. <b>2002</b> , 50, 1293-6	18
1215	Is there a clinically significant gender bias in post-myocardial infarction pharmacological management in the older (>60) population of a primary care practice?. <b>2002</b> , 3, 8	23
1214	An introduction to the KidneyCheck Australia Taskforce. <b>2002</b> , 7, S33-S35	
1213	Feasibility study of the early detection and treatment of renal disease by mass screening. <b>2002</b> , 32, 6-14	25

1212	Renin-angiotensin system inhibition: how much is too much of a good thing?. <b>2002</b> , 32, 616-20	6
1211	Reducing the risk of stroke in diabetes: what have we learned that is new?. <b>2002</b> , 4 Suppl 1, S27-34	20
1210	What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE. <b>2002</b> , 4 Suppl 1, S19-25	11
1209	Vasopeptidase inhibitors and their potential role in diabetes. <b>2002</b> , 4, 89-95	0
1208	Diabetes in tomorrow's world: dark clouds do have silver linings. <b>2002</b> , 4, 351-5	1
1207	The impact of atherosclerotic renovascular disease on diabetic renal failure. <b>2002</b> , 19, 889-94	12
1206	Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. <b>2002</b> , 19, 708-23	821
1205	Clinical trials and tribulations. <b>2002</b> , 29, 951-5	1
1204	Clinical research and trials in developing countries. <b>2002</b> , 21, 2859-67	12
1203	Combined endpoints: can we use them?. <b>2002</b> , 21, 2959-70	85
1202	The value of large, robust trials: the HOPE study. <b>2002</b> , 19, 29-30	1
1201	Interpretation of the HOPE study. <b>2002</b> , 19, 30-31	2
1200	ACE inhibitors and diabetes: from HOPE to PROGRESS. <b>2002</b> , 19, 176-179	0
1199	The need for a national infrastructure to improve the rational use of therapeutics. <b>2002</b> , 11, 319-27	15
1198	The importance of validating the diagnosis of coronary heart disease when measuring secondary prevention: a cross-sectional study in general practice. <b>2002</b> , 11, 311-7	11
1197	Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. <b>2002</b> , 26, 754-64	175
1196	Central role of the AT(1)-receptor in atherosclerosis. <b>2002</b> , 16 Suppl 3, S26-33	60
1195	The potential role of AT(1)-receptor blockade in the prevention and reversal of atherosclerosis. <b>2002</b> , 16 Suppl 3, S34-41	13

1194	The reno-protective role of AT(1)-receptor blockers. <b>2002</b> , 16 Suppl 3, S52-8	20
1193	A population-based European cohort study of persistence in newly diagnosed hypertensive patients. <b>2002</b> , 16, 569-75	90
1192	Inflammation and infection in clinical stroke. <b>2002</b> , 22, 1399-419	212
1191	Inflammation in atherosclerosis. <b>2002</b> , 420, 868-74	6489
1190	Drugs targeting the renin-angiotensin-aldosterone system. <b>2002</b> , 1, 621-36	326
1189	Role of bradykinin in preconditioning and protection of the ischaemic myocardium. <b>2002</b> , 135, 843-54	69
1188	An introduction to the Kidney Check Australia Taskforce. <b>2002</b> , 7, S33-S35	
1187	Progressive renal and cardiovascular disease: optimal treatment strategies. <b>2002</b> , 62, 1482-92	10
1186	The significance of lower extremity peripheral arterial disease. <b>2002</b> , 25, 3-10	53
1185	Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy. <b>2002</b> , 25, 205-12	20
1184	Economics and quality of care for patients with acute coronary syndromes: the impending crisis. <b>2002</b> , 25, 19-15	
1183	Diabetic retinopathyA clinical update. <b>2002</b> , 45, 1617-34	133
1182	Role of nitric oxide in the regulation of substrate metabolism in heart failure. <b>2002</b> , 7, 141-8	13
1181	PERindopril-Function of the Endothelium in Coronary Artery Disease Trial: the PERFECT study--sub study of EUROPA: rationale and design. <b>2002</b> , 16, 227-36	15
1180	Vitamins, antioxidants and endothelial function in coronary artery disease. <b>2002</b> , 16, 401-9	10
1179	Use of cardiovascular drugs after acute myocardial infarction: a marked shift towards evidence-based drug therapy. <b>2002</b> , 16, 451-6	11
1178	Clinical profile of eprosartan. <b>2002</b> , 16, 543-9	3
1177	Literature review and commentary. <b>2002</b> , 34, 425-436	

1176	Peripheral limitations of maximal aerobic capacity in patients with chronic heart failure. <b>2002</b> , 9, 215-25	22
1175	Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications. <b>2003</b> , 15, 217-25	7
1174	Cyclooxygenase-2 inhibitors. <b>2003</b> , 96, 1720-1738	59
1173	Recent developments in the treatment of type 2 diabetes mellitus. <b>2003</b> , 17, 151-8	5
1172	The role of brain natriuretic peptide in population screening. <b>2003</b> , 8, 349-54	4
1171	Coronary heart disease--ACE inhibitors for all patients?. <b>2003</b> , 17, 391-3	
1170	Antihypertensive treatment and prevention of stroke and dementia. <b>2003</b> , 3, 155-164	10
1169	Blood-pressure-related risk factors, stroke, and cognitive function: What are the relationships and what can we do about them?. <b>2003</b> , 3, 138-143	1
1168	Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders. <b>2003</b> , 10, 184-96	40
1167	Stable patients with atherosclerotic renal artery stenosis should be treated first with medical management. <b>2003</b> , 42, 851-7	27
1166	Acute and chronic endothelial dysfunction: implications for the development of heart failure. <b>2003</b> , 8, 87-97	32
1165	Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. <b>2003</b> , 8, 71-86	112
1164	Modulating atherosclerosis through inhibition or blockade of angiotensin. <b>2003</b> , 26, 305-11	19
1163	Angiotensin II blockade: a therapeutic strategy with wide applications. <b>2003</b> , 26, 500-2	4
1162	Prediction of severe hypoglycaemia by angiotensin-converting enzyme activity and genotype in type 1 diabetes. <b>2003</b> , 46, 89-96	81
1161	The management of patients with heart failure in a Slovenian community hospital: what has changed between 1997 and 2000?. <b>2003</b> , 115, 334-9	6
1160	Use of ACE Inhibitors for Secondary Prevention. <b>2003</b> , 5, 51-61	1
1159	Therapies for Preventing Heart Failure. <b>2003</b> , 5, 337-343	



1158	Microalbuminuria and diabetic cardiovascular disease. <b>2003</b> , 5, 350-7	8
1157	Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms. <b>2003</b> , 5, 33-7	14
1156	The renin-angiotensin-aldosterone system as a target in coronary disease. <b>2003</b> , 5, 124-30	11
1155	Uncontrolled hypertension as a risk for coronary artery disease: patient characteristics and the role of physician intervention. <b>2003</b> , 5, 131-8	12
1154	Sex differences in the causes and natural history of heart failure. <b>2003</b> , 5, 193-9	18
1153	Clinical implications of local renin-angiotensin-aldosterone systems. <b>2003</b> , 5, 247-8	4
1152	Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. <b>2003</b> , 3, 279-88	176
1151	Prediabetes mellitus and its links to atherosclerosis. <b>2003</b> , 3, 11-8	14
1150	Lipid abnormalities in the metabolic syndrome. <b>2003</b> , 3, 65-72	12
1149	Prevention of type 2 diabetes. <b>2003</b> , 3, 235-41	28
1148	Combination lipid-lowering therapy in diabetes. <b>2003</b> , 3, 263-8	2
1147	Best bang for the buck?. <b>2003</b> , 5, 3-5	
1146	Aldosterone: a risk factor for vascular disease. <b>2003</b> , 5, 59-65	45
1145	The L-arginine-nitric oxide pathway in hypertension. <b>2003</b> , 5, 80-6	35
1144	Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2003</b> , 5, 293-4	9
1143	Lessons from trials in hypertensive type 2 diabetic patients. <b>2003</b> , 5, 322-8	1
1142	Ongoing trials: what should we expect after ALLHAT?. <b>2003</b> , 5, 340-5	
1141	Angiotensin and insulin resistance: conspiracy theory. <b>2003</b> , 5, 110-6	10

1140	The role of angiotensin II in regulating vascular structural and functional changes in hypertension. <b>2003</b> , 5, 155-64	109
1139	New strategies for prevention of ischemic stroke: the LIFE study. <b>2003</b> , 3, 46-51	2
1138	[Arterial hypertension and metabolic syndrome]. <b>2003</b> , 28, 674-85	3
1137	[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. <b>2003</b> , 98, 218-25	1
1136	[Reduction of cardiovascular events with losartan? The LIFE Study]. <b>2003</b> , 44, 367-70	
1135	[Conflicting evaluations of the PROGRESS Study]. <b>2003</b> , 44, 631-2	
1134	The selenium and vitamin E cancer prevention trial. <b>2003</b> , 21, 21-7	91
1133	Treatment of diabetic nephropathy with angiotensin II receptor antagonist. <b>2003</b> , 7, 1-8	35
1132	[The status of atherosclerosis prevention in Austria]. <b>2003</b> , 153, 354-9	0
1131	[Diabetes and drug treatment of hypertension]. <b>2003</b> , 153, 464-8	
1130	Carotid stents: is the gold standard ready for change?. <b>2003</b> , 21, 132-138	1
1129	The influence of obesity on the frequency and distribution of medication. <b>2003</b> , 30, 51-4	4
1128	Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. <b>2003</b> , 42, 1260-9	46
1127	Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients?. <b>2003</b> , 42, 1301-4	2
1126	Long term angiotensin converting enzyme-inhibition in patients after coronary artery bypass grafting reduces levels of soluble intercellular cell adhesion molecule-1. <b>2003</b> , 26, 387-91	13
1125	Lessons learned from recent lipid-lowering trials: why physicians should change clinical practice. <b>2003</b> , Suppl 1, S11-7	
1124	Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes. <b>2003</b> , 41, 903-24	55
1123	Aldosterone receptor antagonists: focus on eplerenone. <b>2003</b> , 18, 54-9	1

1122	Smoking and endothelial function. <b>2003</b> , 45, 443-58	117
1121	Hormone replacement therapy and coronary heart disease: results of randomized trials. <b>2003</b> , 46, 231-8	2
1120	Coronary heart disease: the female heart is vulnerable. <b>2003</b> , 46, 199-229	105
1119	Implementing guidelines in primary care: can population impact measures help?. <b>2003</b> , 3, 7	23
1118	Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions. <b>2003</b> , 23, 1141-52	29
1117	Clinical pharmacy specialist implementation of lisinopril therapy in patients with coronary artery disease and diabetes mellitus. <b>2003</b> , 23, 1564-72	8
1116	A structured review of the relationship between microalbuminuria and cardiovascular events in patients with diabetes mellitus and hypertension. <b>2003</b> , 23, 1611-6	21
1115	Angiotensin II receptor blockers in heart failure. <b>2003</b> , 23, 173-82	7
1114	Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction. <b>2003</b> , 23, 788-801	22
1113	Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: a meta-analysis. <b>2003</b> , 23, 909-15	16
1112	Comparison of effectiveness of angiotensin-converting enzyme inhibitors after acute myocardial infarction in diabetic versus nondiabetic patients. <b>2003</b> , 92, 1020-5	9
1111	Pharmacogenomics in cardiovascular diseases. <b>2003</b> , 28, 317-47	8
1110	[Factors influencing secondary prevention of atherothrombotic disease in the private outpatient cardiology setting: results of the Prisma survey]. <b>2003</b> , 52, 20-9	4
1109	[Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys]. <b>2003</b> , 52, 1-6	15
1108	Effect of angiotensin-converting enzyme inhibition on restenosis after coronary stenting. <b>2003</b> , 91, 154-8	34
1107	Prevention and management of chronic heart failure in management of asymptomatic patients. <b>2003</b> , 91, 4F-9F	120
1106	Prevention and management of chronic heart failure in patients at risk. <b>2003</b> , 91, 10F-17F	17
1105	Improving clinical outcomes with drug treatment in heart failure: what have trials taught?. <b>2003</b> , 91, 9D-14D	17

1104	Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease. <b>2003</b> , 91, 1116-9	38
1103	Trials on blood pressure-lowering and secondary stroke prevention. <b>2003</b> , 91, 3G-8G	12
1102	Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine. <b>2003</b> , 91, 15G-21G	102
1101	The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. <b>2003</b> , 91, 28G-34G	40
1100	Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases. <b>2003</b> , 91, 12H-18H	227
1099	Prognostic value of endothelial function. <b>2003</b> , 91, 19H-24H	127
1098	Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. <b>2003</b> , 91, 30H-37H	186
1097	Use of angiotensin-converting enzyme inhibitors after coronary artery bypass grafting in patients with diabetes mellitus. <b>2003</b> , 92, 77-9	3
1096	Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. <b>2003</b> , 92, 79-81	92
1095	The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. <b>2003</b> , 92, 3i-9i	21
1094	A practical approach to risk assessment to prevent coronary artery disease and its complications. <b>2003</b> , 92, 19i-26i	62
1093	Prognostic value of myocardial perfusion imaging in predicting outcome after renal transplantation. <b>2003</b> , 92, 146-51	89
1092	Underuse of cardioprotective medications in patients prior to acute myocardial infarction. <b>2003</b> , 92, 209-11	6
1091	Role of endothelial dysfunction in insulin resistance. <b>2003</b> , 92, 10J-17J	193
1090	ALLHAT--all hit or all miss? Key questions still remain. <b>2003</b> , 92, 280-1	12
1089	Leukocytosis and adverse hospital outcomes after acute myocardial infarction. <b>2003</b> , 92, 368-72	56
1088	Roundtable discussion: tadalafil study group. <b>2003</b> , 92, 58M-65M	2
1087	Angiotensin-converting enzyme inhibitors: optimal management of cardiovascular risk. <b>2003</b> , 92, 900	

1086	Current options in the management of coronary artery disease. <b>2003</b> , 92, 4N-8N	15
1085	Hypertension in special populations. <b>2003</b> , 28, 194-223	2
1084	Modern management of acute myocardial infarction. <b>2003</b> , 28, 7-127	
1083	Treatment of heart failure in older persons. Dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis. <b>2003</b> , 9, 142-7	17
1082	Should aspirin be used with angiotensin-converting enzyme inhibitors in patients with chronic heart failure?. <b>2003</b> , 9, 206-11; quiz 212-3	2
1081	Is heart failure in African Americans a distinct entity?. <b>2003</b> , 9, 193-6	3
1080	Aspirin and heart failure: square evidence meets a round patient. <b>2003</b> , 9, 203-5	3
1079	Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. <b>2003</b> , 196, 171-9	98
1078	Early detection of myocardial dysfunction in Chagas disease using novel echocardiographic indices. <b>2003</b> , 97, 528-34	9
1077	HRT, women and heart disease: facts about prevention. <b>2003</b> , 1, 68-71	
1076	Influence of diabetes mellitus on heart failure risk and outcome. <b>2003</b> , 2, 1	125
1075	Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof. <b>2003</b> , 2, 11	36
1074	Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. <b>2003</b> , 64, 1462-71	81
1073	AMGEN International Prize: the history and future of renoprotection. <b>2003</b> , 64, 1163-8	14
1072	The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. <b>2003</b> , 63, 1499-507	365
1071	Retarding the progression of renal disease. <b>2003</b> , 64, 370-8	43
1070	Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. <b>2003</b> , S66-73	43
1069	Cardiovascular risk in patients with mild renal insufficiency. <b>2003</b> , S192-6	48

1068	Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction. <b>2003</b> , S54-7	13
1067	Traditional cardiac risk factors in individuals with chronic kidney disease. <b>2003</b> , 16, 118-27	71
1066	Efforts to determine the role of oxidant stress in dialysis outcomes. <b>2003</b> , 16, 488-91	4
1065	Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. <b>2003</b> , 1, 1575-9	277
1064	Antiarrhythmic drugs: past, present and future. <b>2003</b> , 14, 1389-96	20
1063	[Prevention of stroke]. <b>2003</b> , 153, 6-13	1
1062	Cardiovascular risk in dialysis patients: a comparison of risk factors and cardioprotective therapy between 1996 and 2001. <b>2003</b> , 8, 177-83	18
1061	Stroke prevention: what's new?. <b>2003</b> , 33, 177-81	2
1060	Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study. <b>2003</b> , 33, 414-9	14
1059	Published pharmacoeconomic analyses: science or marketing?. <b>2003</b> , 33, 403-4	6
1058	Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. <b>2003</b> , 5, 214-22	46
1057	Metabolic syndrome - a new risk factor of coronary heart disease?. <b>2003</b> , 5, 359-70	25
1056	Heterogeneity of non-insulin-dependent diabetes expressed as variability in insulin sensitivity, beta-cell function and cardiovascular risk profile. <b>2003</b> , 20, 37-45	22
1055	Pathophysiological implications of insulin resistance on vascular endothelial function. <b>2003</b> , 20, 255-68	198
1054	The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. <b>2003</b> , 20, 607-21	60
1053	Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines. <b>2003</b> , 20, 972-87	37
1052	Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. <b>2003</b> , 4, 43-55	147
1051	Association between ACE inhibitors use and headache caused by nitrates among hypertensive patients: results from the Italian group of pharmacoepidemiology in the elderly (GIFA). <b>2003</b> , 23, 901-6	19

1050	Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods. <b>2003</b> , 55, 299-306	8
1049	Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. <b>2003</b> , 55, 604-8	67
1048	Vasopeptidase inhibitors: will they have a role in clinical practice?. <b>2004</b> , 57, 27-36	22
1047	[Now well established! The importance of ACE inhibitors in high blood pressure therapy]. <b>2003</b> , 32, 24-9	2
1046	[New perspectives for patients at risk for atherosclerosis. The importance of ACE inhibitors in cardiovascular prevention]. <b>2003</b> , 32, 36-44	
1045	Implementing MICRO-HOPE in primary care with extra nurse support. <b>2003</b> , 20, 93-96	0
1044	Antiarrhythmic drugs: past, present, and future. <b>2003</b> , 26, 2340-9	1
1043	Better blood pressure control: how to combine drugs. <b>2003</b> , 17, 81-6	104
1042	The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?. <b>2003</b> , 17, 367-72	3
1041	Diarrhoea, vomiting and ACE inhibitors:--an important cause of acute renal failure. <b>2003</b> , 17, 419-23	36
1040	Accurate measurement of arterial pressure. <b>2003</b> , 17, 445-7	6
1039	Why not prescribe the best drugs for hypertension now?. <b>2003</b> , 17, 505-11	5
1038	Treatment and blood pressure control in isolated systolic hypertension vs diastolic hypertension in primary care. <b>2003</b> , 17, 681-7	22
1037	Aggressive blood pressure control in general practice (ABC-GP) study: can the new targets be reached?. <b>2003</b> , 17, 767-73	10
1036	More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2). <b>2003</b> , 17, 747-50	20
1035	Mechanisms, challenges and opportunities in stroke. <b>2003</b> , 4, 399-415	1363
1034	Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. <b>2003</b> , 10, 420-428	14
1033	Cerebrovascular cases. <b>2003</b> , 87, 755-70, vii	

1032	Renal Ischemia as a Predictor of Cardiovascular Morbidity. <b>2003</b> , 14, P159-P164	
1031	[Combined cardiorenal failure: a rapidly expanding clinical entity]. <b>2003</b> , 121, 710-7	1
1030	Treating type 2 diabetes mellitus: a growing epidemic. <b>2003</b> , 78, 411-3	14
1029	[Analysis of differences in flow-mediated dilation in relation to the treatment of coronary patients]. <b>2003</b> , 56, 128-36	2
1028	[Interaction of angiotensin-converting enzyme inhibitors with aspirin]. <b>2003</b> , 121, 631-3	
1027	[The class effect]. <b>2003</b> , 121, 575-82	2
1026	Estudio comparativo de efectividad y tolerabilidad de quinapril 40 mg frente a la combinaci3n de quinapril 20 mg e hidroclorotiazida 12,5 mg en el tratamiento de la hipertensi3n arterial ligera-moderada. <b>2003</b> , 20, 246-251	
1025	Stroke News: Warfarin, Aspirin, Statins, IIb/IIIa Inhibitors, and Cilostazol TBA. <b>2003</b> , 14, P50-P54	
1024	Despu3s del estudio ALLHAT, ¿qu3 sabemos de lo que desconoc3amos sobre el tratamiento de la hipertensi3n arterial?. <b>2003</b> , 56, 642-648	
1023	Therapeutic role of angiotensin II receptor blockers in the treatment of heart failure. <b>2003</b> , 78, 334-8	17
1022	Putting prevention into daily practice. <b>2003</b> , 21, 471-82	3
1021	Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. <b>2003</b> , 38, 374-9	138
1020	Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies. <b>2003</b> , 15, 423-37, vii-viii	
1019	Actualizaci3n (2003) de las Gu3as de Pr3ctica Cl3nica de la Sociedad Espa3ola de Cardiolog3a en hipertensi3n arterial. <b>2003</b> , 56, 487-497	2
1018	ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic. <b>2003</b> , 87, 373-89	13
1017	Utilizaci3n de antihipertensivos en Atenci3n Primaria. <b>2003</b> , 20, 96-104	
1016	[Atheroma plaque stabilization: a new concept based on the dynamic biology of atherosclerosis]. <b>2003</b> , 121, 583-7	6
1015	Heart failure. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 2007-18	59.2 1497



1014	Nitric oxide-releasing drugs. <b>2003</b> , 43, 97-123	178
1013	Cardiac hypertrophy: the good, the bad, and the ugly. <b>2003</b> , 65, 45-79	1153
1012	Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. <b>2003</b> , 42, 2049-59	35
1011	The less familiar face of heart failure. <b>2003</b> , 41, 224-6	6
1010	Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes. <b>2003</b> , 41, 23S-30S	16
1009	ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). <b>2003</b> , 41, 153-66	546
1008	Antioxidants, statins, and atherosclerosis. <b>2003</b> , 41, 1205-10	56
1007	Atherothrombosis, inflammation, and diabetes. <b>2003</b> , 41, 1071-7	190
1006	Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. <b>2003</b> , 41, 1529-38	380
1005	The race for ACE: a simple answer to the controversial puzzle of angiotensin-converting enzyme (ACE) polymorphisms. <b>2003</b> , 41, 1962-3	0
1004	Statins, skin, and the search for a test of endothelial function. <b>2003</b> , 42, 78-80	13
1003	Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. <b>2003</b> , 42, 698-704	39
1002	Acute coronary syndromes, plaque vulnerability, and carotid artery disease: the changing role of atherosclerosis imaging. <b>2003</b> , 42, 1033-6	18
1001	Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. <b>2003</b> , 42, 1161-70	253
1000	Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 383-93	59.2 3185
999	European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <b>2003</b> , 10, S1-S78	44
998	Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. <b>2003</b> , 23, 26-36	136
997	Pharmacological treatment of patients with peripheral arterial disease. <b>2003</b> , 63, 637-47	9

996	Current management strategies for coexisting diabetes mellitus and obesity. <b>2003</b> , 63, 1165-84	65
995	"Systolic and diastolic dysfunction" in heart failure? Time for a new paradigm. <b>2003</b> , 9, 1-3	51
994	Diets and clinical coronary events: the truth is out there. <b>2003</b> , 107, 10-6	36
993	The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. <b>2003</b> , 96, 465-80	109
992	Insulin sensitivity and the risk of incident hypertension: insights from the Insulin Resistance Atherosclerosis Study. <b>2003</b> , 26, 805-9	84
991	Agents that stabilise atherosclerotic plaque. <b>2003</b> , 12, 1681-92	1
990	Preconditioning the myocardium: from cellular physiology to clinical cardiology. <b>2003</b> , 83, 1113-51	838
989	Are there benefits to specific antihypertensive drug therapy?. <b>2003</b> , 16, 31S-35S	11
988	Recommendations for special populations: diabetes mellitus and the metabolic syndrome. <b>2003</b> , 16, 41S-45S	59
987	Tolerability and treatment compliance with angiotensin II receptor antagonists. <b>2003</b> , 16, 1066-73	36
986	Patient care before and after percutaneous coronary artery interventions. <b>2003</b> , 115, 642-51	6
985	Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. <b>2003</b> , 145, 993-8	22
984	Endothelial dysfunction: clinical strategies for treating oxidant stress. <b>2003</b> , 146, 218-26	64
983	Heart failure: how big is the problem? Who are the patients? What does the future hold?. <b>2003</b> , 146, 1-4	68
982	Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. <b>2003</b> , 146, E20	32
981	Screening for early detection of cardiovascular disease in asymptomatic individuals. <b>2003</b> , 146, 679-85	55
980	Evidence-based care for all patients. <b>2003</b> , 114, 333-5	4
979	Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. <b>2003</b> , 114, 588-98	44

978	Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. <b>2003</b> , 115, 467-72	55
977	Endothelial dysfunction: a marker of atherosclerotic risk. <b>2003</b> , 23, 168-75	1635
976	Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. <b>2003</b> , 5, 202-9	72
975	The differences between ACE inhibitor-treated and calcium channel blocker-treated hypertensive patients. <b>2003</b> , 5, 337-44	1
974	Drugs that interrupt the renin-angiotensin system should be among the preferred initial drugs to treat hypertension. <b>2003</b> , 5, 137-44	7
973	Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. <b>2003</b> , 5, 66-75	24
972	Treatment of hypertension in African Americans and Latinos: the effect of JNC VI on urban prescribing practices. <b>2003</b> , 5, 107-12	13
971	The diagnosis and management of renovascular disease: a primary care perspective. Part II. Issues in management. <b>2003</b> , 5, 261-8	2
970	Common questions and answers in the management of hypertension: Am I more likely to develop diabetes if I have high blood pressure?. <b>2003</b> , 5, 175-6	1
969	Blockade of the renin-angiotensin system in African Americans with hypertension and cardiovascular disease. <b>2003</b> , 5, 12-7	12
968	Hypertension in the metabolic syndrome and diabetes: pathogenesis, clinical studies, and treatment. <b>2003</b> , 5, 3-10	4
967	Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice. <b>2003</b> , 5, 414-20	17
966	Treatment of high-risk African American patients: left ventricular dysfunction, heart failure, renal disease, and postmyocardial infarction. <b>2003</b> , 5, 26-31	2
965	Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. <b>2003</b> , 163, 1296-304	81
964	ACE inhibitors reduce all-cause mortality in people with asymptomatic or symptomatic left ventricular dysfunction. <b>2003</b> , 7, 186-188	
963	Ramipril for the prevention and treatment of cardiovascular disease. <b>2003</b> , 37, 412-9	9
962	The clinical implications of endothelial dysfunction. <b>2003</b> , 42, 1149-60	1219
961	Long-term statin safety and efficacy in secondary prevention: can combination therapy improve outcomes?. <b>2003</b> , 4, 11-6	8

960	Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft für Kardiologie [Herz- und Kreislaufforschung (DGK). <b>2003</b> , 92, 501-521	60
959	Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. <b>2003</b> , 35, 185-93	146
958	Essential hypertension. <b>2003</b> , 361, 1629-41	347
957	Increasing burden of treatment in the acute coronary syndromes: is it justified?. <b>2003</b> , 361, 1813-6	9
956	MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. <b>2003</b> , 361, 2005-16	2185
955	Demographics and concomitant disorders in heart failure. <b>2003</b> , 362, 147-58	118
954	Comparison of cardioprotective effects using ramipril and DanShen for the treatment of acute myocardial infarction in rats. <b>2003</b> , 73, 1413-26	118
953	A major health hazard: the metabolic syndrome. <b>2003</b> , 73, 2395-411	149
952	How to ADVANCE prevention of cardiovascular complications in type 2 diabetes. <b>2003</b> , 52, 24-8	7
951	Ischemic heart disease in type 2 diabetes. <b>2003</b> , 52, 6-12	11
950	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <b>2003</b> , 362, 759-66	1506
949	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. <b>2003</b> , 362, 777-81	2087
948	Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). <b>2003</b> , 362, 782-8	1630
947	Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?. <b>2003</b> , 362, 755-7	31
946	Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. <b>2003</b> , 362, 1527-35	1958
945	The EUROPA trial. <b>2003</b> , 362, 1935; author reply 1936-7	3
944	The EUROPA trial. <b>2003</b> , 362, 1935; author reply 1936-7	
943	Combine EUROPA and HOPE. <b>2003</b> , 362, 1937	4

942	Olmesartan medoxomil: an angiotensin II-receptor blocker. <b>2003</b> , 25, 1041-55	31
941	Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study. <b>2003</b> , 25, 1248-61	7
940	New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione. <b>2003</b> , 25, 1895-917	13
939	The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. <b>2003</b> , 25, 2647-68	21
938	Heart Failure: Current Concepts. <b>2003</b> , 59, 283-5	1
937	Renin-angiotensin system and endothelial function. <b>2003</b> , 1253, 205-208	
936	Diabetes mellitus, oxidative stress and endothelial dysfunction. <b>2003</b> , 1253, 125-138	4
935	Can the premises of the altered homeostatic theory permit improvement in the prevention of ischemic heart disease?. <b>2003</b> , 60, 12-25	3
934	The role of vitamin E in atherosclerosis. <b>2003</b> , 42, 405-22	100
933	Omapatrilat may indeed not be much superior (OMINOUS). <b>2003</b> , 91, 113	3
932	Cilazapril treatment in a cohort of seven patients with congestive heart failure: a seven-year follow-up study. <b>2003</b> , 64, 167-75	
931	Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry. <b>2003</b> , 145, 343-8	27
930	Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. <b>2003</b> , 145, 80-7	63
929	Left atrial thrombus, transient ischemic attack, and atrial fibrillation: does left atrial thrombus predict? Does absence protect?. <b>2003</b> , 145, 582-5	4
928	Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. <b>2003</b> , 107, 1284-90	176
927	Screening for high blood pressure: a review of the evidence for the U.S. Preventive Services Task Force. <b>2003</b> , 25, 151-8	72
926	Coronary artery disease: new insights into the pathophysiology, prevalence and early detection of a monster menace. <b>2003</b> , 24, 114-22	3
925	SELECT: the selenium and vitamin E cancer prevention trial. <b>2003</b> , 21, 59-65	116

924	Different drug classes have variable effects on blood pressure depending on the time of day. <b>2003</b> , 16, 46-50	28
923	[Should type 2 diabetes prevention pharmacological studies prompt us to change our prescription habits?]. <b>2003</b> , 29, 547-53	2
922	The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. <b>2003</b> , 35, 807-25	311
921	Skeletal muscle RAS and exercise performance. <b>2003</b> , 35, 855-66	132
920	Angina pectoris: interventional therapies and treatment of restenosis. <b>2003</b> , 35, 1399-406	3
919	Individualizaci3n del tratamiento antihipertensivo. Pasado, presente y futuro. <b>2003</b> , 203, 55-56	
918	Tratamiento de la hipertensi3n arterial. <b>2003</b> , 120, 108-116	
917	F3rmacos antihipertensivos en Atenci3n Primaria. <b>2003</b> , 20, 91-95	
916	A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 583-92	59.2 903
915	Peripheral arterial disease in people with diabetes. <b>2003</b> , 26, 3333-41	755
914	AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism. <b>2003</b> , 41, 1092-5	56
913	Caracter3sticas de los pacientes con cardiopat3as en un 3rea sanitaria de la provincia de A Coru3a. Estudio Barbanza 2000. <b>2003</b> , 203, 570-576	13
912	Estratificaci3n y objetivos terap3uticos del riesgo cardiovascular. <b>2003</b> , 203, 349-350	
911	Initial treatment of hypertension. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 610-7	59.2 76
910	Benefits of optimising drug treatment in home-dwelling elderly patients with coronary artery disease. <b>2003</b> , 20, 585-95	6
909	The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease. <b>2003</b> , 20, 241-51	13
908	Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. <b>2003</b> , 1, 43-50	64
907	Mechanisms underlying endothelial dysfunction in diabetes mellitus: therapeutic implications. <b>2003</b> , 2, 293-304	35

906	Cost Effectiveness of Diabetes Mellitus Management Programs. <b>2003</b> , 11, 439-453	6
905	Angiotensin-converting enzyme (ACE) inhibitor therapy after myocardial infarction in relation to left ventricular function. <b>2003</b> , 37, 130-4	3
904	Rat models of the metabolic syndrome. <b>2003</b> , 86, 29-46	33
903	Atherosclerotic plaque rupture: local or systemic process?. <b>2003</b> , 23, 2123-30	110
902	Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. <b>2003</b> , 34, 2741-8	408
901	Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. <b>2003</b> , 24, 28-66	946
900	Angiotensin II inhibition increases cellular glucose transport during reperfusion but not ischemia in pig hearts. <b>2003</b> , 37, 205-10	4
899	What are the best first-line antihypertensives: answers and more questions from the ALLHAT study. <b>2003</b> , 12, 879-85	0
898	Treatment of Hypertension. <b>2003</b> , 10, 7-9	
897	Angiotensin Receptor Blockers. <b>2003</b> , 10, 47-49	
896	The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy. <b>2003</b> , 21, 573-85	13
895	Transient ischaemic attacks : new approaches to management. <b>2003</b> , 17, 293-305	
894	Stable Angina. <b>2003</b> , 3, 1-10	7
893	The Pursuit of Optimum Outcomes in Stable Angina. <b>2003</b> , 3, 11-20	8
892	Spotlight on ramipril in the prevention of cardiovascular outcomes. <b>2003</b> , 3, 113-6	2
891	ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control. <b>2003</b> , 3, 351-60	8
890	Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. <b>2003</b> , 3, 389-94	48
889	Angiotensin-converting enzyme gene polymorphisms in patients with pulmonary sarcoidosis: impact on disease severity. <b>2003</b> , 3, 233-43	18

888	Implications of the LIFE trial. <b>2003</b> , 12, 871-7	4
887	Is there HOPE for ALLHat: similarities and differences. <b>2003</b> , 1, 1-2	
886	Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. <b>2003</b> , 42, 1206-52	10207
885	Losartan for LIFE in hypertension with left ventricular hypertrophy?. <b>2003</b> , 4, 115-8	2
884	Candesartan and hydrochlorothiazide in isolated systolic hypertension. <b>2003</b> , 12, 246-54	7
883	A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. <b>2003</b> , 290, 2805-16	912
882	Editor's Note. <b>2003</b> , 16, 156-156	
881	Plaque stabilisation in acute coronary syndromes: clinical considerations. <b>2003</b> , 89, 1268-72	4
880	Type 2 diabetes as an inflammatory disorder. <b>2003</b> , 3, 36-41	14
879	Review: Peripheral arterial disease in diabetes: time for a co-ordinated approach to management. <b>2003</b> , 3, 92-96	3
878	Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction. <b>2003</b> , 4, 180-5	7
877	Early and late effects of clopidogrel in patients with acute coronary syndromes. <b>2003</b> , 107, 966-72	250
876	Potential of renin inhibition in cardiovascular disease. <b>2003</b> , 4, 6-10	57
875	Review: The management of stable angina in diabetes. <b>2003</b> , 3, 18-25	2
874	Downregulation of vascular angiotensin II type 1 receptor by thyroid hormone. <b>2003</b> , 41, 598-603	63
873	C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. <b>2003</b> , 107, 1783-90	433
872	Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"?. <b>2003</b> , 108, 2608-10	23
871	Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. <b>2003</b> , 42, 500-6	73



870	Critical issues in peripheral arterial disease detection and management: a call to action. <b>2003</b> , 163, 884-92	398
869	Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. <b>2003</b> , 289, 2534-44	647
868	Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). <b>2003</b> , 107, 1291-6	200
867	The challenges of treating peripheral arterial disease. <b>2003</b> , 8, 109-14	13
866	Should the multicenter carotid endarterectomy trials be repeated?. <b>2003</b> , 60, 774-5	28
865	Composite outcomes in randomized trials: greater precision but with greater uncertainty?. <b>2003</b> , 289, 2554-9	459
864	Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?. <b>2003</b> , 41, 31-6	85
863	Management of stable angina. <b>2003</b> , 79, 332-6	5
862	Secondary prevention of coronary heart disease in the elderly. <b>2003</b> , 37, 1867-76	23
861	A rational basis for selection among drugs of the same class. <b>2003</b> , 89, 687-94	7
860	Drug therapy and heart failure prevention. <b>2003</b> , 107, 1234-6	15
859	The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease. <b>2003</b> , 8, 273-8	23
858	Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance. <b>2003</b> , 4, 149-54	20
857	Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. <b>2003</b> , 14, 641-7	110
856	Renal Disease. <b>2003</b> ,	1
855	Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?. <b>2003</b> , 4, 62-73	7
854	Pharmacoeconomic implications of large multicenter clinical trials. <b>2003</b> , 37, 447-50	1
853	The prevention or delay of type 2 diabetes. <b>2003</b> , 26 Suppl 1, S62-9	44

852	Treatment of uncomplicated hypertension: are ACE inhibitors and calcium channel blockers as effective as diuretics and beta-blockers?. <b>2003</b> , 16, 156-64	6
851	Effect of chronic treatment with the vasoepitidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits. <b>2003</b> , 4, 191-6	6
850	European Stroke Initiative Recommendations for Stroke Management-update 2003. <b>2003</b> , 16, 311-37	480
849	Detecting occult coronary disease in a high-risk asymptomatic population. <b>2003</b> , 107, 702-7	39
848	Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention. <b>2003</b> , 89, 321-5	15
847	N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. <b>2003</b> , 14, 863-72	71
846	Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. <b>2003</b> , 163, 525-41	314
845	Tissue angiotensin-converting-enzyme (ACE) deficiency leads to a reduction in oxidative stress and in atherosclerosis: studies in ACE-knockout mice type 2. <b>2003</b> , 23, 2090-6	26
844	Secondary prevention of renal and cardiovascular disease: results of a renal and cardiovascular treatment program in an Australian aboriginal community. <b>2003</b> , 14, S178-85	18
843	Selective COX-2 inhibition improves endothelial function in coronary artery disease. <b>2003</b> , 107, 405-9	307
842	Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?. <b>2003</b> , 34, 354-6	14
841	Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register. <b>2003</b> , 25, 29-35	66
840	Drug therapy for prevention of recurrent myocardial infarction. <b>2003</b> , 37, 1465-77	21
839	Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. <b>2003</b> , 107, 251-7	119
838	Meeting the challenge of peripheral arterial disease. <b>2003</b> , 163, 877-8	14
837	Left ventricular size, mass and function in relation to angiotensin-converting enzyme gene and angiotensin-II type 1 receptor gene polymorphisms in patients with coronary artery disease. <b>2003</b> , 41, 522-8	5
836	Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. <b>2003</b> , 139, 169-77	47
835	Angiotensin type 2 receptor (AT2R): a challenging twin. <b>2003</b> , 2003, PE16	30

834	Reducing cardiovascular risk in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 457-9	59.2	43
833	Drug therapy of heart failure in the elderly. <b>2003</b> , 12, 235-42		9
832	Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction. <b>2003</b> , 12, 501-7		3
831	Angiotensin II and Inflammation: The Effect of ACE Inhibition and Angiotensin II Receptor Blockade. <b>2003</b> , 1, 255-9		2
830	Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. <b>2003</b> , 88, 4496-501		172
829	Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes. <b>2003</b> , 4, 1543-50		2
828	ALLHAT and ANBP2: what have we learned from recent mega-trials?. <b>2003</b> , 12, 267-71		3
827	Outcomes of treating hypertension in the elderly: a short commentary on current issues. <b>2003</b> , 12, 14-8		8
826	The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease. <b>2003</b> , 12, 759-70		38
825	How should we implement current evidence on ACE-inhibition in the treatment of patients surviving a myocardial infarction?. <b>2003</b> , 37, 122-3		
824	Validation of the archimedes diabetes model. <b>2003</b> , 26, 3102-10		152
823	Consultations on patients with venous or arterial diseases. <b>2003</b> , 2003, 540-58		2
822	Developing pharmaceutical treatments for peripheral artery disease. <b>2003</b> , 12, 101-8		5
821	Novel pharmacological treatments for heart failure. <b>2003</b> , 12, 1791-801		11
820	Renin inhibitors as novel treatments for cardiovascular disease. <b>2003</b> , 13, 589-603		29
819	Management of glomerular proteinuria: a commentary. <b>2003</b> , 14, 3217-32		166
818	Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. <b>2003</b> , 24, 475-84		35
817	First-trimester C-reactive protein and subsequent gestational diabetes. <b>2003</b> , 26, 819-24		178

816	Heart failure: the frequent, forgotten, and often fatal complication of diabetes. <b>2003</b> , 26, 2433-41	325
815	Beneficial effects of antioxidants and L-arginine on oxidation-sensitive gene expression and endothelial NO synthase activity at sites of disturbed shear stress. <b>2003</b> , 100, 1420-5	93
814	HOPE study impact on ACE inhibitors use. <b>2003</b> , 37, 640-5	9
813	Drug induced QT prolongation and torsades de pointes. <b>2003</b> , 89, 1363-72	650
812	Economic impact of ramipril on hospitalization of high-risk cardiovascular patients. <b>2003</b> , 37, 327-31	8
811	Vitamin E and its role in the prevention of atherosclerosis and carcinogenesis: a review. <b>2003</b> , 22, 258-68	85
810	Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. <b>2003</b> , 17, 1096-8	149
809	Blocking the renin-angiotensin-aldosterone system or lowering the blood pressure: does EUROPA help?. <b>2003</b> , 4, 205-6	1
808	Blood pressure in young adulthood and the risk of type 2 diabetes in middle age. <b>2003</b> , 26, 1110-5	27
807	The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study. <b>2003</b> , 26, 144-9	47
806	Insulin resistance and chronic cardiovascular inflammatory syndrome. <b>2003</b> , 24, 278-301	653
805	Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. <b>2003</b> , 107, 1923-9	46
804	Effect of an educational program on the prevalence of use of antiplatelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease. <b>2003</b> , 58, 1046-8	18
803	Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. <b>2003</b> , 5, 261-70	98
802	Mechanisms of oxidative stress and vascular dysfunction. <b>2003</b> , 79, 195-199; quiz 198-200	119
801	Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. <b>2003</b> , 5, 697-704	11
800	Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. <b>2003</b> , 107, 960-5	51
799	Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. <b>2003</b> , 42, 1137-43	286

798	Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. <b>2003</b> , 289, 1941-9	280
797	The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. <b>2003</b> , 285, R1-13	122
796	AT1 receptors in atherosclerosis: biological effects including growth, angiogenesis, and apoptosis. <b>2003</b> , 5, A9-A13	4
795	Therapeutic effects of evening administration of guanabenz and clonidine on morning hypertension. <b>2003</b> , 21, 701-3	0
794	Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. <b>2003</b> , 24, 1672-80	45
793	New evidence for angiotensin-converting enzyme inhibition in stroke, cardiac and renal patients: the cardiological approach. <b>2003</b> , 5, E1-E3	
792	Anti-platelet function of human endothelial cells: augmentation by angiotensin-converting enzyme inhibitors?. <b>2003</b> , 21, 1259-61	1
791	Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. <b>2006</b> , 2, 221-37	55
790	Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data. <b>2006</b> , 2, 341-9	4
789	Insulin resistance and plasma triglyceride level are differently related to cardiac hypertrophy and arterial stiffening in hypertensive subjects. <b>2006</b> , 2, 485-90	7
788	Effets des inhibiteurs calciques sur la progression de l'athérosclérose et de l'épaisseur intima-média. <b>2000</b> , 59, 39-46	3
787	Etude ADVANCE : objectifs, protocole et état actuel. <b>2003</b> , 63, 39-44	5
786	Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases. <b>2013</b> , 19, 1114-25	32
785	Prevention of Vascular Complications in Diabetes Mellitus Patients: Focus on the Arterial Wall. <b>2019</b> , 17, 6-15	9
784	Heart failure in South Asia. <b>2013</b> , 9, 102-11	49
783	The vulnerable plaque: the real villain in acute coronary syndromes. <b>2011</b> , 5, 123-9	14
782	Trends in the Use of Evidence-based Therapies Early in the Course of Acute Myocardial Infarction and its Influence on Short Term Patient Outcomes. <b>2011</b> , 5, 171-8	5
781	Comparative Effects of Preoperative Angiotensin-converting Enzyme Inhibitor, Statin and Beta-blocker Treatment on Human Internal Mammary Artery Reactivity in Patients with Coronary Artery Disease: A Pilot Study. <b>2013</b> , 7, 69-75	3

780	An electronic clinical decision support tool to assist primary care providers in cardiovascular disease risk management: development and mixed methods evaluation. <b>2009</b> , 11, e51	48
779	Telemedicine in Primary Care for Patients With Chronic Conditions: The ValCrific Quasi-Experimental Study. <b>2017</b> , 19, e400	30
778	Treatment of hypertension in the diabetic patient. <b>2009</b> , 6, 497-505	3
777	[Endothelial dysfunction and diabetes]. <b>2005</b> , 58, 459-64	2
776	Implications of the New 2017 American College of Cardiology/American Heart Association Guidelines for Hypertension. <b>2019</b> , 67, 399-410	4
775	Physician perceptions of blood pressure control in patients with chronic kidney disease and target blood pressure achievement rate. <b>2017</b> , 36, 349-357	2
774	Hypertension and Diabetes. <b>2007</b> , 417-436	0
773	Diabetes Mellitus and Cardiovascular Disease in the Elderly. <b>2008</b> , 179-214	2
772	Angina in the Elderly. <b>2008</b> , 269-292	5
771	Therapy of Acute Myocardial Infarction. <b>2008</b> , 293-326	2
770	Management of the Older Patient After Myocardial Infarction. <b>2008</b> , 327-350	2
769	Ventricular Arrhythmias in the Elderly. <b>2008</b> , 605-626	3
768	Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. <b>2017</b> , 21, 1-218	31
767	Stabilnřangina pectoris. Doporuřenřdiagnostickř lřbnřpostup řskřkardiologickř spoleřosti. <b>2010</b> , 52, 543-561	5
766	Hepatic steatosis: a benign disease or a silent killer. <b>2008</b> , 14, 4120-6	49
765	The urgent call of albuminuria/proteinuria. Heeding its significance in early detection of kidney disease. <b>2001</b> , 110, 79-82, 87-8, 93-6	6
764	Treatment of Heart Failure with Reduced Ejection Fraction: Current Update. <b>2015</b> , 88, 127	4
763	Impact of Angiotensin II Receptor Blockers on Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Based on Data from the Korean National Health Insurance Database (2005-2014). <b>2020</b> , 50, 984-994	1

762	Nitric oxide and cardiovascular risk factors. <b>2007</b> , 3, 18	7
761	Randomized, Open Label, Multicenter Clinical Trial about the Effect of Cilazapril on Vascular Endothelial Function in Patients with Type 2 Diabetes Combined with Hypertension. <b>2006</b> , 30, 450	1
760	Suboptimal use of risk reduction therapy in peripheral arterial disease patients at a major teaching hospital. <b>2011</b> , 31, 371-5	9
759	Postrandomization Confounding Challenges the Applicability of Randomized Clinical Trials in Comparative Effectiveness Research. <b>2017</b> , 130, 993-996	1
758	Stroke management. <b>2011</b> , 14, S82-96	24
757	Antihypertensive Medicines Prescriptions before and after the Nigeria Hypertension Society Guidelines and Prescriber's Awareness of the Guideline. <b>2017</b> , 58, 107-113	2
756	Perioperative myocardial injury and infarction following non-cardiac surgery: A review of the eclipsed epidemic. <b>2020</b> , 14, 91-99	5
755	Atherosclerosis: A Link between Lipid Intake and Protein Tyrosine Nitration. <b>2008</b> , 2, LPI.S1030	6
754	Review of Medical Treatment of Stable Ischemic Heart Disease. <b>2014</b> , 05, 249-259	1
753	Alphabet Strategy for diabetes care: A multi-professional, evidence-based, outcome-directed approach to management. <b>2015</b> , 6, 874-9	11
752	2014 ESC/EACTS guidelines on myocardial revascularization. <b>2015</b> , 10, 1024-94	195
751	Perioperative clinical variables and long-term survival following vascular surgery. <b>2014</b> , 6, 1100-7	3
750	Effect of paricalcitol and enalapril on renal inflammation/oxidative stress in atherosclerosis. <b>2015</b> , 6, 240-8	10
749	The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease. <b>2015</b> , 6,	1
748	Aortic Compliance and Stiffness Among Severe Longstanding Hypertensive and Non-hypertensive. <b>2013</b> , 21, 12-5	4
747	How and why chemicals from tobacco smoke can induce a rise in blood pressure. <b>2012</b> , 1, 10	3
746	TELMISARTAN IN THE TREATMENT OF HYPERTENSION IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY. <b>2004</b> , 148, 69-73	9
745	HEART FAILURE AND FIRST DOSE HYPOTENSION AFTER ANGIOTENSIN CONVERTING ENZYME INHIBITORS. <b>2004</b> , 148, 113-118	1

744	Plaque-stabilizing effect of angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker in a rabbit plaque model. <b>2013</b> , 20, 257-66	11
743	Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee. <b>2020</b> , 27, 809-907	16
742	Clinical outcomes associated with changes in a chronic disease treatment program in an Australian Aboriginal community. <b>2005</b> , 183, 305-9	24
741	The Effect of Chronic Consumption of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists on Blood Pressure and Inotrope Consumption After Separation from Cardiopulmonary Bypass. <b>2018</b> , 8, e74026	1
740	Ramipril-associated hepatotoxicity. <b>2003</b> , 127, 1493-7	41
739	7th Brazilian Guideline of Arterial Hypertension: Chapter 7 - Pharmacological Treatment. <b>2016</b> , 107, 35-43	7
738	The 2017 Focused Update of the Guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the Management of Hypertension. <b>2017</b> , 33, 213-225	37
737	Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate. <b>2018</b> , 7, 212557	10
736	Management of type 2 diabetes: consensus of diabetes organizations. <b>2020</b> , 9, 212607	7
735	The care management institute: harvesting innovation, maximizing transfer. <b>2005</b> , 9, 37-9	2
734	The B-SMART Appropriate Medication-Use Process: A Guide for Clinicians to Help Patients- Part 1: Barriers, Solutions, and Motivation. <b>2009</b> , 13, 62-9	9
733	Implementation and methodology of a multidisciplinary disease-state-management program for comprehensive diabetes care. <b>2011</b> , 15, 43-8	14
732	Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis. <b>2021</b> ,	10
731	Myocardial injury in noncardiac surgery. <b>2021</b> ,	0
730	Benefit/risk ratio profile of single inhaler triple therapy for bronchial obstructive pulmonary disease patients. <b>2021</b> , 31, 645-652	
729	Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. <b>2021</b> , 10, e021412	0
728	Practical efficacy and safety of Konsilar D24 in patients with hypertension: data from the KONSONANS program. <b>2021</b> , 26, 4651	3
727	Incident Heart Failure in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <b>2021</b> , 8, 727727	2



- 726 HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation. **2000**, 17 Suppl 2, 9-10 1
- 725 Prevention. **2000**, 15, 343-7
- 724 Vitamine und Neuropathiepräparate. **2001**, 716-728
- 723 Evaluative and epidemiological approaches of ACE therapy. **2001**, 47-70
- 722 Antihypertensive Therapie bei Diabetes mellitus. **2001**, 191-206 0
- 721 Die Behandlung der Herzinsuffizienz: eine Übersicht. **2001**, 1-10
- 720 Persistierende Ischämie trotz Intervention und/oder Operation: Welche therapeutischen Optionen bleiben?. **2001**, 47-53
- 719 Praktische Konsequenzen der HOPE-Studie. **2001**, 86-90
- 718 Role of Interleukins in Relation to the Renin-Angiotensinsystem in Atherosclerosis. **2001**, 129-140
- 717 Vitamine und Neuropathiepräparate. **2001**, 672-686
- 716 ACE-Hemmer und Angiotensin-rezeptorantagonisten. **2001**, 51-64
- 715 ACE-Hemmer und Angiotensinrezeptorantagonisten. **2001**, 72-88
- 714 ACE-Hemmer bei der Behandlung der Herzinsuffizienz Ein Update. **2001**, 11-23
- 713 Evaluation and Management of the Patient with Hypertension. **2001**, 133-142
- 712 New opportunities for stroke prevention and therapeutics: a hope from anti-inflammatory drugs?. **2001**, 3-10 1
- 711 Coronary artery disease: part 2. Treatment. **2001**, 174, 330-5 1
- 710 A cardiac prevention and rehabilitation programme for all patients at first presentation with coronary artery disease. **2001**, 85, 533-538
- 709 Cost effectiveness of ramipril treatment for cardiovascular risk reduction. **2001**, 85, 539-543

- 708 Matching the right drug to the right patient in essential hypertension. **2001**, 86, 113-120 1
- 707 Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. **2001**, 86, 217-220
- 706 Implementation of the NICE guidelines for the primary prevention of mortality from ventricular tachyarrhythmias: implications for UK electrophysiology centres; activity modelling from the UK-HEART study. **2001**, 86, 219-20 1
- 705 Cross sectional study estimating prevalence of heart failure and left ventricular systolic dysfunction in community patients at risk. **2001**, 86, 172-178 2
- 704 Clinical Assessment of Endothelial Function. **2002**, 691-700
- 703 Microalbuminuria in Perspectives. **2002**, 105-120 2
- 702 Angiotensin-converting Enzyme Inhibition and Angiotensin Receptor Blockade. **2002**, 193-209
- 701 Do ACE inhibitors limit response to EPO and should EPO be continued in patients with sepsis or fever?. **2002**, 99-106
- 700 Coronary Artery Disease and Endothelial Function. **2002**, 887-912
- 699 Pharmaka zur Behandlung der Herzinsuffizienz. **2002**, 305-329
- 698 Koronarpharmaka. **2002**, 343-360
- 697 Antihypertensiva. **2002**, 361-391
- 696 How to Achieve Maximal Renoprotection in Non-Diabetic Chronic Renal Disease. **2002**, 1-8
- 695 Drug Prevention of Sudden Death after Myocardial Infarction: Role of Angiotensin Converting Enzyme Inhibitors. **2002**, 254-257
- 694 Atherosclerotic Lesions: Vulnerability. **2002**, 327-339
- 693 Cardiovascular Disease in Women. **2002**, 317-321
- 692 Metabolic Pathogenesis of Cardio-Renal Disease. **2002**, 39-43
- 691 Vascular Disease in Diabetes Mellitus. **2002**, 995-1008

690 Special Therapeutic Considerations. **2002**, 231-257

689 The 2000s—decade of prevention. **2002**, 9, 127-129

688 References. **2002**, 85-89

687 Insulin: Promise and problems at 80 years. **2002**, 9, 283-284

686 References. **2002**, 106, 3373-3421

1

685 Is There a Role for Vitamin E in the Prevention of Atherosclerosis?. **2003**,

684 Arterielle Hypertonie. **2003**, 224-240

683 Medical Treatment of Carotid Artery Disease. **2003**, 12, 362-369

682 Recent Therapeutic Trials. **2003**, 175-184

681 Empfehlungen der Europäischen Schlaganfall-Initiative zur Versorgung und Behandlung des Schlaganfalls. **2003**, 96-112

680 Coronary Artery Disease in Developing and Newly Industrialized Countries: A Scientific Statement of the International College of Cardiology. **2003**, 473-487

4

679 Koronarinsuffizienz und Herzinfarkt. **2003**, 3-29

678 What are the Effects of Dietary Supplements (Selenium and Vitamin E) or Aspirin/NSAIDs on Prostate Cancer?. **2003**, 193-205

677 The Newer Coronary Risk Factors. **2003**, 193-211

676 Hypertension in Type 2 Diabetes Mellitus. **2003**, 63-84

1

675 ACE-Hemmer und Angiotensinrezeptorantagonisten. **2003**, 67-88

674 Prevention of Stroke. **2003**, 349-362

673 Management of Acute Coronary Syndromes. **2003**, 15-36

672 Renal Artery Disease. **2003**, 81-109

671 Prevention of Heart Failure—Clinical Reality?. **2003**, 549-561

670 Global Approach to Cardiovascular Risk in Type 2 Diabetic Persons. **2003**, 240-276

669 Cerebrovascular Disease in Diabetes Mellitus.

668 Hemostatic Abnormalities in Diabetes.

667 Clinical Features and Treatment of Coronary Heart Disease in Diabetes.

666 Medical Management of Angina Pectoris. **2003**, 127-135

665 Omapatrilat. **2003**, 141-157

664 Screening for Diabetes and Glucose Intolerance.

663 Arterial Hypertension in Diabetes: Etiology and Treatment.

662 Angina. **2003**, 39-53

661 Long-Term Medical Management of Ischemic Stroke and Transient Ischemic Attack Due to Arterial Disease. **2004**, 1129-1150

660 Heart Failure in the Frail Elderly. **2004**, 139-162

659 Inhibitors of the RAS: Evidence-Based Medicine. **2004**, 545-592

658 Kininases. **2004**, 490-496

657 Verordnungsprofil der Internisten. **2004**, 1013-1041

656 Clinical Pharmacology of Angiotensin II Receptor Antagonists. **2004**, 453-484

655 NEP/ACE Inhibitors: Experimental and Clinical Aspects. **2004**, 519-542

654 Combined Blockade of the Renin Angiotensin System with ACE Inhibitors and AT1 Receptor Antagonists. **2004**, 485-516

653 Angiotensin, Neuroplasticity and Stroke. **2004**, 163-189

652 Herz, Gefäß, Lunge. **2004**, 81-196

651 Angiotensin II and Atherosclerosis. **2004**, 21-38

1

650 Medical Management of Renovascular Hypertension. **2004**, 91-107

649 Biologic and Therapeutic Effects of Dehydroepiandrosterone and Structural Analogs. **2004**, 291-300

648 ACE-Hemmer und Angiotensinrezeptorantagonisten. **2004**, 179-206

647 ACE-Hemmer und Angiotensinrezeptorantagonisten. **2004**, 88-114

646 Prävention der koronaren Herzerkrankung. **2004**, 1119-1147

645 Diabetes. **2004**, 79-86

644 Posttransplant Management. **2004**, 123-157

643 Diabetic Nephropathy. **2004**, 353-365

642 Einsparpotentiale. **2004**, 863-914

641 Renin-Angiotensin Inhibitors and Vascular Effects. **2004**, 65-78

640 Angiotensin II/Autonomic Interactions. **2004**, 168-171

1

639 Arterial'naya gipertoniya i ishemicheskaya bolezni' serdtsa: poisk optimal'nykh podkhodov k lecheniyu (po rezul'tatam issledovaniya INVEST). **2004**, 1, 30-34

638 Should We Treat Impaired Glucose Tolerance and Impaired Fasting Glycemia?.

637 The PROGRESS trial three years later: HOPE trial may shed some light. **2004**, 329, 1403-4

- 636 ACE Genotyping. **2004**, 7-11
- 635 Cerebrovascular Disease in the Elderly Hypertensive. **2005**, 255-293
- 634 Inhibition of the Renin-Angiotensin-Aldosterone System. **2005**, 195-212
- 633 Advances in the Acute Treatment and Secondary Prevention of Stroke. **2005**, 21-33
- 632 A Attitudes Regarding Hypertension Among Older African-American Adults. **2005**, 429-450
- 631 Critical Assessment of Hypertension Guidelines. **2005**, 391-399
- 630 The VALUE Trial. **2005**, 366-375
- 629 Vascular Inflammation as a Cardiovascular Risk Factor. **2005**, 577-604
- 628 The care management institute: making the right thing easier to do. **2005**, 9, 56-7 2
- 627 The kaiser permanente northwest cardiovascular risk factor management program: a model for all. **2005**, 9, 19-26
- 626 Screening for type 2 diabetes. **2005**, 714-750
- 625 Renin-angiotensin-aldosterone system (RAAS) blockade in peripheral arterial diseases. **2005**, 65-74
- 624 Blood pressure lowering - is degree more important than method?. **2006**, 060609075558027
- 623 History of Hypertension. **2005**, 3-14
- 622 Myocardial Infarction. **2005**, 367-383
- 621 Medical Treatment of Peripheral Arterial Disease. **2006**, 271-292
- 620 The benefits and pitfalls of evidence-based medicine. **2006**, 48, 24-31 3
- 619 Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention. **2006**, 2006, 94-96

- 618 Epidemiology of Cerebrovascular Disease \* \*This work was supported in part by the National Institute of Neurological Disorders and Stroke Grant No. 5R01 NS17950 and the National Heart, Lung, and Blood Institute's Framingham Heart Study Contract No. N01-HC-25195.. **2006**, 411-432
- 617 Hoe groot is de kans op nierinsufficiëntie bij de oudere patiënt met diabetes en licht verhoogde bloedsuikers?. **2006**, 2395-2396
- 616 Data Monitoring in the Heart Outcomes Prevention Evaluation and the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trials: Avoiding Important Information Loss. **2006**, 158-165
- 615 Arteriopatía coronaria crónica. **2006**, 74-83
- 614 Medical Management of Peripheral Arterial Disease:A Therapeutic Algorithm. **2006**, 13, II-19-II-29 2
- 613 Diastolic Heart Failure. **2006**, 227-246
- 612 Angiotensin II antagonists in acute and post-acute myocardial infarction. **2006**, 1-12
- 611 Polymorphisms in Cardiovascular Medicine. **2006**, 209-242
- 610 Cerebrovascular prevention by angiotensin II receptor antagonists. **2006**, 173-188
- 609 Angiotensin receptor blockers for chronic heart failure. **2006**, 127-171
- 608 Co nñ ðajtklinick'studie s negativnñ a neutrññ zññem?. **2006**, 48, 2
- 607 Effektivnost' i bezopasnost' tsilazaprila u patsientov s arterial'noy gipertoniey, perenesshikh insul't i/ili tranzitornuyu ishemicheskuyu ataku. **2006**, 3, 5-8 2
- 606 Stroke Prevention. **2006**, 545-584
- 605 Comparison of calcium channel blockers with other classes of drugs for hypertension.
- 604 Type 1 Diabetes Mellitus. **2006**, 147-186
- 603 Peripheral Arterial Disease. **2006**, 585-610
- 602 Prescribing options for chronic stable angina. **2006**, 2006,
- 601 Update in the approach to and management of heart failure. **2006**, 99, 1346-55; quiz 1356-7, 1384 3

600 Sudden cardiac death: the size of the problem. **2006**, 25-36

599 Predictors of Adverse Outcome Among Patients With Hypertension and Coronary Artery Disease. **2007**, 2007, 86-88

598 Peripheral Arterial Disease. **2007**, 469-473

597 Coronary Artery Disease. **2007**, 295-308

596 The Heart and the Kidney. **2007**, 2819-2837

595 Percutaneous Coronary Intervention for Unstable Coronary Artery Disease. **2007**, 1005-1020

594 Insulin Resistance and Hypertension. **2007**, 175-186

593 Chronic Stable Angina. **2007**, 290-313

592 Pharmacologic Management of Heart Failure in the Ambulatory Setting. **2007**, 331-362

591 Endothelial dysfunction reversibility. **2007**, 64, 337-43

590 Peripheral Arterial Disease. **2007**, 379-388

1

589 Transplant Hypertension. **2007**, 361-369

588 Cerebrovascular Disease/Transient Ischemic Attack. **2007**, 1911-1921

587 The Metabolic Syndrome. **2007**, 678-690

586 The 2003 Guidelines for the Management of Hypertension of the European Society of Hypertension and European Society of Cardiology. **2007**, 1177-1184

585 The vascular system. **2007**, 298-320

1

584 Cardiovascular Pharmacology. **2007**, 33-52

583 Sudden Cardiac Death. **2007**, 2039-2083



582 Cost-Effectiveness Issues. **2007**, 2771-2790

581 Revascularization Options for Ischemic Heart Disease: Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention. **2007**, 157-177

580 Should We Treat the Metabolic Syndrome or Its Components?. **2007**, 257-272

579 ACE Inhibition in Heart Failure and Ischaemic Heart Disease. **2007**, 21-54

578 Goal-Oriented Hypertension Management in Diabetic and Nondiabetic Patients. **2007**, 205-222

577 Pharmacologic Treatment of Hypertension. **2007**, 578-599

576 ST-Elevation Myocardial Infarction. **2007**, 246-289

575 The Additive Beneficial Effects of Ramipril Combined with Candesartan in Hypertensive Patients on Insulin Resistance, Plasma Adiponectin. **2007**, 37, 173

1

574 [Adjuvant drug treatment in diabetic patients undergoing percutaneous coronary intervention]. **2007**, 51, 334-44

573 INFECTIONS. **2007**, 211-242

572 Ramipril as a universal oragnoprotector. **2007**, 13, 220-224

571 Type 1 Diabetes Mellitus. **2007**, 147-185

570 [Cardiovascular prevention with peripheral artery disease]. **2007**, 148, 1303-9

569 Obesity and Inflammation. **2007**, 139-165

568 Insulin Resistance Syndrome and Its Vascular Complications. **2007**, 375-393

567 The Evaluation of Cardiac and Peripheral Arterial Disease in Patients with Diabetes Mellitus. **2007**, 437-461

566 Pathogenesis of chronic heart failure: change of dominating paradigm. **2007**, 6, 71-79

7

565 CORONARY RISK FACTORS. **2008**, 1-27

564 Pathobiology of Vascular Disease. **2008**, 1317-1336

563 Prevention of Progressive Renal Failure. **2008**, 699-714

562 Angiotensin II Signaling in Vascular Physiology and Pathophysiology. **2008**, 89-115

561 Indications for Implantable Cardioverter Defibrillators. **2008**, 495-546

560 Populations. **2008**, 26-32

559 Treatment of Hypertension in Type 2 Diabetes. **2008**, 251-263

558 Diuretics and  $\beta$ Blockers. **2008**, 591-600

557 Outcomes. **2008**, 49-56

556 Controlling blood pressure in type-2 diabetes. **2008**, 2008,

555 Cardiovascular Pharmacological Agents. **2008**, 17-60

554 Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. **2008**, 127-155

553 ?????????? (????,?????????). **2008**, 120, 215-218

552 Therapy for Diabetic Nephropathy. **2008**, 323-333

551 Diagnosis and Treatment of Unstable Angina. **2008**, 73-85

550 ACE-Hemmer und Angiotensinrezeptorantagonisten. **2008**, 201-229

549 Biochemical Aspects, Laboratory Diagnosis and Follow-Up of High Blood Cholesterol: NCEP ATP III Guidelines. **2008**, 27, 64-85

548 Cerebrovascular Disease in the Elderly Patient. **2008**, 645-672

547 Systemic Hypertension in the Elderly. **2008**, 137-158

546 Management of chronic heart failure. **2008**, 50, 259-267

545 Pharmacological treatment in peripheral arterial disease. **2008**, 811-821

544 Novye vozmozhnosti v lechenii serdechno-sosudistykh zabolevaniy: rezul'taty issledovaniya ONTARGET. **2008**, 5, 9-13 1

543 Ischemic Stroke and Transient Ischemic Attack [Acute Evaluation and Management. **2009**, 9-33 1

542 Renin Angiotensin System and Atherosclerosis. **2009**, 215-230

541 Heart Failure in Racial/Ethnic Groups. **2009**, 269-296

540 Prise en charge des diabétiques: l'enseignement des grandes études contrôlées. **2009**, 105-117

539 References. **2009**, 223-234

538 Inhibitors of Angiotensin-Converting Enzyme, Angiotensin II Receptor, Aldosterone, and Renin. **2009**, 112-159

537 Which Therapy for Which Condition?. **2009**, 388-458

536 CORONARY ARTERY DISEASE. **2009**, 321-365

535 Hemmstoffe des Renin-Angiotensin-Systems. **2009**, 203-235

534 Drugs Used to Treat Hypertension, Heart Failure, and Angina Pectoris. **2009**, 1-196

533 HEART FAILURE. **2009**, 389-399

532 Acute Coronary Syndromes. **2009**, 680-691

531 Coronary Artery Disease Prevention. **2009**, 17-32

530 Aspirin Usage Based on Evidence for the Prevention of Cardio-Cerebrovascular Disease. **2009**, 30, 249

529 NHG-Standaard Cardiovasculair risicomanagement. **2009**, 106-152 2

528 Malattie cerebrovascolari dell'encefalo. **2009**, 3-39

527 CMS and Type 2 Diabetes Mellitus: Bound Together by the Renin Angiotensin Aldosterone System. **2009**, 187-206

526 Chapter 14 ACE inhibitors in hypertension. **2009**,

525 Antihypertensive Drugs. **2009**, 198-234

524 Hypertension in the Tropics. **2009**, 669-684

523 NHG-Standaard Beleid na een doorgemaakt myocardinfarct. **2009**, 87-105

522 Management of Hypertension in Heart Failure. **2009**, 1-15

521 Kinin Receptors and ACE Inhibitors: An Interrelationship. **2009**, 135-150

520 RHYTHM DISORDERS. **2009**, 367-387

519 Dyslipidemia and Atherosclerosis. **2009**,

518 ACE inhibitors or sartans in the management of myocardial infarction survivors?. **2009**, 51, 103-111

1

517 Redox Signaling and Vascular Function. **2009**, 473-507

516 Risk Factor Modification in the Management of Critical Limb Ischemia. **2009**, 85-112

515 AP control of as the most efficacious tool for the prevention of cardiovascular complications in patients with type 2 diabetes mellitus. **2009**, 12, 10-13

514 Hypertension. **2009**, 437-464

513 The Link Between Inflammation and Thrombosis. **2010**, 39-61

512 Cardiovascular Effects of Obesity. **2009**, 1-11

511 Isolated systolic hypertension in the elderly. **2009**, 51, 698-707

510 Pharmacogenomics. **2010**, 273-287

509 Reviewing a patient's secondary prevention treatment. **2009**, 2009,

508 Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy. **2009**, 102, 1201-2

507 Disorders of Blood Pressure. **2010**, 97-130

506 Lower Extremity Arterial Disease. **2010**, 1593-1612

505 Coronary Artery Disease. **2010**, 58-64

504 The Coronary Circulation. **2010**, 903-917

503 Atherosclerosis. **2010**, 53-67

502 Thérapeutique des troubles associés. **2010**, 175-189

501 Prévention des récurrences d'accident vasculaire cérébral. **2010**, 19-25

500 Hemmstoffe des Renin-Angiotensin-Systems. **2010**, 219-252

499 Diabetes Mellitus: Disease Management. **2010**, 350-354.e2

498 Atherosclerotic Risk Factors. **2010**, 421-433

497 Bewegungstherapie bei koronarer Herzkrankheit. **2010**, 115-142

1

496 Angioedema. **2010**, 117-127

495 Chronic Coronary Artery Disease. **2010**, 97-105

494 Atherosclerotic Risk Factors. **2010**, 451-460

493 Peripheral Arterial Disease. **2010**, 196-204.e2

492 Atheromatous Embolization. **2010**, 2422-2434

491 Dřordres cliniques et biologiques associřs. **2010**, 77-98

490 Bypass to the Infrapopliteal Arteries for Chronic Critical Limb Ischemia. **2010**, 231-235

489 Complications cardiovasculaires macroangiopathiques et insuffisance cardiaque chez le diabřtique. **2010**, 250-262

488 Protective Effects of Food on Cardiovascular Diseases. **2010**, 455-471

487 Lipoprotein Metabolism and the Treatment of Lipid Disorders. **2010**, 788-807

486 Carotid Artery Stenting. 103-116

485 A Time to Live: Dynamic Changes in Risk as the Basis for Therapeutic Triage. **2011**, 597-601

484 Heart failure in patients on dialysis. A review of the issue and proposed therapeutic algorithm. **2010**, 52, 229-233

483 Unstable Angina and Non-ST Elevation Myocardial Infarction. **2011**, 195-225

482 Pharmacological Prerequisites for Treatment of Complex Patients with Peripheral Artery Disease. **2010**, 10-21

481 Peripheral Arterial Disease. **2011**, 311-323

480 The Pathogenesis of Macrovascular Complications Including Atherosclerosis in Diabetes. 635-656

1

479 Cerebrovascular Disease. 698-709

1

478 Drug Therapy: Special Considerations in Diabetes. 410-423

477 Newer Coronary Risk Factors. **2011**, 113-139

476 Hypertension. **2011**, 121-140

475 [Do we reach target lipid levels in diabetic and non-diabetic patients with previous myocardial infarction?]. **2011**, 139, 30-6

474 Proteases and Inflammatory Pain. **2011**, 253-274

1

473 Does the Cardiologist Have a Key Role in Long-Term Management of Hypertension?. **2011**, 2, 79-81

472 Metabolic Syndrome and Cardiovascular Disease. **2011**, 371-387

471 Peripheral Arterial Disease Assessment and Management. **2011**, 512-525

470 Kardiovaskuläre Erkrankungen. **2011**, 1-186

469 Antagonism of the Renin-Angiotensin-Aldosterone System in Heart Failure. **2011**, 659-673

468 NHG-Standaard Beleid na een doorgemaakt myocardinfarct. **2011**, 341-359

467 Risk Factors for Atherosclerosis in the Elderly. **2011**, 635-648

466 Diabetic Nephropathy. **2011**, 1411-1454

6

465 Management of the postcoronary patient. **2011**, 650-659

464 Stabilizing unstable plaque in acute coronary syndromes. **2011**, 338-345

463 Acute Coronary Syndromes. **2011**, 548-558

462 Plaque Passivation and Endothelial Therapy. **2011**, 289-298

461 Hemmstoffe des Renin-Angiotensin-Systems. **2011**, 225-260

460 The value of good blood pressure regulation in secondary prevention of coronary artery disease. **2011**, 30, 220-223

459 Training bij hartfalen. **2011**, 175-184

458 ACE-inhibitors and angiotensin receptor blockers. **2011**, 247-252

457 Cardiovascular Pharmacology. **2011**, 235-295

1

456 Heart Failure as a Consequence of Congenital Heart Disease. **2011**, 455-464

455 Heart Failure Prevention. **2011**, 141-160

454 Antihypertensive Drugs and Their Cardioprotective and Renoprotective Roles in the Prevention and Management of Cardiovascular Disease. **2011**, 161-181

453 Diabetes and Cardiovascular Disease. **2011**, 345-370

452 Preventie van hartfalen. **2011**, 247-253

451 Carotid Stenosis: Primary Prevention and Medical Treatment. 109-117

450 Prevention of Cardiovascular Disease. 1-10

449 Identifying opportunities for a medical group to improve outcomes for patients with coronary artery disease and heart failure: an exploratory study. **2011**, 15, 4-14

2

448 Combined antihypertensive therapy in patients with arterial hypertension and coronary heart disease. **2011**, 10, 28-34

447 Zofenopril in the treatment of patients with arterial hypertension and stable coronary heart disease: effects on oxidative stress and flowdependent vasodilatation. **2011**, 10, 15-21

446 Stable Angina. **2012**, 1-18

445 Rational combination therapy in resistant arterial hypertension. **2011**, 17, 384-390

444 Cardiovascular risk, metabolic disturbances, and the choice of antihypertensive therapy. **2011**, 10, 26-32

443 Alternative Therapies for Chronic Refractory Coronary Artery Disease. **2012**, 125-137

442 Carotid and Vertebral Intervention. **2012**, 115-140

441 Vascular Diseases [Peripheral/Aorta. **2012**, 325-346

440 Lower Extremity Intervention. **2012**, 19-39

439 Risk Factor Management of Atherosclerotic Peripheral Vascular Disease. **2012**, 175-192



438 Prevention of Coronary Artery Disease. **2012**, 497-508

437 Safety and efficacy of the sulfhydryl ACE-inhibitor zofenopril in the management of cardiovascular disease. **2011**, 10, 99-104

436 Chronic Stable Angina. **2012**, 271-290

435 Using Exploratory Visualization in the Analysis of Medical Product Safety in Observational Healthcare Data. **2012**, 391-413

434 The Cardiovascular System. **2012**, 395-477

433 Antihypertensive Therapy Benefits: Pleiotropic Versus Blood Pressure-Dependent Mechanisms. **2012**, 249-266

432 Hypertension, Obesity, and Metabolic Syndrome. **2012**, 133-146

431 A Stepped Care Approach to the Management of Chronic Kidney Disease. **2012**, 2205-2239

1

430 Hemmstoffe des Renin-Angiotensin-Systems. **2012**, 225-262

429 Cardiovascular Disease. **2012**, 478-549

428 Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. **2012**, 11, 93-101

1

427 The Endothelium, Cardiovascular Disease, and Therapy. 409-467

426 Treatment algorithm in patients with stable angina. **2012**, 312-330

425 Clinical strategy for treating renal artery stenosis and contemporary tactics for renal artery stenting. **2012**, 4, 429-438

424 Management of Chronic Coronary Artery Disease. 60-85

423 Antihypertensive Drug Development: A Regulatory Perspective. **2013**, 416-424

422 Diabetes and the Cardiovascular System. **2013**, 701-714

421 Umsatzveränderungen in einzelnen Indikationsgruppen. **2013**, 43-376

420 Peripheral Arterial Disease. **2013**, 781-796

419 Clinical follow up of patients with premature coronary artery disease (PCAD) implanted with drug-eluting stents. **2013**, 03, 329-335

418 Ictus: clínica y tratamiento. **2013**, 43-53

417 The fixed-dose combination of losartan/hydrochlorothiazide elicits potent blood pressure lowering during nighttime in obese hypertensive patients. **2014**, 6, 8-16 3

416 Non-antiarrhythmic Drugs in Sudden Death Prevention. **2013**, 525-541

415 Hemmstoffe des Renin-Angiotensin-Systems. **2013**, 217-256

414 The number of antihypertensive agents simply reflects the grade and the risk of atherosclerosis in patients with type 2 diabetes mellitus. **2013**, 03, 161-167

413 Impact of Medical Therapy on Cardiovascular Secondary Prevention. **2013**, 1075-1100

412 Medical therapy for peripheral vascular disease. **2013**, 48-59

411 Chronic Coronary Artery Disease. **2014**, 67-85

410 Treatment of hypertension. **2013**, 222-236

409 Vitamin E. 37-67 1

408 Nitrates for chronic heart failure.

407 A Holistic Integrative Medicine Approach to Cardiovascular Disease. **2014**, 399-412

406 Impact of Diabetes Mellitus and the Metabolic Syndrome on the Female Heart. **2014**, 265-286

405 Preventive Lessons from Hypertension and Myocardial Infarction: Treating Asymptomatic Individuals to Lower the Risk for Subsequent Cardiovascular Events. **2014**, 229-239

404 Reactive Oxygen Species as Potential Mediators of Obesity-Related Cardiovascular Complications. **2014**, 791-816

403 Hypertension in the Kidney Transplant Recipient. **2014**, 205-224

402 Drugs in the Primary and Secondary Prevention of Coronary Artery Disease. **2014**, 1-32

401 Hemmstoffe des Renin- Angiotensin-Systems. **2014**, 259-300

400 Vascular Complications of Diabetes Mellitus. **2014**, 1-65

399 Thfapeutique des dŝordres ́associŝ. **2014**, 189-201

398 ECHOCARDIOGRAPHIC EVALUATION OF DIASTOLIC DYSFUNCTION IN ASYMPTOMATIC TYPE 2 DIABETES MELLITUS PATIENTS. **2014**, 3, 200-209

1

397 Medical Management of Renovascular Disease. **2014**, 305-316

396 Methods of Tertiary Prevention. **2014**, 206-216

395 Oxidative Stress in Diabetes Mellitus and Possible Interventions. **2014**, 237-261

394 Interventional Treatment of the Chronic Ischemic Syndromes of the Lower Extremity. **2014**, 1-37

393 Medical Management of Coronary Artery Disease. **2014**, 1-17

392 Association between angiotensin-converting enzyme inhibitors and troponin in acute coronary syndrome. **2014**, 103, 513-20

1

391 AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND CALCIUM ANTAGONIST COMBINATION IN PHARMACOTHERAPY OF ARTERIAL HYPERTENSION. **2014**, 13, 64-68

390 Hypertension and Cardiovascular Disease and Its Management. 140-164

389 Vaskulŝe und parenchymatŝe Nierenkrankheiten. **2012**, 517-529

388 Angiotensin Converting Enzyme Inhibitors and AT1 Antagonists for Treatment of Hypertension. **2015**, 1-39

387 PERIPHERAL ARTERIAL DISEASE IN THE LEG. **2014**, 3, 10786-10792

386 PAD and Claudication. **2015**, 85-100

385 Target Organ Damage and RAAS Blockade. **2015**, 119-148

- 384 Hallmark Clinical Trials. **2015**, 675-727
- 383 Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. **2015**, 85-127
- 382 Neoatherosclerosis. **2015**, 167-177
- 381 Response to the letter: Angiotensin-II induced insulin resistance. **2014**, 58, 972-3
- 380 The Role of Neurohumoral Activation in Cardiac Fibrosis and Heart Failure. **2015**, 347-381
- 379 Medical Management of Coronary Artery Disease. **2015**, 2369-2382
- 378 Hemmstoffe des Renin-Angiotensin-Systems. **2015**, 267-309 1
- 377 Atherosclerotic Peripheral Artery Disease: Clinical Management. **2015**, 2983-3006
- 376 Ischemic Heart Disease. **2015**, 1-9
- 375 Interventional Treatment of the Chronic Ischemic Syndromes of the Lower Extremity. **2015**, 3119-3149
- 374 Principles of Primary and Secondary Prevention of Cardiovascular Disease. **2015**, 1627-1664
- 373 Executive Summary of the Guidelines on Stable Coronary Disease. **2015**, 105, 328-38
- 372 Koronare Herzkrankheit [Allgemeine und interventionelle Therapie. **2015**, 1-33
- 371 Risk for Sudden Cardiac Death in Heart Failure: Underlying Mechanisms and Therapeutic Modalities. **2015**, 129-149
- 370 Adding T1 Mapping and Extracellular Volume Fraction for Myocardial Fibrosis Assessment: Implications for Cardiovascular Risk Assessment. **2015**, 137-151
- 369 Drugs in the Primary and Secondary Prevention of Coronary Artery Disease. **2015**, 1665-1693
- 368 Angiotensin II-Induced Generation of Reactive Oxygen Species Is Regulated by a Phosphatidylinositol 3-Kinase/L-Type Calcium Channel Signaling Pathway. **2015**, 25, 231-236
- 367 Mechanisms of the Renin Angiotensin System Influencing Atherosclerosis. 207-219

366 The association of arterial hypertension and ischemic heart disease is the main problem in modern cardiology practice. **2015**, 12, 70-75

365 Circadian Rhythms and the Circadian Clock in the Cardiovascular System. **2016**, 199-224

364 Blood Pressure Control and Primary Prevention of Stroke: Summary of Clinical Trial Data. **2016**, 39-59

363 Secondary Stroke Prevention. **2016**, 173-182

362 Hemmstoffe des Renin-Angiotensin-Systems. **2016**, 209-235

361 Stable Ischemic Heart Disease. **2016**, 1-70

360 Hypertension and Ischaemic Stroke Subtypes. **2016**, 75-89

359 Recurrent Stroke Prevention: Diuretic and Angiotensin-Converting Enzyme Inhibitors (ACEIs) The PROGRESS Trial. **2016**, 215-231

358 7th Brazilian Guideline of Arterial Hypertension: Chapter 5 - Therapeutic Decision and Targets. **2016**, 107, 25-29

3

357 Features of zofenopril and enalapril in patients with stable ischemic heart disease in combination with arterial hypertension. **2016**, 7, 42-46

356 The relentless crumbling of the renin-angiotensin system (RAS)-blockade halo. **2016**, 4, 321

355 Cholesterol Emboli. **2017**, 293-304

354 Physiological, Biochemical and Molecular Role of Oxidative Stress in Cardiovascular Disease: A Comprehensive Study. **2016**, 6, 1-16

353 How Big Is the Problem? The Cardiologists' View. **2017**, xxxi-xxxv

352 Hemmstoffe des Renin-Angiotensin-Systems. **2017**, 211-236

351 Five Years Trends in Antihypertensive Monotherapy and Blood Pressure Control in Patients Referred to Tertiary Care Centre.

350 Impact of Garlic on Cardioprotective Potential of Ramipril on Ischemia-Reperfusion Induced Myocardial Dysfunction in Rats. **2017**, 5,

349 COSYREL - an efficient fixed combination for treatment of hypertension, stable ISHD and heart failure. **2017**, 63, 667-671

- 348 Primary detection of arterial hypertension in a patient with a risk history. **2017**, 14, 207-211
- 347 COMBINATION THERAPY OF AH IN CLINICAL PRACTICE. **2017**, 20-27
- 346 The Impact of Antihypertensive Drugs on Adherence. **2018**, 153-172
- 345 Chronic Kidney Disease. **2018**, 325-339
- 344 Transplant Hypertension. **2018**, 321-327
- 343 Microvascular Angina as a Cause of Ischemia: An Update. **2018**, 135-163
- 342 General view and medical therapy for polyvascular disease. **2018**, 24, 101-104
- 341 Hemmstoffe des Renin-Angiotensin-Systems. **2018**, 263-288
- 340 Patient with coronary artery disease and hypertension. **2018**, 37, 35-38
- 339 Traitement de l'infarctus du myocarde avec sus-d'calage du segment ST. **2018**, 99-122.e3
- 338 The Effect of Cortex Lycii on Rattus norvegicus Blood Glucose Level Using a High Glucose Diet. **2018**, 08, 160-170
- 337 Some Peculiarities of Pre-Operating Preparation of Patients with Diabetes Mellitus to Ophthalmosurgical Interventions. **2018**, 4, 27-32
- 336 TO STUDY THE RELATIONSHIP BETWEEN MICROALBUMINURIA AND ISCHAEMIC HEART DISEASE IN NON-DIABETIC SUBJECTS. **2018**, 7, 2562-2565
- 335 Antihypertension drugs in prevention of cognition disorder and dementia: focus on calcium channel blockers and diuretics. **2018**, 17, 79-91
- 334 Complications cardiovasculaires macro-angiopathiques et insuffisance cardiaque chez le diabétique. **2019**, 377-390
- 333 Diabetes and Cardiovascular Disease. **2019**, 709-730
- 332 The Effects of Low Dose Sertraline on Blood Pressure in Patients with Hypertension and Panic Disorder: A Pilot Study. **2019**, 09, 249-266
- 331 Atherosclerosis of peripheral arteries and arterial hypertension. Features of antihypertensive therapy. **2019**, 1, 12-16

- 330 Prise en charge de la maladie rénale diabétique. **2019**, 313-343
- 329 Thérapeutique des troubles associés. **2019**, 253-267
- 328 Troubles cliniques et biologiques associés. **2019**, 91-110
- 327 Effects of discontinuing angiotensin receptor blockers on perioperative hypotension in patients undergoing laparoscopic cholecystectomy. **2019**, 2, 6-11
- 326 Management of Coronary Artery Disease & Dyslipidemia and Pharmacist's Role. **2019**, 169-187
- 325 The place of ramipril in modern guidelines for the management of patients with cardiovascular diseases. **2019**, 34-41 2
- 324 Hemmstoffe des Renin-Angiotensin-Systems. **2019**, 359-388
- 323 [Peripheral arterial disease (PAD) medical treatment: Megalomania?]. **2019**, 44, 181-183
- 322 The Effect of Acupressure at PC6 and REN12 on Vomiting in Patients Undergoing Inguinal Hernia Repair: A Double-Blind Randomized Clinical Trial. **2019**, 7, 1461-1465 0
- 321 Improving the secondary prevention of ST-elevation myocardial infarction. **2019**, 19, s54-s55 78
- 320 Current review with evolving management strategies in critical limb ischemia. **2019**, 29, 258-263 1
- 319 Modification of the daily blood pressure profile in hypertensive patients with type 2 diabetes mellitus. **2019**, 25, 307-318
- 318 Hemmstoffe des Renin-Angiotensin-Systems. **2020**, 231-259
- 317 Ischemic Heart Disease. **2020**, 1-10
- 316 Monotherapy versus combination therapy of statin and renin-angiotensin system inhibitor in ST-segment elevation myocardial infarction. **2020**,
- 315 Correlations between parameters of calcium metabolism and renin-angiotensin-aldosterone system in patients with primary hyperparathyroidism in the pre- and early postoperative periods. **2020**, 25, 630-638 1
- 314 Hypertension in the Time of the COVID-19 Pandemic: New Issues and Enduring Controversies. **2020**, 19, 1-7 1
- 313 Efficiency (advantages) of ramipril in arterial hypertension and diabetes mellitus from the point of view of evidence-based medicine. **2020**, 50-58

- 312 Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition. **2020**, 13, 695-706 2
- 311 Vascular Pain. **2021**, 517-534
- 310 Genetic Variation in Blood Pressure and Lifetime Risk of Peripheral Artery Disease: A Mendelian Randomization Study.
- 309 Hypertension management in older adults. **2020**, 9, 2
- 308 Role of selective Bioactive Compounds as an Angiotensin Converting Enzyme Inhibitor.
- 307 Angiotensin-Converting Enzyme Inhibitors and Contrast-Associated Acute Kidney Injury After Coronary Angiography and Intervention. **2021**, 21, 487-497 0
- 306 Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options. **2020**, 26, 5953-5968 0
- 305 Stable Angina. **2020**, 83-98
- 304 Lower Extremity Ischemia. **2020**, 331-347
- 303 ACE-inhibitor/calcium antagonist combination: is this the first-choice therapy in arterial hypertension?. **2019**, 110, 546-554
- 302 ERKRANKUNGEN DER NIERE. **2020**, G-1-G14-7
- 301 Secondary Prevention of Coronary Artery Disease. **2020**, 75-82
- 300 The influence of patients' knowledge of hypertension on the control of their blood pressure: Qualitative study. **2020**, 7, 942-953
- 299 Early-term results of early coronary artery bypass graft surgery in patients undergoing primary percutaneous coronary intervention due to acute coronary syndrome. 2
- 298 A mayor riesgo, más beneficio: bloqueo del sistema renina-angiotensina tras intervención coronaria percutánea en pacientes con síndrome coronario agudo. **2020**, 73, 104-106
- 297 Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction. **2021**, 1 1
- 296 The Possibilities of Single-Pill Combinations of Antihypertensive Drugs in Cerebroprotection: Focus on the Combination of Amlodipine with Ramipril. **2020**, 16, 487-497
- 295 The effect of renin-angiotensin-aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design. **2020**, 37, 101-107



- 294 Point-of-care Echocardiogram as the Key to Rapid Diagnosis of a Unique Presentation of Dyspnea: A Case Report. **2020**, 4, 424-427
- 293 Vaskuläre und parenchymatöse Nierenkrankheiten. **2008**, 501-514
- 292 Cardiac Protection for Noncardiac Surgery. **2007**, 41-59
- 291 The Basis of Statistical Reasoning in Medicine. **2006**, 33-51
- 290 Ace Inhibitors Directly Activate Bradykinin B1 Receptors to Release NO. **2006**, 163-176 1
- 289 Synthetic Antioxidants and Atherosclerosis: Human Studies. **2006**, 255-277
- 288 Use of Antioxidants in Patients with Congestive Heart Failure. **2006**, 451-476
- 287 Coronary Artery Disease. **2005**, 107-150
- 286 Koronarinsuffizienz und Herzinfarkt. **2005**, 3-33
- 285 Arterielle Hypertonie. **2005**, 237-253
- 284 Arterielle Hypertonie. **2005**, 1146-1160
- 283 Diabetes mellitus Typ 1 und Typ 2. **2005**, 402-418
- 282 Regulationsmechanismen des Renin-Angiotensin-Systems im kardiovaskulären System. **2006**, 377-407
- 281 Arterielle Hypertonie. **2006**, 431-446
- 280 ACE-Hemmer und Angiotensinrezeptorantagonisten. **2006**, 247-276
- 279 Arterielle Verschlusskrankheit (AVK). **2005**, 146-149
- 278 Koronare Herzkrankheit. **2005**, 38-66
- 277 Arterielle Hypertonie bei Diabetes mellitus. **2005**, 26-39

- 276 Stoffwechsel des Herzens bei Diabetes. **2005**, 101-121
- 275 Kardiovaskuläre Pharmakologie. **2006**, 1-30
- 274 Value of Angiotensin-Converting Enzyme Inhibitors to Prevent Sudden Death. **2006**, 409-413
- 273 The Role of the Neurologist in Assessment and Management of Individuals with Acquired Brain Injury. **2007**, 39-63
- 272 Angiotensin Type 2 Receptor (AT2R): A Challenging Twin. **2003**, 2003, pe16-pe16 ○
- 271 The Skeletal Muscle RAS in Health and Disease. **2007**, 221-245
- 270 The Renin-Angiotensin System in Pancreatic Stellate Cells: Implications in the Development and Progression of Type 2 Diabetes Mellitus. **2007**, 73-86
- 269 Diabetes Mellitus. **2005**, 563-575
- 268 Assessment of the Role of ACE Inhibitors in the Elderly. **2005**, 321-348
- 267 Stable Angina. **2005**, 451-470
- 266 Heart Disease in the Elderly. **2005**, 705-727
- 265 Peripheral Arterial Disease. **2005**, 807-828
- 264 Obesity, Diabetes, and Hypertension. **2006**, 169-192 1
- 263 Atherosclerosis and Peripheral Vascular Disease. **2006**, 221-231
- 262 Medical Therapy for Carotid Artery Stenosis. **2007**, 11-31
- 261 An Evidence-Based Approach to Type 2 Diabetes. **2006**, 303-321
- 260 Subclinical Atherosclerosis. **2006**, 239-264
- 259 Management of Hypertension. **2006**, 93-112

258 Diabetes Mellitus, Hyperinsulinemia, and Coronary Artery Disease. **2006**, 113-143

257 Epidemiology and Prevention of Cardiovascular Disease in Diabetes. **2009**, 19-33

256 Treatment in Advanced Renal Disease in Type 1 and Type 2 Diabetes. **2006**, 419-436

255 Insulin Resistance and Cardiovascular Disease. **2008**, 207-228

254 Management of Angina. **2007**, 159-181

253 Hallmark Clinical Trials. **2007**, 381-394

252 Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. **2007**, 43-61

251 Therapies for Delay or Prevention of Type 2 Diabetes. **2008**, 85-96

1

250 Nonantiarrhythmic Drugs in Sudden Death Prevention. **2008**, 760-771

249 Cerebrovaskuläre Erkrankungen. **2007**, 107-124

248 Renal protective capacity of the angiotensin receptor antagonists. **2004**, 1, 331-339

247 Analogpräparate. **2007**, 105-181

246 ACE-Hemmer und Angiotensinrezeptorantagonisten. **2007**, 247-272

245 Arterielle Hypertonie. **2007**, 1288-1304

244 Diabetes mellitus Typ 1 und Typ 2. **2007**, 448-465

243 ACE-Hemmer und Angiotensinrezeptorantagonisten. **2008**, 207-232

242 Stellenwert der frühzeitigen Diagnostik und Behandlung der Peripheren Arteriellen Verschlusskrankheit für die Prävention kardiovaskulärer Ereignisse. **2008**, 787-805

241 Cardiovascular System Response to Chronic Exposure to Emissions from Gas Turbines Power Plants. **2020**, 10, 208-224

240	Reactivation of fatty acid oxidation by medium chain fatty acid prevents myocyte hypertrophy in H9c2 cell line. <b>2021</b> , 476, 483-491	1
239	Expert roundtable: use of ramipril to treat hypertension in elderly patients. The view of the GP and cardiologist. <b>2020</b> , 16-24	
238	Stable Ischemic Heart Disease. <b>2021</b> , 125-154	
237	The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension. <b>2020</b> , 15, e0242314	1
236	Nocturnal hypoxemia severity influences the effect of CPAP therapy on renal renin-angiotensin-aldosterone system activity in humans with obstructive sleep apnea. <b>2021</b> , 44,	3
235	Congestive heart failure: what can we offer our patients?. <b>2001</b> , 165, 1053-5	1
234	Intention-to-treat principle. <b>2001</b> , 165, 1339-41	159
233	A qualitative study of evidence in primary care: what the practitioners are saying. <b>2002</b> , 166, 1525-30	23
232	The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. <b>2003</b> , 168, 553-7	15
231	Ramipril use in Canada: HOPE or HYPE?. <b>2003</b> , 168, 568-9	4
230	Should hypertension be treated with angiotensin-converting-enzyme inhibitors, calcium-channel blockers or diuretics?. <b>2003</b> , 168, 874-5	
229	Nephrology: 4. Strategies for the care of adults with chronic kidney disease. <b>2003</b> , 168, 1553-60	7
228	More than just hype. <b>2003</b> , 168, 1646; author reply 1647-8	
227	More than just hype. <b>2003</b> , 168, 1646-7; author reply 1647-8	
226	More than just hype. <b>2003</b> , 168, 1647; author reply 1647-8	
225	ACE inhibition in stable coronary artery disease. <b>2003</b> , 169, 939	
224	Preventing stroke with ramipril. Results should have been presented in ways that help practising clinicians. <b>2002</b> , 325, 439	2
223	Diabetes care needs evidence based interventions to reduce risk of vascular disease. <b>2000</b> , 320, 1554-5	3

222	Advances in diabetes for the millennium: the heart and diabetes. <b>2004</b> , 6, 7	
221	Management of carotid artery stenosis. Update for family physicians. <b>2005</b> , 51, 984-9	8
220	Treatment- and disease-related complications of prostate cancer. <b>2006</b> , 8 Suppl 2, S56-67	5
219	Executive summary of the African-American Initiative. <b>2007</b> , 9, 28	3
218	Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. <b>2007</b> , 3, 125-37	71
217	Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme. <b>2007</b> , 3, 1-9	28
216	Trandolapril/verapamil combination in hypertensive diabetic patients. <b>2007</b> , 3, 77-82	2
215	Identifying and slowing progressive chronic renal failure. <b>2001</b> , 47, 2512-8	4
214	Peripheral arterial disease and ankle-brachial pressure index as predictors of mortality in residents of Metlika County, Slovenia. <b>2006</b> , 47, 327-34	7
213	Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination. <b>2007</b> , 3, 453-65	10
212	Arterial stiffness and pharmacological interventions--the TRanscend arterial stiffNess Substudy (TRANS study). <b>2007</b> , 3, 381-7	15
211	Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. <b>2007</b> , 3, 521-6	15
210	Multivariate risk assessment and risk score cards in hypertension. <b>2007</b> , 3, 313-20	3
209	Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. <b>2007</b> , 3, 299-305	2
208	Cardiovascular high-risk patients--treat to protect, but whom?. <b>2008</b> , 10 Suppl, S2	2
207	No HOPE without proof: do ARBs meet the standard for cardiovascular protection?. <b>2008</b> , 10 Suppl, S6	3
206	Cardiac and vascular protection: the potential of ONTARGET. <b>2008</b> , 10 Suppl, S7	1
205	Targeting cardiovascular protection: the concept of dual renin-angiotensin system control. <b>2008</b> , 10 Suppl, S4	6

204	Prospects for renovascular protection by more aggressive renin-angiotensin system control. <b>2008</b> , 10 Suppl, S5	2
203	Treating to protect: current cardiovascular treatment approaches and remaining needs. <b>2008</b> , 10 Suppl, S3	1
202	Clinical trial update: focus on the ONTARGET study. <b>2007</b> , 3, 901-8	3
201	Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. <b>2007</b> , 3, 937-45	20
200	Rationale for multiple risk intervention: the need to move from theory to practice. <b>2007</b> , 3, 985-97	11
199	Knowledge and attitude of physicians in a major teaching hospital towards atherosclerotic risk reduction therapy in patients with peripheral arterial disease. <b>2007</b> , 3, 1019-27	18
198	Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. <b>2007</b> , 12, 17-28	58
197	Hypertension in perspective. <b>2005</b> , 13, 186-189	
196	Unexpected news from the scientific sessions of the American College of Cardiology. <b>2002</b> , 10, 265-266	
195	An update on 'progression promoters' in renal diseases. <b>2003</b> , 95, 30-42	17
194	Arterial stiffness in insulin resistance: the role of nitric oxide and angiotensin II receptors. <b>2009</b> , 5, 73-8	44
193	Results of the ONTARGET and TRANSCEND studies: an update and discussion. <b>2009</b> , 5, 21-9	15
192	Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. <b>2009</b> , 5, 129-40	23
191	You can do more to slow the progression of heart failure. <b>2009</b> , 58, 122-8	2
190	Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma. <b>2007</b> , 1, 217-23	20
189	Hypertension treatment and control rates: chart review in an academic family medicine clinic. <b>2009</b> , 55, 735-41	10
188	Stroke Best Practices: a team approach to evidence-based care. <b>2004</b> , 96, 5S-20S	2
187	Development of a patient decision aid for prevention of myocardial infarction in type 2 diabetes - rationale, design and pilot testing. <b>2009</b> , 6, Doc05	6

186	Atherosclerosis: A Link Between Lipid Intake and Protein Tyrosine Nitration. <b>2008</b> , 2008, 75	12
185	Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact. <b>2010</b> , 4, 1-11	3
184	President's address. Common mechanisms of multiple diseases: why vegetables and exercise are good for you. <b>2010</b> , 121, 1-20	4
183	Increased expression and co-localization of ACE, angiotensin II AT(1) receptors and inducible nitric oxide synthase in atherosclerotic human coronary arteries. <b>2010</b> , 2, 111-24	12
182	Perindopril: the evidence of its therapeutic impact in hypertension. <b>2007</b> , 2, 63-79	2
181	Arterial hypertension management with conversion enzyme inhibitors in hemodialysis patients. <b>2010</b> , 3, 67-9	
180	Strategies for initial management of hypertension. <b>2010</b> , 132, 531-42	20
179	Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. <b>2011</b> , 36, 22-40	34
178	Diabetes mellitus update. <b>2006</b> , 10, 29-34	
177	The russert impact: a golden opportunity to promote primary coronary prevention. <b>2008</b> , 8, 108-13	2
176	ACE inhibitors and ARBs: one or the other--not both--for high-risk patients. <b>2009</b> , 58, 24-7	5
175	The predicted impact of heart disease prevention and treatment initiatives on mortality in Lithuania, a middle-income country. <b>2011</b> , 8, A139	2
174	Difficulties in achieving arterial hypertension control. <b>2011</b> , 6, 114-9	
173	Optimal management of peripheral arterial disease for the non-specialist. <b>2011</b> , 80, 33-41	9
172	Glycemia and cardiovascular risk: challenging evidence based medicine. <b>2011</b> , 15, 199-204	3
171	Multifactorial approach to the primary and secondary prevention of atherosclerosis. <b>2003</b> , 5, 12-7	1
170	Treatment of systemic hypertension. <b>2012</b> , 2, 160-70	15
169	Taking blood pressure-lowering medications at night. <b>2012</b> , 58, 965	1

168	Carotid artery stenting, endarterectomy, or medical treatment alone: the debate is not over. <b>2011</b> , 6, 1-13	
167	Perindopril: do randomised, controlled trials support an ACE inhibitor class effect? A meta-analysis of clinical trials. <b>2009</b> , 20, 127-34	6
166	Heart failure: epidemiology and prevention in India. <b>2010</b> , 23, 283-8	64
165	Using evidence for the care of practice team populations. <b>2014</b> , 60, 223	5
164	Hypertension in the elderly: new blood pressure targets and prescribing tips. <b>2014</b> , 60, 453-6	1
163	An Inside Look at Managed Care Executive Conversations within the Health Payer Council: What Is Evidence?. <b>2013</b> , 6, 209-11	
162	Managing hypertension in the elderly: a common chronic disease with increasing age. <b>2012</b> , 5, 146-53	9
161	Prehypertension: What is the Current Status?. <b>2008</b> , 3, 72-6	4
160	Recurrent stroke: what have we learnt?. <b>2007</b> , 2, 70-3	
159	Diabetic hypertensive control and treatment: a descriptive report from the audit diabetes control and management (adcm) registry. <b>2010</b> , 5, 134-9	4
158	A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy. <b>2014</b> , 19, 1090-8	29
157	Impact of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers on mortality of coronary artery bypass grafting. <b>2013</b> , 8, 177-81	2
156	Doppler ultrasound findings in kidney transplant recipients with and without of new onset diabetes mellitus beyond 5 years after transplantation. <b>2015</b> , 8, 16709-13	
155	Response. <b>2015</b> , 61, 1048-9	
154	Effects of Anti-Hypertensive Monotherapy with Either Calcium Channel Blocker or Angiotensin Receptor Blocker on Arterial Stiffness, Central Hemodynamics, and Ventriculo-Arterial Coupling in Uncomplicated Hypertension Patients. <b>2013</b> , 29, 19-27	1
153	Effect of High-dose Telmisartan on the Prevention of Recurrent Atrial Fibrillation in Hypertensive Patients. <b>2010</b> , 3, 289	0
152	Evidence and evidence gaps of medical treatment of non-tumorous diseases of the head and neck. <b>2016</b> , 15, Doc02	
151	Long-term clinical outcome between beta-blocker with ACEI or ARB in patients with NSTEMI who underwent PCI with drug-eluting stents. <b>2019</b> , 16, 280-290	4



150	Ramipril significantly attenuates the development of non-alcoholic steatohepatitis in hyperlipidaemic rabbits. <b>2019</b> , 9, 8-17	3
149	Different prognostic association of systolic blood pressure at different time points with postdischarge events in patients hospitalized for decompensated heart failure. <b>2019</b> , 16, 676-688	2
148	Renin-angiotensin system gene polymorphisms and coronary artery disease in Saudi patients with diabetes mellitus. <b>2017</b> , 10, 10505-10514	2
147	PURL: Is it better to take that antihypertensive at night?. <b>2020</b> , 69, 362-364	
146	The role of the characteristics of exercise-based cardiac rehabilitation program in the improvement of lipid profile level: A systematic review and meta-analysis. <b>2020</b> , 16, 192-207	1
145	Renin-Angiotensin System Blockade is Associated with Exercise Capacity, Sympathetic Activity and Endothelial Function in Patients with Chronic Kidney Disease. <b>2021</b> ,	3
144	Sex Differences in Heart Failure. <b>2021</b> ,	3
143	Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTEMI-ACS). <b>2021</b> , 6-59	1
142	Diagnosis and management of acute coronary syndromes.. <b>2021</b> , 44, 180-184	
141	Hemmstoffe des Renin-Angiotensin-Systems. <b>2021</b> , 131-161	
140	Kardiovaskuläre Inflammation: Stand von Klinik und Forschung.	
139	Role of renin-angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction.. <b>2022</b> , 1	0
138	Ischemic Heart Disease. <b>2022</b> , 1055-1063	
137	KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD.. <b>2022</b> ,	1
136	Impairment of Anti-Aggregatory Responses to Nitric Oxide and Prostacyclin: Mechanisms and Clinical Implications in Cardiovascular Disease.. <b>2022</b> , 23,	2
135	Stable Ischemic Heart Disease and Approach to Chronic Chest Pain. <b>2022</b> , 74-101	
134	Building your Peripheral Artery Disease Tool Kit: Medical Management of PAD in 2022.. <b>2022</b> ,	1
133	Correlation Between Smoking Paradox and Heart Rhythm Outcomes in Patients With Coronary Artery Disease Receiving Percutaneous Coronary Intervention.. <b>2022</b> , 9, 803650	0

- 132 Type 1 diabetes is associated with significant changes of ACE and ACE2 expression in peripheral blood mononuclear cells.. **2022**, 1
- 131 Methodological Aspects of Meta-Analyses Assessing the Effect of Blood Pressure-Lowering Treatment on Clinical Outcomes.. **2021**, HYPERTENSIONAHA12118413 3
- 130 Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure. **2001**, 3 Suppl 1, S25-8 1
- 129 Clinical trials report. The sweet secret of dark chocolate. **2004**, 6, 45-6
- 128 Mineralocorticoid-receptor blockade in hypertensive patients during angiotensin-converting enzyme inhibition: effects on left ventricular mass. **2004**, 6, 113-4
- 127 Cholesterol lowering with simvastatin in people with diabetes. **2004**, 6, 85-6
- 126 Diuretics should continue to be one of the preferred initial therapies in the management of hypertension: the argument for. **2005**, 7, 111-6; quiz 121-2 2
- 125 Mechanisms for the development of heart failure and improvement of cardiac function by angiotensin-converting enzyme inhibitors. **2022**, 53, 51-76 1
- 124 Role of inflammation in diabetic cardiomyopathy.. **2022**, 13, 20420188221083530 2
- 123 Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.. **2022**, 5, e2148030 3
- 122 Perioperative Renin Angiotensin System Inhibitors Improve Major Outcomes of Heart Failure Patients Undergoing Cardiac Surgery: A Propensity-Adjusted Cohort Study.. **2022**,
- 121 Plaque characteristics and prognosis in patients with peripheral arterial disease by angioscopic analysis.. **2022**,
- 120 The Blood Pressure Lowering Treatment Trialists' Collaboration: methodological clarifications of recent reports.. **2022**, 2
- 119 Prior Cardiovascular Treatments-A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction.. **2022**, 13, 834898
- 118 Association of the medical therapy with beta-blockers or inhibitors of renin-angiotensin system with clinical outcomes in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction.
- 117 Cardiovascular risk factors for cognitive deficiency and options for correction. **2022**, 35-43
- 116 Diuretics versus others for long-term clinical outcomes as first-line antihypertensive medications: analysis of national real-world database.. **2022**, 0
- 115 Does the ISCHEMIA Trial Apply to My Patients?. **2022**, 1

114	Current challenges in the treatment of cardiac fibrosis: recent insights into the sex-specific differences of glucose-lowering therapies on the diabetic heart: IUPHAR Review 33.. <b>2022,</b>	0
113	High Density Lipoprotein Reduces Blood Pressure and Protects Spontaneously Hypertensive Rats Against Myocardial Ischemia-Reperfusion Injury in an SR-BI Dependent Manner.. <b>2022,</b> 9, 825310	
112	The interaction among OSA, CPAP, and medications in patients with comorbid OSA and cardiovascular/cerebrovascular disease: a randomized controlled trial.. <b>2022,</b> 22, 99	0
111	Impact of Antihypertensive Drug Class on Outcomes in the SPRINT.. <b>2022,</b> HYPERTENSIONAHA12118369	1
110	Management and outcomes of acute myocardial infarction in patients with preexisting heart failure: an analysis of 2 million patients from the national inpatient sample.. <b>2022,</b> 1-8	0
109	Intravascular imaging assessment of pharmacotherapies targeting atherosclerosis: advantages and limitations in predicting their prognostic implications.. <b>2022,</b>	0
108	An Update on Refractory Hypertension.. <b>2022,</b> 1	1
107	Risk factor control among heart failure patients in the United States: Results from the NHANES 1999-2018.. <b>2022,</b> 13, 200128	0
106	A fixed-dose combination as an opportunity to reduce the morbidity and mortality in patients with coronary artery disease. <b>2021,</b> 20, 140-143	
105	Primary and Secondary Prevention of CAD: A Review.. <b>2022,</b> 31, 16-26	
104	Understanding diabetes-induced cardiomyopathy from the perspective of renin angiotensin aldosterone system.. <b>2021,</b> 474, 63	1
103	Association between CRP/Albumin ratio and long-term mortality in patients with chronic Limb-threatening ischemia undergoing Endovascular therapy Below The Knee: The ACHILES-BTK Registry.. <b>2021,</b>	1
102	COPD - do the right thing.. <b>2021,</b> 22, 244	5
101	The Bidirectional Signal Communication of Microbiota-Gut-Brain Axis in Hypertension.. <b>2021,</b> 2021, 8174789	0
100	Antiremodeling Efficacy of Zofenopril in Patients with Arterial Hypertension Taking into Account I/D Polymorphism of the ACE Gene. <b>2020,</b> 541-550	
99	Prognostic Impacts of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome Patients Without Heart Failure.. <b>2022,</b> 13, 663811	0
98	Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. <b>2022,</b>	1
97	Update on Stroke Prevention. <b>2005,</b> 31, 113-118	

96	Data_Sheet_1.PDF. 2020,	
95	Data_Sheet_2.PDF. 2020,	
94	Data_Sheet_3.PDF. 2020,	
93	Image_1.tif. 2018,	
92	Image_2.tif. 2018,	
91	A Novel Combination of High-Load Omega-3 Lysine Complex (AvailOm <sup>®</sup> ) and Anthocyanins Exerts Beneficial Cardiovascular Effects. 2022, 11, 896	0
90	European Stroke Organisation (ESO) Guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. 239698732211000	5
89	Unstable Angina as a Component of Primary Composite Endpoints in Clinical Cardiovascular Trials: Pros and Cons.. 2022,	1
88	Beneficial effects of carvedilol modulating potassium channels on the control of glucose. 2022, 150, 113057	
87	Cerebrovascular Disease. 2000, 102,	
86	Inhibitors of the renin-angiotensin-aldosterone system. 2013, 119-168	6
85	Antihypertensive therapies. 2013, 224-271	
84	Which therapy for which condition?. 2013, 463-541	
83	Fibrotic Signaling in Cardiac Fibroblasts and Vascular Smooth Muscle Cells: The Dual Roles of Fibrosis in HFpEF and CAD. 2022, 11, 1657	0
82	Hybrid CoreShell Nanofibrous Scaffolds/Stents Deliver Angiotensin II Receptor Blocker to Treat Diabetic Artery Disease.	0
81	Medical Management of Peripheral Arterial Disease. 2022, 100837	
80	Ramipril Improves Endothelial Function and Increases the Number of Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus. 3, Publish Ahead of Print,	
79	Coronary Angioplasty and Stenting in Acute Coronary Syndromes Using Very Low Contrast Volume and Radiation Dosage Improves Renal and Cardiovascular Outcomes. 2022, 8, 1-13	

78	Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up. 13,	0
77	Post-myocardial Infarction Heart Failure: A Review on Management of Drug Therapies. 2022,	1
76	Revascularization in stable coronary artery disease. e067085	0
75	Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study. 2022, 12, e057510	1
74	Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time. 2022, 23, 6648	1
73	Diagnosis 101: Diabetic kidney disease.	
72	Tratamiento de la hipertrigliceridemia con icosapento de etilo en pacientes de alto/muy alto riesgo cardiovascular. Documento de consenso de la Sociedad Española de Cardiología y Sociedad Española de Diabetes. 2022,	0
71	Cardiovascular protection by SGLT2 inhibitors Do anti-inflammatory mechanisms play a role?. 2022, 101549	1
70	Pharmacotherapy and Mortality in COPD.	1
69	Retrospective Evaluation of In-Hospital and Thirty-Month Mortality Parameters in Cases of Acute Coronary Syndrome.	
68	Sex differences in hypertension. Do we need a sex-specific guideline?. 9,	2
67	A Case Series Analysis of Major Vascular Revascularization. 2022,	
66	Association of Renin-Angiotensin-Aldosterone System Inhibitor Usage Patterns with Mid-Term Amputation Free Survival After Lower Extremity Bypass for Peripheral Arterial Disease. 2022,	
65	Differential Sex-Specific Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blocker Therapy on Arterial Function in Hypertension: CALIBREX Trial.	1
64	Role of Renin-Angiotensin-Aldosterone System Inhibition in Patients Undergoing Carotid Revascularization.	
63	Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. Publish Ahead of Print,	2
62	Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.	6
61	THE TREATMENT OF HYPERTENSION IN PATIENTS WITH DIABETES. 2001, 36, 273-289	0

- 60 Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease. **2022**, 79, 2115-2126 ○
- 59 Sex Differences in Pharmacotherapy and Long-Term Outcomes in Patients with Ischaemic Heart Disease and Comorbid Left Ventricular Dysfunction. ○
- 58 Door to balloon time in primary percutaneous coronary intervention in ST elevation myocardial infarction: every minute counts. **2022**, 33, 341-348 1
- 57 Long-term use of renin-angiotensin-system inhibitors after acute myocardial infarction is not associated with survival benefits: Analysis of data from the Korean acute myocardial infarction registry-national institutes of health registry. 9, ○
- 56 Masked nocturnal hypertension as a result of high prevalence of non-dippers among apparently well-controlled hypertensive patients with type 2 diabetes mellitus: data from a prospective study. **2022**, 14, 1
- 55 Left main coronary disease: evolving management concepts. ○
- 54 Risk factors for a broken heart: understanding drug-induced causes for Takotsubo syndrome and pharmacological treatment options. **2022**, 15, 1017-1025 ○
- 53 Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials. 9, ○
- 52 The Effects of a Perindopril-Based Regimen in Relation to Statin Use on the Outcomes of Patients with Vascular Disease: a Combined Analysis of the ADVANCE, EUROPA, and PROGRESS Trials. ○
- 51 Association of the medical therapy with beta-blockers or inhibitors of renin-angiotensin system with clinical outcomes in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction. **2022**, 101, e30846 ○
- 50 Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study. **2022**, 28, 2056-2065 ○
- 49 Does the Naked Emperor Parable Apply to Current Perceptions of the Contribution of Renin Angiotensin System Inhibition in Hypertension?. ○
- 48 Update on trials examining effects of night-time blood pressure lowering drug treatment on prevention of cardiovascular disease. **2021**, 2, 461-467 ○
- 47 Benefits and risks of antihypertensive medication in adults with different systolic blood pressure: A meta-analysis from the perspective of the number needed to treat. 9, ○
- 46 Timed-averaged blood pressure showed a J-curve association with stroke in elderly chronic kidney disease patients. **2022**, 44, 1677-1686 ○
- 45 Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension. ○
- 44 Associations of short- and long-term mortality with admission blood pressure in Chinese patients with different heart failure subtypes. ○
- 43 The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. ○

- 42 Hypotensive and HbA1c reducing effect of novel dietary intervention program  $\square$ OMB meal program  $\square$ Two randomized clinical trials. **2022**, 98, 105279 ○
- 41 Big Data and Cardiology: Time for Mass Analytics?. ○
- 40 Hypertension management in patients with cardiovascular comorbidities. ○
- 39 Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Espa la de Cardiolog a [Spanish Society of Cardiology] and the Sociedad Espa la de Diabetes [Spanish Diabetes Society]. **2022**, ○
- 38 Closing gaps in medication taking for secondary prevention of coronary heart disease patients among US adults. **2022**, 8, e11530 ○
- 37 Hypertension. **2022**, 329-353 ○
- 36 Secondary Diseases of the Kidney. **2022**, 366-399 ○
- 35 Use of point-of-care ultrasound by internists to rapidly diagnose acute decompensated heart failure. **2023**, 41, 101789 ○
- 34 Medical Therapy for Heart Failure with Preserved Ejection Fraction. **2022**, 18, 17-26 ○
- 33 Toward Precision Medicine: Circadian Rhythm of Blood Pressure and Chronotherapy for Hypertension - 2021 NHLBI Workshop Report. ○
- 32 Revisiting secondary prevention in coronary heart disease. **2022**, 74, 431-440 ○
- 31 Angina in 2022: Current Perspectives. **2022**, 11, 6891 ○
- 30 Cardiorenal Effects of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in people underrepresented in trials: analysis of routinely collected data with validation against a target trial. ○
- 29 Incident stroke events in clinical trials of antihypertensive drugs in cardiovascular disease patients: A network meta-analysis of randomized controlled trials. **2022**, 101551 ○
- 28 A reference-free R-learner for treatment recommendation. 096228022211443 ○
- 27 PAVK bei Diabetikern: Interventionen und Sekund prophylaxe. **2022**, 16, 30-36 ○
- 26 Blood Pressure-Lowering Treatment and Macrovascular Events. **2023**, 305-326 ○
- 25 Coexistence of Diabetes Mellitus and Hypertension. **2023**, 3-17 ○

- 24 Pathophysiology of cough with angiotensin-converting enzyme inhibitors: How to explain within-class differences?. **2023**, ○
- 23 Renin Angiotensin System and Thyroid Hormone Crosstalk: From Experimental Approaches to Clinical Perspectives. **2023**, 23-37 ○
- 22 The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes. ○
- 21 Outcomes in Patients with Cardiometabolic Disease Who Develop Hyperkalemia While Treated with a RAAS Inhibitor. **2023**, ○
- 20 Arterielle Hypertonie. **2022**, 155-204 ○
- 19 Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis. ○
- 18 Risk Factor Profile and Treatment Patterns of Patients with Atherothrombosis in Singapore: Insight from the REACH Registry. **2008**, 37, 365-371 ○
- 17 Vaccines and cardiovascular outcomes: lessons learned from influenza epidemics. **2023**, 25, A17-A24 ○
- 16 Association between renin-angiotensin-aldosterone system blockade and clinical outcomes in patients with hypertension: real-world observation from a nationwide hypertension cohort. ○
- 15 Comparison of cardiocerebrovascular disease incidence between angiotensin converting enzyme inhibitor and angiotensin receptor blocker users in a real-world cohort. **2023**, 21, 7-14 ○
- 14 Premorbid Use of Beta-Blockers or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with Acute Ischemic Stroke. **2023**, 2023, 1-14 ○
- 13 L'aspirine a-t-elle une place dans la prévention cardiovasculaire primaire par la polypill? Étude de simulation sur une population virtuelle réaliste. **2023**, ○
- 12 Association of Long-term Change in N-Terminal Pro-B-Type Natriuretic Peptide With Incident Heart Failure and Death. **2023**, 8, 222 1
- 11 Oral combined hydrochlorothiazide and lisinopril vs nifedipine for postpartum hypertension: a comparative-effectiveness pilot randomized controlled trial. **2023**, ○
- 10 Guideline-Directed Medical Therapy and Long-Term Mortality and Amputation Outcomes in Patients Undergoing Peripheral Vascular Interventions. **2023**, 16, 332-343 ○
- 9 The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in elderly (≥65) patients with acute myocardial infarction without hypertension. ○
- 8 A Motivational Interviewing Intervention to Improve Adherence to ACEIs/ARBs among Nonadherent Older Adults with Comorbid Hypertension and Diabetes. **2023**, 40, 377-390 ○
- 7 THE ACUTE CORONARY SYNDROME: THE POSSIBILITY OF THE MODERN THERAPY (REFERENCES REVIEW. PART I). **2009**, 12-18 ○



- 6 Role of angiotensin in different malignancies. **2023**, 505-544 ○
- 5 Role of percutaneous coronary intervention in the modern-day management of chronic coronary syndrome. heartjnl-2022-321870 ○
- 4 Fasting Glucose, Glycated Hemoglobin, and 2h Post-load Blood Glucose Are Independently Associated With Arterial Stiffness in Diabetes: The ELSA-Brasil Study. 000331972311661 ○
- 3 Blood Pressure in CKD. **2023**, 115-129 ○
- 2 Sex-specific Mendelian randomisation to assess the causality of sex differences in the effects of risk factors and treatment: spotlight on hypertension. ○
- 1 Optimal Medical Management in Patients undergoing Peripheral Vascular Interventions for Chronic Limb Threatening Ischemia is associated with Improved Outcomes. **2023**, ○